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1 - Summary 
 
 
Adenosine is a paradoxical inflammatory modulator, which can contribute both to 
inflammatory shutdown and to the persistence of inflammation. In one hand, 
adenosine acts as an anti-inflammatory molecular by inhibiting several immune cell 
functions. On the other, the concentration of adenosine is potent increased in the 
bronchoalveolar lavage (BAL) of asthmatics patients [1]. Adenosine mediates its 
biological effects through activation four G-protein coupled adenosine receptors 
(ARs), namely the A1, A2A, A2B and A3 adenosine receptors. These four types of AR 
differ in their affinity to adenosine, in the type of G protein they recruit and their 
differentially expressed in different cells and organs. Although some of the functions 
of the ARs have been characterized in animal models, cellular effectors of adenosine 
have remained largely unknown. The aim of this work was, first, to identify AR-
subtype specific downstream cellular factors that mediate adenosine’s pro- or anti-
inflammatory effects and, second, to characterize the interplay between the anti-
inflammatory A2AAR and other inflammatory stimuli. 
In the first part of this thesis, we employed a transcriptomics approach for the 
identification downstream effector mechanisms of ARs. By combining selective AR 
activation with genome wide transcriptional screening, we were able to establish a 
novel link between adenosine inflammatory signaling and the nuclear orphan receptor 
4A family of transcription factors. The central finding of this study was that the 
concomitant treatment with the A2AAR antagonist SCH-58261 significantly enhanced 
the effect of the adenosine analogue NECA on NR4A2 and NR4A3 induction. Further, 
we characterized the intracellular signaling pathways associated with the upregulation 
of these factors, and established that activation of ERK1/2 kinases downstream of 
PKC mediated NR4As induction by AR, at least partially. Given the multiple roles of 
these transcription factors, adenosine’s effect on NR4A2 and NR4A3 could have 
broad pathophysiological implications. 
The second part of this thesis was aimed at analysing the effect of A2AAR activation 
on other inflammatory stimuli, namely combination of phorbol 12-myristate 13-
acetate, PMA (P) and the calcium ionofore Ionomycin (I), in LAD-2 human mast cells. 
This study allowed us to characterize several aspects of NR4A2 signaling in activated 
mast cells. First, we observed a strong upregulation of NR4A2 coupled to 
phosphorylation-dependent ubiquitination, a previously unknown post-translational 
modification of NR4A2. Second, cell fractionation and immunofluorescence 
experiments showed that P/I-induced phosphorylation-dependent ubiquitination led to 
an accumulation of NR4A2 in the endoplasmic reticulum and in the endolysosomal 
compartment 6 h after treatment, and that inhibition of the proteasome with MG132 
increased the accumulation of NR4A2 in these organelles. Third, we established IL-4 
as a downstream effector of NR4A2, which was largely dependent on the PKC and 
ERK kinases and that could be reverted NR4A2 silencing. Fourth, we observed that 
proteasome inhibition through MG132 pretreatment enhanced P/I-induced IL-4 
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release 6 h after treatment (in correlation with the accumulation of NR4A2 in 
cytoplasmic organelles), but that strongly reduced IL-4 release, despite NR4A2 
stabilization. These observations suggested the late release of IL-4 could depend on 
another factor, and since proteasome degradation of IκB is required for the activation 
of NF-κB, we reasoned that this signaling pathway could be involved in late phase IL-
4 release. In fact, pretreatment with the NF-κB inhibitor BAY 11-7082 significantly 
inhibited the release of this cytokine at a late time point and MG132 also inhibited 
NF-κB activation, strongly suggesting that the late inhibitory effect of MG132 on IL-
4 release could be mediated by inhibition of NF-κB signaling. Furthermore, NR4A2 
silencing partially reduced NF-κB-LUC reporter activity, suggesting that NR4A2 is 
required for the activation NF-κB at a later time-point. These results indicate that 
while NR4A2 is the central transcriptional factor driving IL-4 release in the early 
phase (6 h), NF-κB becomes determinant factor in IL-4 synthesis later time point, 
explaining the biphasic effect of proteasome inhibition. Finally, we showed an 
inhibitory effect of the adenosine receptor A2A on NR4A2 and NF-κB dependent IL-4 
induction, suggesting that through the modulation of IL-4 release, A2AAR activation 
in mast cells can negatively influence the development of allergic Th2 responses. 
2
 
 
2- Introduction 
 
2.1 Orphan nuclear receptor 4A family: NR4A  
 
The orphan nuclear receptor 4A family (NR4A) belongs of nuclear hormone receptor 
superfamily. These receptors were first recognized based on their resemblance to 
classical nuclear receptors and their ligands were unknown [2]. It consists of three 
members, NR4A1 (also known as the nerve growth factor inducible B, NGFI-B, 
Nur77, TR3, N10, DHR38, NAK-1, TIS1), NR4A2 (nur-related factor 1, Nurr1, 
TINUR, NOT, RNR-1) and NR4A3 (neuron derived orphan receptor 1, Nor1, 
MINOR, TEC, CHN) [3-5]. NR4A1 was found to be induced when cells were treated 
with the nerve growth factor, and NR4A2 and NR4A3 were cloned due to their 
resemblance to other nuclear receptors [4, 5]. Based on their sequence homology, 
NR4A1, NR4A2 and NR4A3 were suggested to form a subfamily [2, 4, 5].  
 
 
2.1.1  Structure of NR4As 
 
The members of NR4A group are high homology in the DNA binding domain (DBD) 
and C-terminal ligand binding domain exhibit ~91-95% and ~60% homology, and 
moderate in the ligand binding domain (LBD), but the N-terminus has more 
differences [6] (Figure 1).  
 
 
 
Fig. 1 Domain structure of NR4A orphan receptors (Adapted from [7]) 
 
 
The crystal structures of NR4A2 LBDs have been resolved and reveal that both of 
them consist of 12 helices and that the ligand-binding pocket is loaded with bulky 
side chains from residues which are conserved in the family (Figure 2). This implies 
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that these receptors do not exclude the existence of endogenous or synthetic ligands, 
but also advises that activation of NR4As may be ligand-independent [8, 9]. 
 
 
 
Fig. 2 Crystal structure of NR4A2 LBD. It contains a three-layered antiparallel α-helical sandwich 
formed by 12 α-helices (H1–H12) and one β-sheet of two strands (S1, S2). The AF2 helix (H12) is 
shown in red. (from Protein Data Bank?
http://www.rcsb.org/pdb/explore/jmol.do?structureId=1OVL&bionumber=1 [8]) 
 
 
2.1.2 NR4As expression and localization 
 
NR4As are widely expressed in various tissues, such as lung, brain, liver, skeletal 
muscle, blood vessels, adipose tissues and immune cells [10]. The expression of the 
receptors of the NR4A subfamily is strongly induced by external stimuli. NR4As are 
classified as early response genes (stress response genes) with maximum induction 
within 2 h after stimulation in immune cells such as mast cells [11]. The range of 
physiological signals that induce the expression of NR4A receptors is wide, from fatty 
acids and peptide hormones to stress and magnetic field [10]. The activation of NR4A 
receptor is dependent on several kinase pathways, including PI3K/Akt, PKA and 
MAPK pathways [12-14]. NR4A2 promoter also contains the binding sites for these 
transcription factors [15]. 
NR4A receptors are usually located in the nucleus [29]. Katagiri et al. have studied 
the pathways mediating the localization of NR4A1. They have demonstrated that in 
NR4A1, there are two nuclear localization signal sequences in the DBD and three 
nuclear export signal sequences in the LBD. They have shown that the nerve growth 
factor can induce NR4A1 relocalization to the cytoplasm by phosphorylating serine 
105. This phosphorylation was shown to be regulated by the MAPK pathway. In their 
studies, the nerve growth factor also induced relocalization of RXR as a heterodimer 
with NR4A1 [30]. Relocalization of NR4A1 to cytoplasm has also been observed in 
response to apoptotic factors [31]. Cytoplasmic NR4A1 was found to associate with 
mitochondria which led to depolarization of the mitochondrial membrane and release 
of cytochrome c [31]. It was further demonstrated that these events were the result of 
interaction with an anti-apoptotic protein Bcl-2 and that the interaction changed the 
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nature of Bcl-2 from anti- to pro-apoptotic [32]. It seems that the cytoplasmic NR4A1 
has functions that are distinct from the nuclear NR4A1.  
 
 
2.1.3 NR4As transcriptional activity  
 
NR4A family members bind as monomers to the consensus DNA sequence 
AAAGGTCA. This element is termed NBRE (NGFI-B response element) (Figure 3). 
The A-box of the DBD is responsible for recognizing the AA sequence preceding the 
classical response element of non-steroidal nuclear receptors (AGGTCA) [16, 17]. 
NR4A1, NR4A2 and NR4A3 have been shown to bind DNA as homodimers and as 
heterodimers with each other on the NurRE (nur-response element, 
AAAT(G/A)(C/T)CA) (Figure 3), which is an inverted repeat of two slightly 
converted NBRE half-sites [18]. Heterodimers formed within the NR4A family also 
bind NurRE much more efficiently than monomeric or homodimeric NR4As [18] 
(Figure 3). Maybe differential expression of the NR4A receptors can influence the 
abundance in which the highly active and less active NR4A heterodimers are present 
in the cell. In addition, the amounts of homodimers and monomers may be affected. 
The promoters of different genes can be activated depending on the expression levels 
of NR4As. Gene activation is also determined by the differential activity of NurRE 
and NBRE on target genes. Moreover, NR4A1 and NR4A2 (not NR4A3) bind DNA 
as heterodimers while using RXR on DR5 elements. NR4A2/RXR heterodimers can 
also be formed on NBREs without RXR binding to DNA [19-21]. Activation or 
suppression genes by NR4As have been investigated and the list of genes is extensive 
[22] 
 
 
 
Fig. 3 NR4A response elements (Adapted from [10]) 
 
The transcriptional activity of NR4As can also be regulated by co-repressors and co- 
activators. NR4A-mediated trans-activation (LBD) involves unusually active N-
terminal AF-1 domains that mediate coactivator recruitment [23]. Silencing mediator 
of retinoid and thyroid hormone receptor (SMRT) binds to NR4A2 LBD, and has 
been suggested to function as a coregulator surface in NR4A1 [9]. This binding site 
has been shown to bind both corepressors and coactivators [24, 25]. However, the 
differences in coactivator and corepressor binding compared to other nuclear 
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receptors are likely to explain partially the constitutive activity of the NR4A receptors 
and the permissive nature of NR4A1/RXR and NR4A2/RXR heterodimers.  
In addition to dimerization and cofactors, several mechanisms have been described to 
control the transcriptional activity of the NR4A receptors. NR4As are regulated by 
phosphorylation. Phosphorylation can either enhance or repress the transcriptional 
activities of the NR4A receptors.  For example, the MAPK pathway phosphorylates 
NR4A1 and enhances its transactivation on POMC (pro-opiomelanocortin) promoter 
[12]. Phosphorylation of serine 350 in the NR4A1 DBD has been shown to decrease 
its binding to NBRE [26], thus offering another possible target for regulation by 
phosphorylation. NR4A2 has also been shown to possess two putative sumoylation 
sites at lysines 91 and 577. Mutational analyses have shown that sumoylation at 
position 91 can repress the transcriptional activity of NR4A2, and sumoylation at 
position 577 can enhance it [27]. Post-translational modifications could thus provide 
an important ways of controlling the activity of orphan nuclear receptors. It 
demonstrated ubiquitination and degradation of NR4A1 were triggered by JNK 
activation [28]. Methylation of the receptors of the NR4A family has not been 
reported.  
 
 
2.1.4 Biological functions of NR4As   
 
NR4A receptors therefore have varied functions in controlling multiple physiological 
events. Mice with targeted deletion of the NR4A2 gene die after birth, probably due 
to problems with the control of respiratory functions [33]. NR4A1, NR4A2 and 
NR4A3 could be induced by physiological and physical stimuli, including 
inflammatory cytokines, growth factors, calcium phorbol esters, prostaglandins, fatty 
acids, growth factors, neurotransmitters, hormonally-active peptides, and other 
cellular stressors including fluid sheer stress, magnetic fields, and membrane 
depolarization [10]. Activation of NR4A receptors by multiple stimuli is consistent 
with the increasing number of tissue-specific receptor-mediated effects that are 
important for their function [10].  
 
NR4As and inflammation 
The extensive roles of NR4A1, NR4A2 and NR4A3 in inflammation, vascular 
function, metabolic processes and central nervous system (CNS) have been reviewed. 
NR4A knockout animal models have provided insights into a few of the endogenous 
functions of NR4A receptors. However, some redundancies among these receptors 
(particularly NR4A1 and NR4A3) may mask specific functions in mouse models [34, 
35]. The first evidence linking NR4A expression with inflammatory signaling was 
reported by Woronicz et al., who noted that NR4A1 is induced in apoptotic T-cells 
and that inhibition of NR4A1 function prevented apoptosis [36, 37]. However, 
knockdown of NR4A1 in mice exhibits unimpaired T-cell apoptosis, and functional 
redundancy of NR4A1 and NR4A3 in T-cell apoptosis has been reported [38, 39]. 
NR4A2 expression has elevated levels of inflammatory arthritis and can be 
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downregulated with glucocorticoids [35]. Recently study has shown that NR4A2 
induces Foxp3 and regulates differentiation of CD4+ T cells, indicating that NR4A2 is 
able to maintain T-cell homoeostasis [40]. Much like T-cells, NR4A1 expression is 
increased in apoptotic macrophages and, contrary to the experiments performed in T-
cells, peritoneal macrophages isolated from NR4A1 deficient mice reveal a phenotype 
of reduced cell death [41]. Responding to inflammatory activation, all NR4A 
receptors are potently induced in macrophages [42, 43]. This inducible expression of 
NR4A receptors in macrophages depends on the activation of NF-κB signaling, as 
exemplified by the recruitment of NF-κB to response elements in the NR4A1 
promoter [42]. Functional studies have established that NR4A receptors both activate 
and repress inflammatory genes in macrophages [43-45]. Microarray analysis of 
macrophages overexpressing NR4A1 showed increased pro-inflammatory gene 
expression [44]. Interestingly, among the identified direct NR4A1 target genes was 
the inducible kinase IΚKi, which functions as a NF-κB activating kinase, providing a 
potential mechanism for the activation of inflammatory gene expression by NR4A1 in 
macrophages [45]. In contrast, another study showed over-expression of each NR4A 
member reduces certain inflammatory genes (i.e. IL-1α, IL-6, IL-8, MIP-1α and 
MCP-1) and the uptake of oxidized low density lipoprotein (LDL) [43]. Finally, it has 
recently been shown that NR4A2 transcriptionally represses the inflammatory genes 
TNF-α, iNOS, and IL-1α in a mouse macrophage cell line [45]. This repression was 
mediated through NR4A2-dependent recruitment of the co-repressor for element-1-
silencing transcription factor (CoREST) complex to the target promoter and the 
subsequent clearance of NF-κB [45].  
 
NR4As and cancer 
NR4As expression has been reported in multiple cancer cell lines [46, 47]. Higher 
level of NR4A1 was found in colon and pancreatic tumors in patients [48, 49] 
Cytoplasmic and nuclear NR4A2 was found in cohort of bladder cancer patients, and 
it was shown that cytosolic and nuclear NR4A2 staining was higher in patients 
compared with healthy donors, moreover, NR4A2 levels were associated with 
increasing histopathological grade of the tumor [50]. NR4A1, NR4A2 and NR4A3 
protein expression was variable with different types of cancers, and they could have 
prognostic significance for patients with tumor. Studies with overexpression of NR4A 
or NR4A knockout animal models provided valuable insights some insights into the 
function of NR4As in cancer cells. Knockdown NR4A1 resulted in induction of 
apoptosis, inhibition of cell proliferation and decreased angiogenesis, indicating 
NR4A1 is a pro-oncogenic factor in cancer [48, 49]. Overexpression of NR4A1 in 
lung cancer cells enhances proliferation and cell cycle progression [51]. The 
knockdown effect of NR4A2 in bladder cancer cells did not affect cell proliferation, 
but decrease cell migration, suggesting NR4A2 was anti-apoptotic factor [50]. These 
results reveal some differences between breast cancer cells and other cancer cell lines. 
It was also shown that NR4A1/NR4A3 double knockout mice rapidly developed 
lethal acute myeloid leukemia (AML) and died 2 to 4 weeks after birth [52]. Loss of 
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both orphan nuclear receptors was accompanied by dysregulation of multiple 
pathways and this included enhanced production of hemapoietic stem cells. These 
results suggested a potential role for these receptors in leukemia. In agreement with 
this hypothesis, it was reported that both NR4A receptors were also decreased in 
leukemia patients [52]. In conclusion, NR4A1, NR4A2 and NR4A3 play different 
roles in cancer. These properties can potentially be utilized as targets for cancer 
therapy.  
 
 
 
 
2.2 Adenosine and adenosine receptors  
 
 
2.2.1 Adenosine metabolism 
 
The endogenous nucleoside adenosine plays a central role as a structural element of 
nucleic acid and in the energy metabolism of all living organisms (Figure 4). 
Adenosine is a byproduct of ATP degradation, acting as a sensor of the metabolic 
state, in turn modulating biological functions in a variety of cell types, tissue and 
organs. The physiological effects of adenosine were first described in the 
cardiovascular system and gastrointestinal tract [53], although modulatory functions 
in a much broader spectrum of organ systems has been described.  
 
 
 
 
 
Fig. 4 Adenosine structure 
 
 
Adenosine concentration is related to energy consumption and under basal conditions 
is kept within a narrow range (30-300 nM) [54]. During metabolic stress conditions, 
such as hypoxia or ischemia, extracellular levels of adenosine can reach a 
concentration of 30 µM or higher [55, 56]. 
 
Adenosine arises mainly from the cleavage of adenosine monophosphate (AMP) by 
either intracellular or extracellular 5’ nucleotidase or efficient equilibrative 
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transporters balance intracellular and extracellular adenosine level. S-adenosyl 
homocysteine has also been reported to be a minor pathway of adenosine formation 
[57] (Figure 5) Adenosine degradation involves either phosphorylation by adenosine 
kinase or  deamination to inosine by adenosine deaminase, respectively [58, 59]. 
Adenosine deaminase also degrades 2’-deoxy adenosine, which is a lymphotoxic 
product of the purine metabolism [60].  
 
 
 
Fig. 5 Metabolic pathway of adenosine (Adapted from Adair, 2005) [61] 
 
 
2.2.2  Adenosine receptors  
 
Adenosine binds four different ARs: A1, A2A, A2B and A3, which belong to G protein-
coupled membrane receptors (GPCRs) (Figure 6). Adenosine receptors have a 
variable distribution in different tissues (central nervous system, cardiovascular, renal, 
respiratory, immune and gastrointestinal), where they modulate biological functions 
[62].  
 
 
 
Fig. 6 Adenosine receptor [63] 
 
 
The four AR subtypes are encoded by distinct genes and have different 
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pharmacological profiles in regard to agonist and antagonist binding properties. A1AR 
and A2AAR are activated by low levels of adenosine (0.01 to 1 µM), whereas A2BAR 
and A3AR require higher amounts (>10 µM). All of the AR subtypes can be 
characterized according to the affinity to the natural agonist adenosine. In physiologic 
conditions the rank order of potency for adenosine is as follows: A1 ≥ A2A >> A3 ≈ 
A2B [64]. However, in artificial systems overexpressing ARs, A3AR can also be 
activated by low adenosine concentrations [64].  
 
The affinity of various AR agonists and antagonists at the AR subtypes are 
summarized in Table 1. 
 
Table 1. Binding affinity of agonists and antagonists at human adenosine receptor 
subtypes (adapted from [65, 66]) 
 
 Compound Ki value for AR (nM)  
  A1AR  A2AAR  A2BAR A3AR  
 CPA 2.3 794 18,600 72 
 Selodenoson 1.1 306 N.D* N.D 
CGS21680 289 27 >10,000 67 
Agonist  
 
CV-3146 >10,000 290 >10,000 >10,000 
BAY-60–6583 >10,000 >10,000 4 >10,000 
IB-MECA  51 2,900 11,000 1.8 
 CP-608039 7,200 N.D N.D 5.8 
 DPCPX 3.9 129 56 3,980 
 FR194921 2.9 >10,000 N.D >10,000 
SCH 58261 725 5.0 1,100 1,200 
 
Antagonist 
 
SCH 442416 1,100 0.048 >10,000 >10,000 
MRS1754 403 503 2.0 570 
 MRE 2029-F20 245 >1,000 3.0 >1,000 
OT-7999 >10,000 >10,000 >10,000 0.61 
 MRS3777 >10,000 >10,000 >10,000 47 
*:   Not determined  
Figures in bold indicate the receptor with the highest affinity 
 
 
2.2.3 Adenosine receptor signaling and regulation 
 
The four subtypes AR couple to an intricate network of G proteins (Table 2), which 
enable the endogenous modulator adenosine to communicate with cells in complex 
manner. Table 2 summarizes the chromosomal location, length G-protein partners and 
downstream signaling by each receptor subtype.   
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Table 2. Properties of human adenosine receptor subtype 
 
AR 
Subtype 
Genebank 
Number 
Chromosomal 
Location 
Length 
(Amino 
Acids) 
G-protein 
Coupling 
Downstream  
Signaling 
[67] 
A1AR S45235 1q32.1 326 i, o, q ?cAMP [67] 
?PLC [68] 
?Ca2+ channels [69] 
?K+ channels [70] 
A2AAR S46950 22q11.2 412 s, olf ?cAMP [71] 
?PLC [71] 
?IP3 [72] 
A2BAR X68487 17p11.2-12 332 s, q ?cAMP [73] 
?IP3 [73] 
?PLC [74] 
A3AR L22607 1p13.3 318 i, o ?cAMP [75] 
?Ca2+ channels [76] 
?PLD [77] 
?PLC [78] 
 
 
A1AR 
A1ARs were found in several species including human, dog, rat, cow and rabbit A1AR 
[79]. It has been demonstrated that the A1AR can not only inhibit adenylate cyclase 
(AC) by interacting with Gi or Go proteins (Table 2), but can also inhibit G protein-
coupled activation of voltage dependent Ca2+-channels and induced phospholipase C 
(PLC) activation via Gq protein [68]. It determines the activation of the family of 
extracellular signal-regulated kinase 1/2 (ERK 1/2), thus leading to pro-inflammatory 
response [69]. Meanwhile, A1ARs are involved in responses that reduce oxygen 
demand by directly decreasing heart rate, force of contraction and conduction of 
action potential (through opening of K+-channels) as well as by indirect 
antiadrenergic effects (through inhibition of AC) [80] (Figure 7).   
 
 
 
Fig. 7 Adenosine A1 receptor signal transduction pathway [81, 82] 
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In heart, selective A1AR agonist has a potential to control arrhythmia, such as 
Selodenoson, which influences on heart rate without lowering blood pressure [83]. It 
has been tested in Phase II clinical trials for its capacity to slow heart rate in atrial 
fibrillation. In CNS, A1AR agonist, GW-493838, was found to inhibit electrically 
induced nociception-specific blink reflex responses [84]. In endocrine system, A1AR 
agonist GR79236 has been tested in humans for adjuvant therapy in insulin resistance 
(type 2 diabetes) [85, 86]. A1AR-selective antagonist FR194921 had been found to 
have ability in the treatment of dementia and anxiety disorders [85, 86]. A1AR 
antagonists are effective diuretic agents that are useful in treating fluid-retention 
disorders, in renal system, A1AR antagonist, BG9719 was for the treatment of acute 
renal disorders in patients with congestive heart failure [87].  
 
 
A2AAR 
The A2AARs are expressed in mast cells, T cells, neutrophils, CNS, and vascular 
smooth muscle cells [88]. It has been shown that adenosine exerts predominantly 
effects on the immune system, also A2AAR molecule has been identified as an 
important endogenous immunosuppressing regulator as it has been observed that lung 
A2AAR activate a protective mechanism in the downregulation of inflammation and 
tissue damage in different models [89].  
A number of effects described activation of A2AAR seems to affect multiple aspects 
of the inflammatory process, modulating neutrophil activation and degranulation, 
oxidative species production, adhesion molecules expression, cytokine release and 
mast cell degranulation [90]. Moreover, A2AAR agonist have been proposed to control 
inflammation and inflammation-related tissue injury [91, 92]. Despite the beneficial 
aspects of quenching inflammation the described A2AAR-mediated down-regulation 
of the immune response is potentially dangerous on its own. Indeed, the premature 
inhibition of immune cell function may allow pathogens to survive and as a result the 
overall damage to the organism. On the other hand, the lack of A2AARs signaling may 
result in excessive damage with important biological consequences. Therefore, the 
level of the activation of A2AARs is the key issue for the balance between the 
requirement to destroy invading pathogens and the desire to protect host tissue from 
excessive damage. Manipulation of inflammatory processes may include not only 
efforts to inhibit inflammation, but also the development of approaches to enhance 
local inflammatory processes [93].  
A2ARs are coupled to the intracellular transduction pathway through Gs proteins and 
stimulate the activation of AC resulting in the elevation of intracellular cAMP [88, 
94]. A2AAR also activates mitogen-activated protein kinase (MAPK) activity. 
Adenosine agonists through activation of ERK1/2 using the cAMP-ras-MEK1 
pathway, exert mitogenic effects on human endothelial cells via the A2AAR subtype 
[69]. A2AAR triggers the activation of PKA and subsequently activation of cAMP 
responsive element-binding protein (CREB), which in turn inhibits NF-κB [95]. 
Moreover, A2AAR can also induce SOCS-3 expression through EPAC-1 in a cAMP 
dependent manner [95].  However, the signaling pathways used by A2AAR seem to 
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vary with the cellular background and the signaling machinery of each cell type 
(Figure 8).  
 
 
 
Fig. 8. Adenosine A2A receptor signal transduction pathway (Adapted form Fredholm et.al., 2007) [96] 
 
As a potent anti-inflammatory player, A2AAR agonist can be used in pulmonary 
disorders and inflammation. Activation of the A2AAR by CGS21680 produces potent 
anti-inflammatory activity in the allergic asthma rat model [97]. ATL-146e, another 
selective agonist of the A2AAR can protect mouse liver from reperfusion injury, and 
the protection effect is reversed by the A2AAR antagonist ZM241385 [98].  
Furthermore, the A2AAR agonist ATL-146e has also shown potential for the treatment 
of sepsis [99] and inflammatory bowel disease [100]. Selective activation of the 
A2AAR is able to control ulcer formation and inflammation [101]. In heart, selective 
A2AAR agonist binodenoson (WRC-0470) is tested in Phase III clinical trials and 
seems to be well tolerated as a coronary vasodilator [102]. In addition, an A2AAR 
antagonist, KW-6002 (istradefylline), has shown potential in a recently completed 
Phase II clinical trial (now in Phase III trials) as a novel treatment for Parkinson's 
disease [103]. 
 
 
A2BAR 
The A2BAR, although structurally closely related to the A2AAR and able to activate 
AC, is functionally very different. It has been postulated that this subtype may utilize 
signal transduction systems other than AC because of these functional differences 
[104]. A2BAR has been enigmatic due to the lack of good selective high affinity 
agonists and antagonists. The A2BARs, on the contrary with the other adenosine 
receptor subtypes, are characterized by a low density and it needs high adenosine 
levels to their activation.   
 
A2BAR has been identified in different tissues and to determine their function, 
including in the brain, human bronchial epithelium, endothelial cells, muscle cells, 
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neurons, glial cells, fibroblasts and mast cells [105]. A2BARs predominantly 
expressed in human microvascular cells, modulate expression of angiogenic factors 
[106]. A2BAR subtype appears to mediate the actions of adenosine to increase growth 
factor production (i.e. VEGF) and cell proliferation of human retinal endothelial cells 
[107]. In the immune system, A2BAR activation has been documented to be involved 
in mast cell degranulation and cytokine release, which are the major triggers of 
asthma [108]. In heart, adenosine causes inhibition of cardiac fibroblasts growth and 
of vascular smooth muscle cells by activating A2BAR [109, 110]. It is interesting to 
note that, in contrast to smooth muscle cells, A2BAR induces growth of endothelial 
cells [111, 112]. Moreover, A2BARs have been implicated in the regulation of gene 
expression, intestinal function, neurosecretion and vascular tone [113]. 
 
Gs-mediated A2BAR signaling can increase cAMP level leads to activate not only 
MAPK but also p38 and stress-activated protein/Jun kinase (SAPK/JNK) signaling 
pathway [69]. In most cell types A2AAR subtype inhibits intracellular Ca2+ levels 
whereas A2BAR, via Gq proteins are linked with the stimulation of PLC and induces 
Ca2+ increase [108]. These two pathways can be activated simultaneously, which 
enables additional levels of fine-tuning of cellular process (Figure 9). 
 
 
 
 Fig. 9 Adenosine A2B receptor signal transduction pathway (Adapted form Hasko et. al., 2009)[114] 
 
In asthmatic lung, selective antagonist for the A2BAR, could have therapeutic 
potential in asthma treatment [115] In addition, theophylline and other xanthines 
might have anti-asthmatic effects by blocking A2BAR, although the evidence for this 
is still controversial due to the lack of a property animal model. A2BAR antagonists 
are also under consideration for diabetes treatment [116]. So far there is no 
commercial A2BAR-selective agonists available, however, recently, A2BAR-knockout 
mice have hampered further clarification of the functional significance of this receptor. 
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A3AR 
In comparison with the other adenosine receptors, A3AR exhibits large differences in 
structure, tissue distribution and its functional and pharmacological properties among 
species [117]. However, marked differences exist in expression levels within and 
among species [118]. The classical pathways associated with A3AR activation are the 
inhibition of AC activity, through the coupling with Gi proteins, and the stimulation 
of PLC, inositol triphosphate (IP3) and intracellular Ca2+, via Gq proteins [69, 119]. 
In addition, in different recombinant and native cell lines, A3AR is involved, like the 
other adenosine subtypes, in the modulation of MAPK activity [120] (Figure 10). The 
functional role of this AR subtype remains controversial, mainly due to interspecies 
difference.  In rat, mast cell degranulation seems to be dependent on A3AR activation 
and A3AR antagonism attenuates pulmonary inflammation, reduces eosinophil 
infiltration and decreases airway mucus production. In contrast, A3AR agonists IB-
MECA may be a new family of orally bioavailable drugs to be developed as potent 
inhibitors of autoimmune-inflammatory diseases [121]. 
 
 
Fig. 10 Adenosine A3 receptor signal transduction pathway (Adapted from Fishman et.al.,2012) [122] 
 
It was shown that the A3AR is more highly expressed in tumor than in normal cells, 
which may justify A3AR as a potential target for tumor growth inhibition [123]. 
A3AR activation has been implicated in inhibition of tumor growth both in vitro and 
in vivo [122], and selective A3AR agonist IB-MECA is in clinical trials for colon 
carcinoma. In heart, The A3AR agonist CP608039 is in development for use in 
perioperative cardioprotection [124], and the A3AR agonist Cl-IB-MECA protects rat 
cardiac myocytes from the toxicity induced by the cancer chemotherapeutic agent 
doxorubicin [125]. 
 
 
2.2.4 Biological functions of adenosine  
 
In many tissues and organs, adenosine acts as a chemical messenger with varied 
functions.  
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A role for adenosine in pulmonary disease was first described in the late 1970s when 
it was discovered that adenosine and related synthetic analogues were potent 
enhancers of IgE-dependent mediator release from isolated rodent mast cells [126]. A 
couple years later, adenosine administered by inhalation was shown to be a robust 
bronchoconstrictor of asthma patient but, importantly, not of normal airways [127]. 
Further work indicated that both allergic and non-allergic asthmatics responded in a 
similar way and that the effect was also seen with AMP, ADP and ATP [128].  
 
First, Increased formation of adenosine occurs in chronically inflamed airways. 
Adenosine as well as ARs are intimately involved in defining the pathophysiology of 
asthma and chronic obstructive pulmonary disorder (COPD). Adenosine receptors on 
immune cells included in the lung seem to have particularly crucial roles. Most 
compelling are the observations that inhaled adenosine can induce 
bronchoconstriction in patients suffering from asthma or COPD, but not in healthy 
individuals, and AR blockade can prevent this bronchoconstrictive response [129]. 
Second, expression of the four identified ARs has been shown in a large number of 
proinflammatory cells as well as in the peripheral lung parenchyma of patients with 
COPD. This basic concept of AR activation on mast cells has been confirmed by 
studies using animal models of asthma. These studies have also identified A2BAR 
[130] and A3AR [131, 132] as the main contributors that mediate the stimulatory 
effect of adenosine on mast-cell activation. Third, beside mast cells, pro-inflammatory 
effects of A2BAR stimulation have also been observed with human bronchial smooth 
muscle cells [133], human bronchial epithelial cells [134] and human lung fibroblasts 
[135], which respond to adenosine by increased release IL-19 [134]. A2BAR 
activation on human lung fibroblasts promotes their differentiation into 
myofibroblasts that are capable of overproducing extracellular matrix [135], which 
suggests that adenosine may participate in the fibrosis and remodeling of the lung 
during asthma and COPD. Furthermore, increased A2AAR agonists have been found 
to decrease permeability of microvascular and inhibit release of chemotactic 
cytokines in lung inflammation. Mice lacking A2AAR was shown enhanced lung 
inflammation [136]. In addition, using A2AAR knockout mice, the A2AAR-cAMP axis 
was identified as a potent endogenous anti-inflammatory signaling pathway that 
reduces airway reactivity and inflammatory cell migration [137]. Thus, A2AAR 
agonists appear to be effective at curbing inflammatory lung tissue damage. 
In CNS, adenosine acts as a neuromodulator, integrating different brain functions. It 
can modulate CNS excitability at different levels and play a role in mechanisms of 
seizure susceptibility [138], cerebral blood flow [139], pain perception [140], basal 
ganglia function [141], sleep induction [142] and respiration [143].  
Adenosine has a potent function of vasodilation in most vascular beds. This 
nucleoside is marketed for myocardial perfusion scintigraphy in humans. It has also 
shown robust angiogenic effects and the main pro-angiogenic actions of adenosine is 
mediated by the induction of pro-angiogenic factors, such as basic fibroblast growth 
factor (bFGF) and vascular endothelial growth factor (VEGF). Adenosine also 
protects the myocardium form hypoxia and reperfusion injury through ischemic 
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preconditioning. Moreover, adenosine shows antiarrhythmic effect [144].  
Extracellular adenosine plays a role in kidney by affecting vascular and tubular 
functions.  By activating A1AR on afferent arterioles, adenosine lowers glomerular 
filtration rate by constricting afferent arterioles [145]. In contrast, it induces 
vasodilation in deep cortex and medulla via activation A2AAR [146]. Moreover, 
adenosine can also inhibit renin release and stimulates NaCl transport [147]. 
Adenosine has also contributed in glucose metabolism by increasing insulin 
sensitivity and glucose uptake [85].  
 
Adenosine, whose concentration increases within hypoxic regions of solid tumors, has 
been recognized able to interfere with the recognition of tumor cells by cytolytic 
effector cells of immune system [148]. Each of its receptor subtypes has pro- and 
anticancer effects. It appears that all the ARs are possible targets for the development 
of novel approaches to the treatment of cancer. The antitumorigenic role of A1AR in 
cancer was mainly studied in A1AR knockout mice, demonstrating that activation of 
the A1AR on microglia inhibits the growth of glioblastomas [149]. As for A2AAR, it 
has been suggested that this subtype blocks antitumor immunity. In the tumor 
environment of hypoxia and high adenosine levels, activation of A2AARs leads to 
immunosuppressive effects [150], which decreases antitumor immunity and thus 
encourages tumor growth. The role of the A2BAR in cancer is characterized as pro-
cancer player. Activation of A2BARs leads to the release of angiogenic factors that 
promote tumor growth [151, 152]. Adenosine accumulates at high levels in hypoxic 
regions of solid tumors, and several lines of evidence indicate that the A3AR is 
overexpressed in several solid tumors suggesting that it may be a tumor marker [153]. 
Furthermore it has been reported that it plays a pivotal role in the adenosine-mediated 
inhibition of tumor cell proliferation [154]. Therefore clinical trials have 
demonstrated the possibility of using A3AR agonists for treatment of cancer [155]. In 
vivo studies have shown that adenosine exerts a profound inhibitory effect on the 
induction of mouse cytotoxic T-cells, without substantially affecting T-cell viability 
[156]. The ability of adenosine to specifically inhibit tumor cell growth in vitro and in 
vivo suggests that the activation and/or blockade of the pathways downstream of 
adenosine receptors may contribute to tumor development. Furthermore, the 
extracellular adenosine concentration may be a crucial factor in determining the cell 
progression pathway, either in the apoptotic or in the cytostatic state [148].  
 
 
Alternate roles of adenosine in inflammation 
In many tissues and organs, adenosine receptor system has been taken as both a rapid 
sensor of tissue injury and the major ‘first-aid’ machinery [157]. Adenosine interacts 
with ARs on immune cells to modulate the inflammatory processes. Animal models 
of asthma, ischemia, inflammatory bowel disease, sepsis, arthritis and wound healing 
have shown the regulatory functions of different AR in dictating the development and 
progression of disease [157]. On one hand, increased concentration of extracellular 
adenosine represents a potent alarm molecule for reporting tissue. On the other, it 
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decrease tissue energy demand via a direct inhibitory effect on parenchymal cell 
function and provides a more favorable cellular environment by increasing nutrient 
availability via vasodilatation [158]. Adenosine receptors are expressed on different 
kinds of immune cells, such as mast cells, macrophages, neutrophil and lymphocytes.  
A large number of studies show that mast cell mediators, such as cytokines and 
histamine may play an important role in inflammatory diseases in response to 
adenosine [157]. Although A2A, A2B and A3ARs are all expressed on the cell 
membrane of mast cells [129], there is still not clear which receptors take response for 
the increased mast cell activation following AR activation. Adenosine can increase 
the secretion of the major asthma-promoting cytokine IL-13 by wild type mouse mast 
cells but not A2BAR knockout mouse cells. This result implies that A2BAR is the 
receptor that involved in pro-inflammatory effects of adenosine, such as cytokine and 
histamine release [130]. Furthermore, studies using ADA knockout mice suggested 
that elevated endogenous adenosine induced lung mast cell degranulation by engaging 
A3AR [131]. Thus, A2B and A3AR played different pro-inflammatory roles in primary 
mouse mast cells. A2BAR stimulation in human HMC-1 cells induces secretion of 
cytokines IL-4 and IL-13, as well as a number of other pro-inflammatory cytokines 
such as IL-1β and IL-8. In addition, IL-4 incubation resulted in the increased 
expression of A2B and reduced expression of A2AAR on human mast cells. These 
results suggest that Th2 cytokines in the asthmatic lung may alter adenosine receptor 
expression on airway mast cells to promote increased responsiveness to adenosine 
[159]. The observation of increased IL-4 and IL-13 production following AR 
activation strongly implicates human mast cell ARs as important players of human 
asthma. In chapter 4 of this thesis, new insights about IL-4 release in activated mast 
cells and the modulatory effect of A2AAR are presented. 
 In macrophages, the activation of A2AAR can limit tumor necrosis factor α (TNF-α) 
production following macrophage activation. Several studies agree that the A2AAR is 
the primary AR subtype that mediates inhibition of TNF-α [160-162]. A key role for 
A2AAR was discovered when adenosine failed to upregulate E.coli-induced IL-10 
release by macrophages lacking A2AARs but not in wild-type macrophages [163]. 
While A2BAR can be critical to the stimulatory effect of adenosine on IL-6 production, 
as NECA cannot induce the secretion of IL-6 in A2BAR knockout however, not wild-
type macrophages [162]. 
Adenosine is also a potent modulator of neutrophil functions. Through the activation 
of ARs in this cell type, this molecule can regulate phagocytosis and the production of 
reactive oxygen species (ROS) [164, 165]. Also, engagement of A2AAR has been 
shown to inhibit the production of a range of cytokines including TNF-α, macrophage 
inflammatory protein 1α (MIP-1α), MIP-1β, MIP-2α and MIP-3α [166]. A2AAR 
prevents neutrophils from undergoing apoptosis in inflamed site [167-169]. Thus, 
adenosine can be regarded as a general neutrophil function regulator. Lymphocyte 
function also appears to be potently regulated by A2AAR. For example, adenosine 
inhibits IL-2 production in CD8+ T cells, via A2AAR [170]. However, the production 
of neither IFN-γ nor IL-4 cytokines was influenced by A2AAR activation [78]. In 
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summary, A2AAR can regulate different inflammatory signaling pathways on different 
cell types, and represents a promising pharmacological target.  
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2.3 Aims and outline of this study 
 
Drugs aimed at regulating the adenosinergic system have been identified as promising 
therapeutic candidates with potential as inflammatory regulators. Medicinal chemistry 
has produced a large number of compounds capable of selectively binding the 
adenosine receptors  (a selection of which is presented in table 1). However, our 
understanding about the underlying signaling pathways and the cellular effector 
mechanisms dictating adenosine’s role in inflammation perpetuation or resolution has 
lagged behind, what has prevented the translation of promising candidate molecules 
(i.e. from disease models) into meaningful therapies. For this reason, the further 
development of AR-based strategies of immunomodulation requires knowledge of the 
molecular mechanisms that mediating adenosine’s effects in inflammatory processes.  
 
The aim of this work was to identify and characterize the cellular signals triggered by 
the activation of alternate ARs. A central aspect of adenosine’s role in inflammation 
is the interplay between different signaling cascades activated by the different AR 
subtypes, which in turn determine the shutdown or the perpetuation of inflammation. 
Our work was focused on mast cells, a key cellular type in the initiation and 
maintenance of inflammatory responses. Mast cells are strategically located at the 
host-environment interface, and upon activation by intruder pathogens and derived 
molecules they can release a large number of mediators that act locally and that also 
initiate cell recruitment and thereby acquired immune responses. Beyond their 
function in initiating allergic responses through the release of pre-formed vasoactive 
amines and other immediate inflammatory mediators though degranulation, mast cells 
can influence the function of neutrophils, monocytes and even lymphocytes through 
de novo synthesis of cytokines and chemokines, and thereby influence the direction of 
the immune response being the actual effector cells. The LAD-2 cell line (Laboratory 
of Allergic Diseases-2) has more recently been established [171]. These resemble 
primary cultures of CD34+-derived human mast cells, and are considered to be a well-
differentiated mast cell line. Based on this, HMC-1 and LAD-2 cells have been 
employed as an in vitro surrogate model to study molecular processes associated to 
adenosine signaling.  
 
In the first part of this thesis, we investigated A2AAR signaling translated into 
inflammatory downregulation, in the human mast cell line HMC-1, which expresses 
A2A, A2B and A3AR, and although it is an immature cell line, they have are suitable 
for the study degranulation independent process [172]. Transcriptional re-
programming of HMC-1 cells upon treatment with a non-selective AR agonist 
(adenosine analogue) was compared with the pattern obtained by selective A2AAR 
activation (A2AAR agonist) and by those of non-A2AAR mediated response (adenosine 
analogue plus an A2AAR antagonist). We reasoned that genome-wide transcriptional 
screening would allow the identification of AR-specific downstream factors involved 
in the modulation of inflammatory signaling in mast cells. Furthermore, a sharp 
induction of transcriptionally active NR4A2 and NR4A3 by the adenosine analogue 
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NECA was observed. These results were confirmed by RT-PCR and western blot at 
protein level. Furthermore, through the combination of receptor assays and 
pharmacological inhibition of signaling kinase we established a previously unknown 
link between AR activation and nuclear orphan receptors NR4A2 and 3. 
 
In the second part of this work the focus of our investigation was regulation of 
NR4As. The combination of PMA/ionomycin was employed to activate LAD-2 mast 
cell line. This cell line resembles the general characteristics and functions of primary 
tissue mast cells more closely than other cell lines. In particular, we wanted to 
determine whether modulation of the other pro-inflammatory signaling pathways by 
the A2AAR plays a significant role in suppressing inflammation. In addition, it was 
also necessary to study the post-translational modification of NR4A and its 
translocation. Moreover, we would like to identify the new downstream targets and 
interaction partners of NR4A2. This was to be achieved by identifying stimuli that 
induce NR4A2 expression and A2AAR could have consequences for regulating 
interactions between the A2AAR and NR4A2. 
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Abstract Nuclear orphan receptors 4A (NR4A) are early
responsive genes that belong to the superfamily of hormone
receptors and comprise NR4A1, NR4A2 and NR4A3. They
have been associated to transcriptional activation of multiple
genes involved in inflammation, apoptosis and cell cycle
control. Here, we establish a link between NR4As and
adenosine, a paradoxical inflammatory molecule that can
contribute to persistence of inflammation or mediate inflam-
matory shutdown. Transcriptomics screening of the human
mast cell-line HMC-1 revealed a sharp induction of transcrip-
tionally active NR4A2 and NR4A3 by the adenosine analogue
NECA. The concomitant treatment of NECA and the
adenosine receptor A2A (A2AAR) selective antagonist SCH-
58261 exaggerated this effect, suggesting that upregulation of
these factors in mast cells is mediated by other AR subtypes
(A2B and A3) and that A2AAR activation counteracts NR4A2
and NR4A3 induction. In agreement with this, A2AAR-
silencing amplified NR4A induction by NECA. Interestingly,
a similar A2AAR modulatory effect was observed on ERK1/2
phosphorylation because A2AAR blockage exacerbated
NECA-mediated phosphorylation of ERK1/2. In addition,
PKC or MEK1/2 inhibition prevented ERK1/2 phosphoryla-
tion and antagonized AR-mediated induction of NR4A2 and
NR4A3, suggesting the involvement of these kinases in AR to
NR4A signaling. Finally, we observed that selective A2AAR
activation with CGS-21680 blocked PMA-induced ERK1/2
phosphorylation and modulated the overexpression of func-
tional nuclear orphan receptors 4A. Taken together, these
results establish a novel PKC/ERK/nuclear orphan receptors
4A axis for adenosinergic signaling in mast cells, which can
be modulated by A2AAR activation, not only in the context of
adenosine but of other mast cell activating stimuli as well.
Keywords Nuclear orphan receptor 4A .Mast cells .
Adenosine . Adenosine receptor
Abbreviations
AR Adenosine receptor
HMC-1 Human mast cell line 1
NBRE-LUC Nerve-growth factor I-B responsive
element-luciferase reporter gene
NR4A1 Nuclear orphan receptor 4 A1
NR4A2 Nuclear orphan receptor 4 A2
NR4A3 Nuclear orphan receptor 4 A3
PKC Protein kinase C
RT-PCR Reverse transcriptase polymerase chain
reaction
Introduction
NR4A orphan receptors are transcription factors that belong
to the superfamily of steroid nuclear hormone receptors that
have been associated with different cellular processes,
including inflammation (Murphy et al. 2001; Pei et al.
2005), steroidogenesis (Manna et al. 2002), apoptosis
(Winoto and Littman 2002), development of dopaminergic
Concise summary Non-selective AR engagement triggers robust
induction NR4A orphan receptors in mast cells. Induction of these
early responsive genes can be blocked by selective activation of the
anti-inflammatory A2AAR not only in the context of adenosine but
also of PMA signaling, suggesting a general mechanism of mast cell
regulation.
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neurons (Zetterstrom et al. 1997) and glucose metabolism
(Pei et al. 2006b). This subfamily of nuclear orphan receptors
is constituted by 3 members: NR4A1 (also known as Nur77
or nerve growth factor inducible B, NGFI-B), NR4A2 (also
known as Nurr1) and NR4A3 (also known as NOR1). In the
context of inflammation, these factors represent NF-κB and
LPS-inducible genes in macrophages (Pei et al. 2005) and
NR4A1 expression leads to induction of inflammatory genes,
potentiating NF-κB pro-inflammatory signaling by IKKi
kinase upregulation (Pei et al. 2006a). In addition, NR4A2
has been recognized as an important inducible factor in
inflamed synovium and as a target of anti-inflammatory
effects of methotrexate (Ralph et al. 2005).
Adenosine is a purine nucleoside normally present in the
nanomolar range but its concentration in the extracellular space
rises with increased oxygen consumption during hypoxia,
tissue injury and inflammation. The rapid accumulation of
adenosine is followed by biological responses through activa-
tion of 4 types of G-coupled adenosine receptors (ARs): A1,
A2A, A2B and A3. Each of the receptor subtypes has a different
pharmacological profile, tissue distribution and effector cou-
pling profile. During chronic inflammatory processes the
sustained formation of adenosine has been associated with
deleterious effects. Elevated adenosine concentrations can be
found, for example, in bronchoalveolar lavage and exhaled
breath condesate of human patients with asthma (Driver et al.
1993; Huszar et al. 2002) where it perpetuates inflammation
and contributes to airway hyperresponsiveness. However,
activation of the A2AAR has been associated to the
suppression of inflammation and tissue remodelling (Fozard
2003; Ohta and Sitkovsky 2001) and inhibition of histamine
and tryptase release from human mast cells (Suzuki et al.
1998). However, the transcriptional effectors downstream of
AR activation responsible for adenosine’s pro or anti-
inflammatory effects remain to be characterized.
In this study, we employed the human mast cell HMC-1 to
characterize subtype specific effectors of AR activation and
we established a link between adenosine receptor activation
and nuclear orphan receptors. Furthermore, we determined
that activation of the A2AAR counterbalances the induction of
these transcription factors and that this effect is not limited to
adenosinergic signaling but that it is also conserved for other
mast cell activating stimuli. These observations describe a
novel regulatory mechanism by A2AAR, with implications in
the progression of inflammation and related pathologies.
Materials and methods
Reagents and cell culture
All chemicals were obtained from Sigma-Aldrich (Switzerland)
unless otherwise indicated. The human mast cell line-1
(HMC-1) was a kind gift from Dr. J. H. Butterfield, Mayo
Clinic, Rochester, MN, USA and was grown in Iscove’s
Modified Dulbecco’s Medium (IMDM, Invitrogen) supple-
mented with 10% iron supplemented fetal bovine serum
(Invitrogen), 1.2 mM alphathiglycerol (Sigma) and 100’000
U/l Penicillin and 100 mg/l Streptomycin (complete IMDM)
at 37°C in 5% CO2.
Cell treatments
HMC-1 cells were seeded at 8×105 cells/ml and allowed
to settle overnight. They were then treated at the indicated
concentrations with the following chemicals: the adeno-
sine analogue NECA (5′-N-Ethylcarboxamido-adenosine),
the A2AAR agonist CGS-21680 (9-Chloro-2-(2-furanyl)-
[1,2,4]triazolo[1,5-c]quinazolin-5-amine), the A2AAR an-
tagonist SCH-58261 (7-(2-phenylethyl)-5-amino-2-(2-
furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine)
and PMA (phorbol 12-myristate 13-acetate). The length of
treatment varied between 30 min and 72 h. Cells were
pretreated with 1 U/ml adenosine deaminase (Roche) to
remove any pre-existing endogenous adenosine for
20 min.
RNA extraction and cDNA synthesis
Cells were collected by centrifugation at the corresponding
time points and total RNA was recovered using the
Qiashredder and Rneasy mini kit (Qiagen). Concentration
and quality of total RNA were measured with the Ultraspec
2100 pro spectrophotometer (Amersham Biosciences).
Samples with a UV absorbance 260/280 ratio of 1.8–2.1
were considered to be suitable for cDNA synthesis. RNA
samples were stored at −20°C until use. Complementary
DNA (cDNA) was synthesized using the one-cycle cDNA
synthesis kit followed by a sample cleanup to optimize
volumes and concentration of the cDNA (GeneChip sample
cleanup module, Affymetrix).
Genome wide gene expression analysis
Global gene expression analysis was done in 4 independent
experiments, consisting of the treatment with 10 μM NECA
and untreated cells as a baseline control. After 3 h treatment
of HMC-1 cells total RNAwas extracted as described in the
previous section. The quality of RNA was determined on
the Agilent Lab-on-a-chip Bioanalyzer 2000 (Palo Alto,
USA). Samples with a total area under 28S and 18S bands
of less than 65% of total RNA, as well as a 28S/18S ratio of
less than 1.5, were considered to be degraded and therefore
excluded from microarray analysis. cRNA was synthesized
from cDNA with the IVT labeling kit (Affymetrix). cRNA
quality was assessed with the Agilent Lab-on-a-chip
174 L. Zhang et al.
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Bioanalyzer 2000. The biotin-labeled cRNA was frag-
mented and hybridized on Human Genome U122 plus
2.0 microarrays (Affymetrix), which cover sequences of
47’000 human transcripts, following the manufacturer’s
instructions. After hybridization periods of 16 h the
microarrays were automatically washed and stained on
the Affymetrix Fluidics Station 450. Staining of the
hybridized probes was performed with fluorescent
streptavidin-phycoerythrin conjugates (1 mg/ml; Molecu-
lar Probes). The subsequent scanning of DNA micro-
arrays was carried out on an Affymetrix scanner 3000
7 G. The generated data was then normalized and
subsequently filtered using a significance value of P<
0.05 using the GeneSpring 7.3.1 sofware (Agilent, Palo
Alto, CA, USA). We employed pair-wise analysis based
on B - Fabric infrastructure tool (Functional Genomics
Center Zurich, University of Zurich-Irchel, Switzerland)
and the GeneGo Metacore (www.genego.com) integrated
software for data mining and functional analysis of
experimental data. Hierarchical clustering was performed
with gplots library from CRAN.
Real time polymerase chain reaction (RT-PCR)
Specific primers for the selected transcripts as well as
TaqMan probes and TaqMan master mix were obtained
from Applied Biosystems. 40 ng of cDNA were mixed
with 1 μl of forward and reverse primers and 10 μl of
master mix supplemented with 25 nM of the
corresponding TaqMan probe in a final volume of
20 μl. The reactions were performed in a 7500 Fast
Real-time PCR-System ABI 7500 (Applied Biosystems)
in 40 cycles (95°C for 3 s, 60°C for 30 s) after an initial
20 s incubation at 95°C, and was analyzed with the 7500
Fast System SDS Software System (Applied Biosys-
tems). The fold change in expression of each gene was
calculated with the 2-Delta Delta C(T) method. Each of
these values had been normalized to the endogenous
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
Western blot
Thirty microgram of total protein in 1× Laemmli buffer
were separated on a 10% polyacrylamide gel by standard
SDS-PAGE technique from each sample, followed by
transfer onto Immune-Blot polyvinylidene difluoride
(PVDF) membranes (0.2 μm pore size, Bio-Rad) and
blocking 16 h at 4°C with blocking solution (5% non-fat
dry milk, 3% BSA in TBST (10 mM Tris, 150 mM
NaCl, 0.05% Tween 20, pH 7.4). NR4A2 and total ERK
protein levels were assessed employing a monoclonal
antibody (Alpha Diagnostic and R&D, respectively) and
phosphorylated ERK1/2 by a specific T185/Y187
phopsho-antibody (R&D, USA). GAPDH and β-actin
antibodies (Ambion, USA) were employed as internal
loading controls. Enhanced chemiluminescence was
performed with SuperSignal West Femto Maximum
(Thermo Fisher Scientific, Switzerland) and images were
acquired on a LAS-3000 image reader (Fujifilm Life
Science, Japan). NR4A2 induction was quantified by
calculating the ratio of intensity signals to GAPDH
(Quantity 1 software, BioRad) and compared to untreat-
ed controls (value=1).
siRNA silencing of A2AAR
0.4×106 HMC-1 cells in 1 ml were seeded in 24 well-
plates. Cells were transcfected with 20nM A2AAR siRNA
(Santa Cruz, Cat. sc-39850) using 4 μl lipofectamine
RNAiMax (Invitrogen) according to the manufacturer’s
instructions in Opti-MEM serum and antibiotics-free
medium. After 5 h of incubation, the medium was
replaced with complete medium. As a scramble negative
control, control (FITC Conjugate)-A siRNA (Santa Cruz,
sc-36869) was employed. Silencing of ARs was tested
by RT-PCR with specific TaqMan probes (Applied
Biosystems) as indicated above, and was maximal at
36 h. Therefore, this time point was selected for further
analysis of AR signaling.
Transient transfection and luciferase reporter gene assay
1.5×106 HMC-1 cells in 1 ml were co-transfected with the
tk-NBREx3-luc plasmid, which was a kind gift Dr. R
Evans (Howard Hughes Medical Institute, San Diego, CA)
and the pRL-TK vector (Promega, USA) at a ratio 30:1 in
serum- and antibiotics-free Iscove’s medium containing
8 μl of Lipofectamine 2000 reagent (Invitrogen). After 5 h
of incubation, the medium was replaced with complete
medium and were allowed to recover at 37°C for 24 h and
were subsequently stimulated as indicated. For luciferase
activity assay, cell lysates were prepared and assayed
using the Luciferase Assay System (Promega, USA),
according to the manufacturer’s instructions. All lumines-
cent measurements were performed automatically in a 96
well-plate in a Luminescence Spectrometer (MLX,
Dynex).
Data analysis
Statistical analysis was performed using the PASW Statis-
tics software (SPSS Inc., USA). Data were analyzed by
nonparametric tests (Mann-Whitney U-test) and differences
between groups were considered significant when p-values
were less than 0.05.
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Results
Transcriptional profiling of human mast cells reveals
upregulation of NR4A family memebers by adenosine
receptor activation
The human mast cell line HMC-1 exhibits a phenotype,
which in several aspects is similar to tissue resident mast
cells (Nilsson et al. 1994). However, these cells do not
degranulate and therefore represent a suitable system for
studying degranulation-independent de novo synthesis of
inflammatory mediators.
Previous studies have successfully used this cell line to
analyze adenosine signaling on human mast cells (Ryzhov
et al. 2006; Ryzhov et al. 2004), which prompted us to
employ a systematic genome-wide approach for the
identification of novel effector molecules involved in AR
signaling. For this, we stimulated HMC-1 cells to the
adenosine analogue NECA and 3 h after exposure the total
fraction of RNA transcripts was extracted, processed and
hybridized to Affymetrix microarrays (4 replicates). To
identify differentially expressed genes, the data sets of each
replicate were analysed in a pair-wise fashion with the
untreated controls as described in the methods section. This
analysis yielded 19 NECA-induced transcripts with fold
changes of three or higher (Table 1). The resulting heat map
reflects the degree of similarity between the individual
replicates (vertical dendogram, Fig. 1a). Gene ontology
analysis of these transcripts revealed that most of these
transcripts encode protein products involved in transcrip-
tion regulation (NR4A2, NR4A3, CREM , EGR1, 2 and 3,
FOSB, ELL2, ZEB1), signal transduction (HOMER1, ITK,
IL2RB), hormone activity (STC1, CGA), DNA metabolism
and repair (JMY, TP53INP2 ITK), cell cycle regulation
(RGC32), apoptosis (BCL2L11) and tissue remodeling
(PLAUR). Remarkably, two nuclear orphan receptors
(NR4A2 and NR4A3), which had not been associated to
adenosine signaling before, were among the highest
upregulated genes. Interestingly, the third member of
orphan receptor family, NR4A1, was induced only margin-
ally (2.05 fold). These results were confirmed by real time
RT-PCR (Fig. 1b) and suggest that NR4A2 and NR4A3
could mediate proinflammatory signaling by adenosine in
mast cells.
A2AAR inactivation amplifies NECA-mediated induction
of NR4A2 and NR4A3
Human mast cells express A2A, A2B, and A3ARs (Feoktistov
and Biaggioni 1998; Feoktistov et al. 2003). Therefore, the
observed response to NECA reflects the composite effect of
activation of all 3 receptor subtypes. Because AR subtypes
can promote (A2B and A3ARs) or downregulate (A2AAR)
inflammation, we wanted to determine the influence of
A2AAR in NR4A induction. To address this issue cells were
stimulated either with NECA, with the selective A2AAR
agonist CGS-21680, or with a combination of NECA plus
the A2AAR antagonist SCH-58261, and NR4A induction
Gene Name Description NECA FC
NR4A2 Nuclear receptor subfamily 4, group A, member 2 33.52
STC1 Stanniocalcin 1 25.37
NR4A3 Nuclear receptor subfamily 4, group A, member 3 24.13
CREM CAMP responsive element modulator 13.57
EGR3 Early growth response 3 10.16
RGC32 Response gene to complement 32 9.54
HOMER1 Homer homolog 1 (Drosophila) 7.95
FOSB FBJ murine osteosarcoma viral oncogene homolog B 6.91
CGA Glycoprotein hormones, alpha polypeptide 6.14
ELL2 Elongation factor, RNA polymerase II, 2 6.14
JMY Junction-mediating and regulatory protein 5.96
ZEB1 Transcription factor 8 5.42
EGR1 Early growth response 1 5.07
BCL2L11 BCL2-like 11 (apoptosis facilitator) 4.99
ITK IL2-inducible T-cell kinase 4.76
PLAUR Plasminogen activator, urokinase receptor 4.58
TP53INP2 p53 induced nuclear protein 2 3.88
IL2RB Interleukin 2 receptor, beta 3.78
EGR2 Early growth response 2 (Krox-20 homolog, Drosophila) 3.72
Table 1 Top regulated tran-
scripts by non-selective AR
stimulation. Cells were treated
with 10 μM NECA and fold
changes (FC) calculated against
untreated control as described
(fold change cut-off=3,
P<0.005)
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was assessed by RT-PCR. Figure 2a and b show time-
dependent induction of NR4A2 and NR4A3. While NECA-
mediated induction of NR4A2 and NR4A3 reached maximal
induction of 240-fold and 98-fold respectively 1 h after
treatment, selective activation of A2AAR with 1 μM CGS-
21680 did not induce them. In contrast, blockage of A2AAR
with the combined treatment of NECA and SCH-28261,
results in further upregulation of these nuclear receptors,
with fold changes up to 429 and 376 over the untreated
controls respectively. These observations point out that the
induction of these two transcription factors rely on the
activation of non-A2A ARs. Interestingly, NECA plus SCH-
58261 did not upregulate NR4A1 further when compared to
NECA (4.2-fold, Fig. 2c), indicating that this interplay
between non-selective and selective A2AAR activation is
not conserved to the third member of this family of
receptors. Also, induction of the cAMP-response element
modulator (CREM, a top-regulated gene from the tran-
scriptomics screening, see Table 1) reaches 55-fold when
treated with NECA, while CGS-21680 or the combination of
NECA plus SCH-58261 induce CREM only marginally,
indicating that simultaneous activation of all ARs is required
to achieve maximal CREM induction (Fig. 2d).
To confirm the role of A2AAR dependent changes in
NR4A2 and NR4A3 expression, HMC-1 cells were trans-
fected with A2AAR-specific siRNA, which led to 63%
silencing 36 h after transfection (Fig. 3a). Treatment of
A2AAR silenced cells with NECA resulted in higher
NR4A2 expression levels as compared to mock silenced
cells, mimicking the effect of pharmacological blockage of
A2AAR with the combination of NECA plus SCH-58261
(Fig. 3b). Altogether, these results indicate that activation of
A2AAR counterbalances NR4A2 and NR4A3 induction by
A2BAR and A3AR.
Adenosine receptor activation increases NR4A2 protein
abundance
Next, we wanted to determine whether AR-mediated
increment of NR4A2 mRNA levels translate into changes
in protein abundance. Western blot analysis of NR4A2
protein revealed that NECA treatment results in a remark-
able induction of this factors reaching maximal levels at
12 h, with values returning to background levels 24 h after
exposure (Fig. 4). As expected, selective A2AAR activation
with CGS-21680 did not upregulate NR4A2 (not shown).
However, induction of NR4A2 protein by the concomitant
treatment of NECA plus SCH-58261 was higher than with
NECA but also returned to basal levels within 24 h. These
results confirm that transcriptional upregulation of NR4A2
by AR activation results in increased protein levels.
AR-induced NR4As are transcriptionally active
In view of the strong induction of NR4A2 and NR4A3, we
performed a functional assay based on an exogenous
reporter gene to determine how the activity of these factors
is affected by AR activation. NR4A receptors bind to the
octanucleotide 5′-A/TAAAGGTCA (NGFI-B response ele-
ment, NBRE) and therefore we employed an NBRE-
luciferase reporter plasmid (tk-NBREx3-luc) and quantified
luciferase induction upon AR activation. Figure 5 shows
Fig. 1 a Hierarchical clustering analysis of transcriptional changes of
HMC-1 cells induced by NECA. Each column represents a single
experiment (4 replicates for each condition, untreated and treated with
10 μMNECA, 3 h) and contains all genes that were significantly
upregulated in at least one of replicates and a minimum induction of 3
fold. The resulting vertical dendrogram indicates the degree of
similarity between different transcriptomes. Expression levels are
expressed in a log 2 scale and transcripts with values of 5 or lower
(blue and light blue) are marginally expressed or absent. Repeated
gene names indicate different probe sets for a single gene (different
expression signals for alternative probe sets could indicate alternative
splicing or poor probe performance). b Confirmation of NR4A induction
by RT-PCR. Fold changes are calculated in relation to untreated
controls. Values represent the mean of three experiments ± SEM
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time-dependent induction of luciferase activity upon treat-
ment with NECA, CGS-21680 or NECA in combination
with SCH-58261. Both NECA and NECA plus SCH-58261
induced a robust response, which peaked between 12 h and
24 h with nearly a 30- and 40-fold reporter induction as
compared to untreated controls respectively. NBRE reporter
activity decreased sharply by 48 h and returned to
background values 72 h after treatment. On the contrary,
CGS-21680, did not induce luciferase expression signifi-
cantly. Interestingly, reporter induction by NECA plus
SCH-58261 was not statistically significantly higher than
by NECA, despite the remarkable difference in induction of
these transcription factors. This discrepancy can be
explained by the intrinsic limitations of the artificial
reporter gene system employed. The luciferase construct
includes a minimal promoter region in the 5′-regulatory
Fig. 4 Western blot analysis of NR4A2. HMC-1 cells were treated
with 10 μM NECA, or the combination of 10 μM NECA and 1 μM
SCH-58261 (SCH) for the indicated time points. GAPDH is included
as an internal control. Fold change of NR4A2 protein (FC) are
calculated from the ratio to GAPDH and compared to baseline
expression in untreated cells (lane 1)
Fig. 3 Effect of A2AAR silencing on NR4A2 induction. a Transfec-
tion of HMC-1 cells with A2AAR-siRNA (A2AAR si) specifically
downregules this receptor subtypeation of A2AAR. Scramble siRNA
was included as a control b A2AAR silenced cells were treated with
for 2 h with 10 μM of NECA or 10 μM of NECA plus 1 μM SCH-
58261 (SCH). Values represent the mean of three independent
experiments ± SEM
Fig. 2 Time dependent induc-
tion of NR4A2 (a), NR4A3 (b),
NR4A1 (c) and CREM (d).
Cells were treated with 10 μM
NECA, 1 μM CGS-21680
(CGS) or 10 μM NECA plus
1 μM SCH-58261 (SCH) and
RNA was collected at the indi-
cated time points and analyzed
by RT-PCR. Fold changes are
calculated against untreated
controls. Values represent the
mean of three independent
experiments ±SEM
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region of the NBRE repeats. Therefore, this assay may not
allow the full response (gene expression) that could be
expected in the context of endogenous chromatin to take
place, thereby limiting the amplitude of the responses
measured and of the differences between treatments.
Nevertheless, these results confirm that AR activation
induces transcriptionally active NR4As that could have
profound biological implications.
AR-mediated NR4A2 and NR4A3 upregulation
involves PKC and MEK kinases, and correlates
with A2AAR-, PKC- and MEK-sensitive ERK1/2
phosphorylation
NR4As can be induced by a variety of stimuli, which are
signaled through diverse intracellular regulators in a cell
type and stimulus-dependent fashion (Martinez-Gonzalez
and Badimon 2005). Therefore, we wanted to determine the
intracellular signaling pathways participating in NR4A2
and NR4A3 induction by ARs. To address this issue we
interrogated the role of the mitogen-activated kinase p38,
protein kinase A (PKA), phosphoinositide 3 kinase (PI3K),
protein kinase C (PKC) and MEK kinase with selective
inhibitors, by assessing the AR-mediated induction of
NR4A2 and NR4A3 (NECA plus SCH-58261). While
30 min pretreatment with SB203580 (p38 inhibitor), H89
(PKA inhibitor) and wortmannin (PI3K inhibitor) did not
affect NR4A induction, blockage of either PKC or MEK
with GF109203X or PD98059 respectively partially
reverted AR-mediated induction of these factors (Fig. 6a).
Based on previous reports that showed that ERK phosphor-
ylation is involved in AR inflammatory signaling in HMC-
1 cells (Feoktistov et al. 1999), and because ERK1/2 is a
downstream target of PKC, we wanted to determine
whether activation of A2AAR correlates with ERK phos-
Fig. 5 Time-dependent induction of NBRE by AR engagement. The
results are shown as ratio against the respective untreated control. For
each measurement the ratio between the reporter gene (firefly) between
and the internal Renilla standard was calculated (three independent
determinations). Cells were treated with 10 μM NECA, 1 μM CGS-
21680 (CGS) or 10 μM NECA plus 1 μM SCH-58261 (SCH)
Fig. 6 Effect of kinase inhibi-
tors on AR-mediated NR4A
induction and ERK1/2 activa-
tion a Pretreatment with MEK
and PKC inhibitors partially
reversed NR4A2 and NR4A3
induction by 10 μM NECA and
1 μM SCH-58261. 0.5 μM
SB203580 (SB), 1 μMH89,
0.1 μM wortmannin (Wt),
100 μM PD98059 (PD) or
10 μM GF109203X (GF) were
employed for preincubation. b
A2AAR-blockage excacerbates
NECA-induced phosphorylation
of ERK1/2 (N+SCH). This ef-
fect is blocked by preincubation
with PD98059 (PD) and
GF109203X (GF) in a concen-
tration dependent way
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phorylation. NECA readily induced phosphorylation of
ERK1/2 while CGS-21680 did not (Fig. 6b, lanes 2 and 3).
Interestingly, NECA plus SCH-58261 resulted in exaggerated
ERK1/2 phosphorylation (lane 4), demonstrating an inverse
relationship between A2AAR activation status and ERK1/2
phosphorylation. Furthermore, this pattern of ERK phos-
phorylation could be reverted by preincubation with
GF109203X or with PD98059 in a concentration dependent
manner (lanes 5–8). Taken together, these results indicate
that PKC and MEK kinases are required for AR-dependent
ERK1/2 phosphorylation and NR4A2 and NR4A3 upregu-
lation, and that activation of A2AAR opposes ERK1/2
activation by other ARs.
A2AAR activation modulates PMA-induced ERK
phosphorylation, NR4A2 and NR4A3 induction
and NBRE transcriptional activity
Next, we wanted to assess whether A2AAR activation is
able to influence NR4A induction by stimuli other than
adenosine. Therefore, we selected PMA, a diester of
phorbol that acts as a PKC activator, which is a central
regulatory molecule with a role in cytokine production,
arachidonic acid release and mast cell degranulation (Chang
et al. 1997; Cho et al. 2004). Stimulation of HMC-1 cells
with PMA resulted in robust ERK1/2 phosphorylation that
could be reverted with increasing concentrations CGS-
21680 (Fig. 7a). In addition, 1 μM CGS-21680 significant-
ly decreased PMA-mediated NR4A2 and NR4A3 induction
(by 35 and 53% respectively, Fig. 7b) and, moreover, levels
of PMA-induced NR4A2 protein were also reduced
(Fig. 7c). In light of these findings, we tested whether
A2AAR activation could affect the transcriptional activity of
PMA-induced NR4As, by means of the NBRE-LUC
reporter assay. Remarkably, preincubation with 1 μM
CGS-21680 caused a significant reduction in PMA-
induced NBRE-LUC activity (35%, Fig. 7d).
Altogether, these results show that the inhibitory effect
of A2AAR on nuclear orphan receptor 4A stimulation is
conserved beyond adenosinergic inflammatory signaling
and that activation of this receptor can regulate intracellular
signaling by other inflammatory stimuli.
Discussion
Mast cells have been traditionally associated to immediate-
type hypersensitivity reactions through the release of
preformed inflammatory mediators. However, in recent
years it has become clear that these cells can regulate
immune responses through de novo synthesis of cytokines,
chemokines, and eicosanoids without degranulation (differ-
ential release inflammatory mediators), supporting a role of
Fig. 7 Effect of A2AAR activation on PMA-mediated NR4A activity.
a Increasing concentrations of CGS-21680 (CGS) antagonize PMA-
induced ERK1/2 phosphorylation. β-Actin is included as an internal
control, b Reduction of PMA-mediated NR4A2 and NR4A3 tran-
scriptional induction by increasing concentrations of CGS-21680
(CGS). Values are relative to induction by PMA and indicate the
mean of three independent experiments ± SEM. *, **: p<0.05 for
reduction in NR4A2 and NR4A3 induction respectively (Mann-
Whitney U test), c Western blot analysis of NR4A2 induced by
PMA alone or with the indicated concentrations of CGS-21680, d
CGS-21680 (CGS) reduces the transcriptional activity of PMA-
mediated NBRE-LUC reporter activity. For each measurement the
ratio between the reporter gene (firefly) and the internal Renilla
standard was calculated. Values are relative to LUC expression by
PMA, and represent the mean of three independent experiments ±
SEM. PMA concentration in all experiments was 50 nM. *p<0.05 for
NBRE-LUC activity reduction (Mann-Whitney U test)
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mast cells in more persistent (chronic) inflammatory and
immunological responses such as chronic bronchitis and
asthma-related pulmonary inflammation (Brightling et al.
2003; Church and Levi-Schaffer 1997), renal injury (Mack
and Rosenkranz 2009), and tumorigenesis (Blatner et al.
2010; Groot Kormelink et al. 2009).
The engagement of activating and inhibitory cell-surface
receptors, as well as the intensity and duration of these
signals, will determine the activation state of mast cells; in
response to these stimuli, gene expression patterns of
inflammatory mediators are altered according to the sum
of positive and negative signaling events, thereby affecting
the course of inflammation. Based on adenosine’s ability to
both positively and negatively regulate mast cell activation
through the engagement of alternate AR subtypes, it has
been argued that selective activation of the A2AAR (anti-
inflammatory) or blockage of A2BAR and A3AR (proin-
flammatory) may represent a pharmacological tool for
modulating their adenosinergic inflammatory signaling.
However, transcriptional effectors downstream of ARs
responsible for adenosine’s pro- or anti-inflammatory
effects remained to be fully characterized.
In this study we present a novel link between AR
activation and NR4A orphan receptors in human mast cells,
and we show that selective activation of the A2AAR can
negatively regulate the induction of these factors. Our
initial genome-wide screening revealed strong upregulation
of NR4A2 and NR4A3. Recent evidence shows that
NR4A2 induction represents a common point of conver-
gence of distinct cytokine signaling pathways, suggesting
an important common role for this family of transcription
factors as mediating inflammatory signaling (McEvoy et al.
2002). Therefore, we reasoned that the anti-inflammatory
A2AAR could influence the expression of these pro-
inflammatory factors. In fact, we observed that the concom-
itant treatment with the A2AAR antagonist SCH-58261
significantly amplified NECA’s effect on NR4A2 and
NR4A3 induction. In view of the pleiotropic physiological
roles of NR4As, adenosine’s effect on this group of
transcription factors could have broad biological implications.
In contrast to other members of the nuclear hormone
receptor superfamily, the crystal structure and NMR data
indicate that the ligand-binding pocket of NR4A receptors
is covered by hydrophobic residues (Wang et al. 2003). In
fact, these receptors have been shown to function as ligand-
independent transcription factors that are constitutively
active and whose activity is controlled at the level of
protein expression and post-translational modifications
(Codina et al. 2004; Fahrner et al. 1990). For this reason,
adenosine’s effects on the abundance of these transcription
factors could have immediate biological implications. On one
hand, the activation of pro-inflammatory ARs (i.e. A2B and
A3ARs) in inflammatory cells could act as an amplification
signal resulting in even higher levels of NR4As and in the
expression of a larger set of NBRE-responsive genes. On the
other, A2AAR activation could mediate inflammation reso-
lution indirectly by limiting the expression of NR4A2 and
NR4A3-dependent inflammatory genes.
NR4As also influence the function of other inflammation-
associated transcription factors. For example, NR4A1 and
NR4A2 form heterodimers with retinoic acid receptor and
can influence retinoid signaling (Wallen-Mackenzie et al.
2003). Therefore, AR activation could affect the number of
NR4A-containing complexes: AR-mediated accumulation
of NR4A2 and NR4A3 would translate in a higher
proportion of transcriptional complexes containing these
orphan receptors. Conversely, A2AAR activation would
limit the availability of NR4A2 and NR4A3 for hetero-
dimerization with other TFs. In addition, NR4A receptors
can also crosstalk with other TFs and influence their
activity without necessarily interacting with them. A recent
study has established that NR4A receptors and the
estrogen-related receptors NR3B mutually repress each
others transcriptional activity (Lammi et al. 2007). Similar-
ly, NR4A1 has been shown to negatively cross-talk with
NF-κB (Harant and Lindley 2004). As a consequence, by
virtue of the induction of reamarkably high levels of
functional NR4A2 and NR4A3, adenosine is likely pro-
foundly affect the expression of large sets of genes both
directly (NBRE-responsive transcripts) and indirectly, by
affecting the nature of transcriptional complexes and/or
crosstalking with other TFs.
Activation of mast cells (for example by the high affinity
IgE receptor) requires the activation of receptor-proximal
tyrosine kinases, mobilization of internal Ca2+ and the
formation of signaling complexes coordinated by adaptor
proteins (Rivera and Gilfillan 2006). PI3K is a central player
in mast cell activation that signals to regulatory molecules
such as PKC and phospholipases C and D (PLC and PLD)
among others, which ultimately regulate mast cell degranu-
lation, arachidonic acid metabolite production and cytokine
gene transcription. AR activation has traditionally been
linked to stimulation or inhibition of the adenylyl cyclase;
A2AAR and A2BAR activation lead to increased cAMP
levels that in turn activate the canonical PKA pathway and
the exchange protein directly activated by cAMP (Epac)
(Palmer and Trevethick 2008), while A1AR and A3AR
activation leads to cAMP decrease (Zhou et al. 1992). In
addition, AR signaling in mast cells has also been linked to
PLC and calcium mobilization (A2BAR and A3AR), PI3K
(A3AR), as well as PKC and MAP kinases (A1, A2A and
A3AR) (Jacobson and Gao 2006; Spicuzza et al. 2006).
Several intracellular regulators have been linked to
NR4A induction (Martinez-Gonzalez and Badimon 2005).
In this study we established that AR-mediated NR4A2 and
NR4A3 upregulation in HMC-1 did not involve PKA nor
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PI3K nor p38. Instead, PKC and MEK kinase inhibition
could partially revert the induction of these factors and,
moreover, the activity of these kinases correlated with
ERK1/2 phosphorylation. Interestingly, some studies have
also shown the involvement of ERKs in adenosine
signaling (Feoktistov et al. 1999) but downstream targets
of ERK upon AR activation had remained elusive. The
results presented here suggest that activation of ERK1/2
kinases downstream of PKC mediates NR4As induction by
AR. Remarkably, A2AAR can counterbalance NECA-
induced ERK1/2 phosphorylation, correlating with its
modulatory effect on NR4A2 and NR4A3 induction.
However, blockage of PKC and a complete inhibition of
ERK phophorylation resulted only in about a 50% decrease
NR4A2 and NR4A3 induction, suggesting the involvement
of at least one additional intracellular signaling pathway in
AR-dependent nuclear orphan receptor upregulation in mast
cells. The contribution of other intracellular signaling
pathways remains to be investigated.
Finally, we examined whether the antagonistic effect of
A2AAR on ERK1/2 phosphorylation and NR4A2 and
NR4A3 induction is preserved to other mast cell activating
stimuli, by the concomitant activation of A2AAR and mast
cell stimulation with PMA. Strikingly, A2AAR engagement
resulted not only in a modulation of PMA-mediated ERK1/
2 phosphorylation, but also limited NR4A2 and NR4A3
induction, and their activity as assessed by the NBRE-LUC
reporter assay. These results show that A2AAR modula-
tory’s effect on the ERK1/2-NR4A signaling axis is not
limited to adenosinergic signaling.
Taken together, the results presented in this study
establish a novel effector signaling axis downstream of
adenosine, and suggest NR4A antagonism as a mechanism
mediating A2AAR anti-inflammatory effects in mast cells.
Thus, this data contributes to the understanding of how
receptor-specific signals are integrated towards modulation
of the inflammatory response, which could facilitate the
development of AR-based strategies of immunomodulation.
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Abstract 
Nuclear orphan receptors 4A (NR4A) are early responsive genes that belong to the 
superfamily of hormone receptors and comprise NR4A1, NR4A2 and NR4A3. Here 
we report that the stimulation of LAD-2 human mast cells with a combination of 
phorbol 12-myristate 13-acetate PMA (P) and the calcium ionofore Ionomycin (I) led 
to NR4A2 upregulation. In addition, we describe that this treatment induces 
phosphorylation-dependent ubiquitination of NR4A2. Cell fractionation and 
immunofluorescence approaches showed that P/I-induced phosphorylation-dependent 
ubiquitination led to an accumulation of NR4A2 to the endolysosomes and 
endoplasmic reticulum 6 h after treatment, and that inhibition of the proteasome with 
MG132 increased the accumulation of modified NR4A2 in these organelles. To 
characterize the biological meaning of NR4A2 post-translational modifications we 
analysed changes in NR4A2 downstream effectors, in particular of IL-4. P/I treatment 
strongly induced IL-4 transcription and release, which was dependent on 
PKC/MEK/ERK signaling and could be reverted NR4A2 silencing. MG132 
pretreatment enhanced P/I-induced IL-4 release 6 h after treatment (in correlation 
with the accumulation of NR4A2 in cytoplasmic organelles), but strongly reduced IL-
4 release, despite the effect of MG132 on stabilizing NR4A2 in cytoplasmic 
organelles. These observations suggested the late release of IL-4 could depend on 
another factor. In fact, pretreatment with the NF-κB inhibitor BAY 11-7082 
significantly inhibited the release of this cytokine at a late time point and MG132 also 
inhibited NF-κB activation, strongly suggesting that the late inhibitory effect of 
MG132 on IL-4 release could be mediated by inhibition of NF-κB signaling. 
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Furthermore, NR4A2 silencing partially reduced NF-κΒ-luc reporter activity, 
suggesting that NR4A2 is required for the activation NF-κB at a later time-point. 
These results indicate that while NR4A2 is the central transcriptional factor driving 
IL-4 release in the early phase (6 h), NF-κB becomes determinant factor in IL-4 
synthesis later time points. Finally, selective A2AAR activation (CGS-21680) showed 
the inhibitory effect on NR4A2 expression and NF-κB activity, as well as IL-4 
induction. Thus, our data presented here suggests that through the modulation of IL-4 
release via NR4A2 and NF-κB signaling, A2AAR activation in mast cells can 
negatively influence the development of allergic Th2 responses. 
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Introduction 
The NR4A subfamily of orphan nuclear receptors include NR4A1 (Nur77), NR4A2 
(Nurr1) and NR4A3 (NOR-1). NR4A receptors are rapidly and strongly induced by a 
wide array of stimuli, such as stress, growth factors and inflammatory signals [1-3], 
and they have been implicated as important transcriptional mediators of inflammatory 
signals in several organs including lung [4], brain [5], liver [6], skeletal muscle [7], 
blood vessels [8], adipose tissue [9] and immune cells [10]. NR4A2 has been 
recognized as an important inducible factor in inflamed synovium and as a target of 
anti-inflammatory effects of methotrexate [11]. 
Because they are constitutively active, ligand-independent transcription factors, the 
activity of NR4As is tightly controlled at the level of expression. In addition, NR4A1 
has been shown to be modulated by phosphorylation modifications that shuttles this 
factor to the mitochondria acting as an apoptotic signal [12]. In the case of NR4A2, 
phosphorylation has been shown to affect the transcriptional activity of this factor 
[13]. However, although NR4A2 has been shown to possess putative sumoylation 
sites [14], no furhter post-translational modifications of this factor have been 
characterized to date. A recent study has shown a different expression and 
nucleocytoplasmic pattern for NR4A2, suggesting that yet undescribed post-
translational modifications could control the cellular distribution of this factor [15] . 
Adenosine is a purine nucleoside that accumulates in the extracellular space in 
response to increased oxygen consumption during hypoxia, tissue injury and 
inflammation [16]. This nucleoside acts as a rapid inflammatory signal, triggering 
divergent biological responses through the activation of 4 types of G-coupled 
adenosine receptors (ARs). While the ARs A1 and A2B and A3 have been mainly 
associated with pro-inflammatory signaling [17-19], activation of the A2AAR in a 
wide variety of immune cells results in a wide range of anti-inflammatory and 
immunosuppressive responses, including cytokine production, immune cell 
proliferation, leukocyte recruitment and phagocytosis [20-22] and the suppression 
tissue remodeling [23, 24].  
The role of mast cells as effector cells in a variety of pathological conditions [25] is 
becoming better understood. Classically, mast cells have been associated with the 
release of preformed mediators stored in the secretory granules upon the engagement 
of high affinity IgE receptors (FcεRI) [26]. However, several other stimuli are capable 
of inducing upregulation of inflammatory cytokines independently of degranulation, 
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including inflammatory mediators, complement factors, and bacterial and viral 
components [27]. Recently, we established that activation of pro-inflammatory ARs 
induce a rapid and robust upregulation of NR4A2, which could be counterbalanced by 
the simultaneous activation of the anti-inflammatory A2AAR receptor [1-3].  
To further our understanding of the mechanisms involved in NR4A2 signaling in 
activated mast cells, in this study we characterized the sequence of events triggered 
by the concomitant activation with PMA and the calcium ionofore ionomycin in 
LAD-2 human mast cells. We we report that this treatment results in upregulation and 
phosphorylation-dependent ubiquitination of NR4A2 and that this post-translational 
modfication induces its accumulation in endoplasmic reticulum (ER), and the endo-
lysosomal compartment, which correlated with the induction of ER-stress markers. 
Furthermore, this treatment results in a NR4A2-dependent sustained release of IL-4, 
although NF-κB is required for the late phase release of this interleukin. 
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Materials and methods 
 
Reagents and cell culture 
All chemicals were obtained from Sigma-Aldrich (Switzerland) unless otherwise 
indicated. LAD-2 cells were kindly provided by Dr. A. Kirshenbaum (Laboratory of 
Allergic Diseases, National Institute of Allergy and Infectious Diseases, National 
Institute of Health, Bethesda, MD 20892-1881). Cells were incubated at 37 °C, 5% 
CO2 in StemPro-34 serum-free medium (Invitrogen, Switzerland), supplemented with 
2 mM glutamine, 100 IU/mL penicillin, 50 µg/mL streptomycin and 100 ng/mL 
recombinant human stem cell factor (Peprotech, UK). Cells were not grown above a 
density of 0.5 × 106 cell/ml.  
 
Cell treatments 
LAD-2 cells were seeded at 8 × 105 cells/ml and allowed to settle overnight. They 
were then treated at the indicated concentrations with the following chemicals: PMA 
(phorbol 12-myristate 13-acetate), ionomycin (calcium ionophore A23187), the 
adenosine analogue NECA (5′-N-Ethylcarboxamido-adenosine), ubiquitin E1 ligase 
inhibitor UBEI-41 (4 [4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl]-
benzoic acid ethyl ester) (BioGenova, US), the A2AAR agonist CGS-21680 (9-
Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine) and the proteasome 
inhibitor MG132 (N-(benzyloxycarbonyl) leucinylleucinylleucinal Z-Leu-Leu-Leu-
al).  
 
RNA extraction and cDNA synthesis 
Cells were collected by centrifugation and total RNA was recovered using the 
NucleoSpin RNA II (Macherey-Nagel, Switzerland). Concentration and quality of 
total RNA were measured with the Ultraspec 2100 pro spectrophotometer (Amersham 
Biosciences, Switzerland). Samples with a UV absorbance 260/280 ratio of 1.8–2.1 
were considered to be suitable for cDNA synthesis. RNA samples were stored at 
−20°C until use. Complementary DNA (cDNA) was synthesized using high-capacity 
cDNA reverse transcription kits according to the manufacture’s protocols (Applied 
biosystem, Switzerland). 
 
 
39
Real time polymerase chain reaction (RT-PCR) and RT-PCR human chemokine array 
Specific RT-PCR primers for the selected transcripts as well as TaqMan probes and 
TaqMan master mix were obtained from Applied Biosystems. 40 ng of cDNA were 
mixed with 1 µl of forward and reverse primers and 10 µl of master mix 
supplemented with 25 nM of the corresponding TaqMan probe in a final volume of 
20 µl. The reactions were performed in a 7500 Fast Real-time PCR-System ABI 7500 
(Applied Biosystems, Switzerland) in 40 cycles (95°C for 3 s, 60°C for 30 s) after an 
initial 20 s incubation at 95°C. For RT-PCR array, cDNA (40 µg) was mixed with 500 
µl Taqman master mix, and the final volume of 10 µl/well was loaded on 96 well 
human chemokine gene array, which was preloaded 96 Taqman probes in the plates 
(Applied Biosystems, Switzerland). Quantitative RT-PCR was run for 35 cycles in 
standard mode using an ABI 7500. Raw data were processed using SDS 2.2.1 
software (Biorad, Switzerland). The fold change in expression of each gene was 
calculated with the 2-Delta C(T) method. Each of these values had been normalized to 
the control gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
 
siRNA knockdown 
LAD-2 cells were transcfected with 20 nM siNR4A2, siA2AAR, siCHOP, siRELA 
(NF-κB p65) (Qiagen, Switzerland) using 4 µl lipofectamine RNAiMax (Invitrogen, 
Switzerland) according to the manufacturer’s instructions in Opti-MEM (Invitrogen, 
Switzerland) serum and antibiotics-free medium. After 5 h of incubation, the medium 
was replaced with complete medium for 48 h. As a scramble negative control, control 
(FITC Conjugate)-A siRNA (Santa Cruz, Switzerland) was employed. Knockdown 
efficacy was tested by rt-PCR or western blot analysis. 
 
Co-immunoprecipitation assay 
 LAD-2 cells were stimulated with PMA/ionomycin (P/I), and lysed 6 h in the 2x 
detergent lysis buffer containing 2% SDS, 100 mM Tris (pH 7.5), 10 mM DTT, 
Proteinase Inhibitor Cocktail (Roche, Switzerland). They were immediately boiled for 
10 min and sonicated for 4 s. After centrifugation, the supernatant was diluted with 4 
volumes of NP-40 buffer with containing 25 mM Tris (pH 7.5), 1 mM EDTA, 10% 
glycerol, 1% Nonidet P-40, 0.25 mM PMSF, 200 mM NaCl and Proteinase Inhibitor 
Cocktail. The mixture was incubated with anti-NR4A2 antibody or IgG protein 
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overnight at 4 °C. Complexes were covered by incubation with 30 µl of protein A 
agarose/Salmon Sperm DNA (Millipore, Switzerland) for 10 h at 4 °C. Precipitates 
were washed serially with 1 ml of TNET buffer twice (50 mM Tris, pH 7.5, 140 mM 
NaCl, 1% Triton X-100), and then twice with 1 ml of TNE buffer (50 mM Tris, pH 
7.5, 140 mM NaCl). The proteins remaining with the resin were analysed by 
immunoblot assays using the anti-NR4A2 (Santa Cruz, Switzerland) and anti-
Ubiquitin (FK-2, Millipore, Switzerland). 
 
Subcellular fractionation 
Briefly, LAD-2 cells were harvested and washed twice with PBS. Cell pellets were 
resuspended in fraction buffer which contained 250 nM sucrose, 20 nM HEPES, 10 
mM KCL, 1.5 mM MgCl2, 1 mM EDTA, and left on ice for 20 min. Spun it for 5 min 
at 720× g. The supernatant (cytoplasmic) was collected for further analysis. The pellet 
was washed once with fraction buffer and dispersed with a pipette and pass through a 
25 G needle 10 times. Centrifuged again at 3,000 rpm for 10 min. Removed the wash 
buffer and resuspended the pellet (nuclei) in Laemmli buffer, sonicated briefly on 
once before further analysis. Mitochondria and endoplasmic reticulum (ER) fractions 
were isolated according to the published protocols [28]. Briefly, 4 x 107 LAD-2 cells 
were wash with PBS twice and resuspensed in homogenization buffer (0.25 M 
cucrose, 10 mM HEPES, pH 7.4). Crude ER (supernatant, SN) was separated form 
crude mitochondria (pellet) by centrifugation at 15,000 g for 10 min. For ER 
purification, SN was loaded to discontinuous sucrose gradients and centrifuged at 
28,000 rpm for 70 min (AH-629 rotor, Sovall). Collected ER gradients and 
centrifuged at 26,000 rpm for 45 to pellet, and then resuspended ER pellet for further 
analysis. For mitochondrial purification, crude mitochondrial (pellet) was 
resuspended to sucrose gradients and centrifuged at 27,000 rpm for 22 min (TLA 
100.4 rotor). Collected mitochondrial gradients and spun at 15,000 g for 10 min to get 
mitochondrial pellet. Lysosomal fraction was performed mainly as described by 
Kjeldsen et.al for neutrophils [29]. Briefly, 3x107 LAD-2 cells were washed once with 
25 ml of phosphate buffered saline (PBS). The pellet was resuspended in 700 µl of 
homogenization buffer (HB; 340 mM sucrose, 10 mM HEPES, 0.3 mM EDTA, pH 
7.3) and subjected to 2 freeze/thaw cycles. The homogenate was sonicated and then 
spun at 3,000 rpm for 10 min to pellet nuclei. The PNS was collected and applied on a 
two-layer Percoll gradient. The Percoll was diluted with HB and gradient densities 
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were 1.05 and 1.12 (1.2 ml/layer). The gradient was layered in 3.2 ml polycarbonate 
ultracentrifugation tubes (Beckman, Switzerland). After applying the PNS on top of 
the gradient, the samples were spun at 30,000 rpm for 50 min (TLA 100.4 rotor) in a 
Beckman Optima TLX ultracentrifuge (Beckman). Fractions of 100 µl were collected 
starting from the top of the gradient. The fractions were washed twice at 43,000 rpm 
for 45 min for removing percoll and stored for further analysis. 
 
Western blot 
30 µg of total protein in 1× Laemmli buffer was separated on a 10% polyacrylamide 
gel by standard SDS-PAGE technique from each sample, followed by transfer onto 
Immune-Blot polyvinylidene difluoride (PVDF) membranes (0.2 µm pore size, Bio-
Rad, Switzerland) and blocking 16 h at 4°C with blocking solution (5% non-fat dry 
milk, 3% BSA in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.4). 
NR4A2 protein levels were assessed employing the NR4A2 antibody (1:2,000), 
phosphorylated ERK1/2 (1:2,000) by a specific T185/Y187 phospho-antibody and 
quantified by total ERK1/2 (1:2,000) (R&D, UK. Anti-tubulin (1:5,000, Ambion, 
Switzerland), anti PARP-1 (1:2,000, Alexis, Switzerland), anti-MnSOD (1:2,000, BD 
biosciences, Switzerland), anti-PERK (1:2000, Cell signaling, Switzerland), anti-
LAMP1 (1:2,000, Santa cruz) were using as the marker for cytoplasm, nuclear, 
mitochondrial, endoplasmic reticulum and lysosome, respectively. Anti-GAPDH 
antibody (1:10,000, Ambion) was employed as internal loading control. Enhanced 
chemiluminescence was performed with SuperSignal West Femto Maximum (Thermo 
Fisher Scientific, Switzerland) and images were acquired and quantified on a LAS-
3000 image reader (Fujifilm Life Science, Japan). Protein induction was calculated 
the ratio of intensity signals to GAPDH (Quantity 1 software, BioRad) and 
normalized to untreated controls. 
 
Immunofluorescence  
1x106 LAD-2 cells were transfected with 2 µg eGFP-Rab5, eGFP-Rab7, eGFP-
LAMP1 and eGFP control plasmids with 10 µl Lipofectamine 2000 (Invitrogen) for 4 
h. After different stimulations, the cells were cytospun on the slides and fixed with 
4% paraformaldehyde (PFA) in PBS for 10 min at room temperature (RT), 
permeabilized with 0.2% triton X-100 in PBS for 5 min at RT, blocked with 0.1% 
BSA in PBS for 30 min at 37°C, and incubated 1 h at 37°C with the anti-NR4A2 
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antibody (1?200, Santa cruz) or anti-calnexin antibody (1:200, Santa cruz). Next, 
coverslips were incubated for 1 h with AlexaFluor594-conjugated goat anti-rabbit 
secondary antibody (1:200, Invitrogen) or AlexaFluor488-conjugated goat anti-mouse 
secondary antibody (1:200, Invitrogen). For counterstaining, cells were incubated for 
10 min at 37°C with 1 µg/ml 4′,6-diamidino-2-phenylindole (DAPI) in PBS. Between 
each step, the sections were washed in PBS 3 times for 5 min each. After washing, 
coverslips were mounted on microscope slides with Fluoromount G (Interchim, 
Switzerland) and analyzed in a confocal microscope (SP5, Leica Microsystems, 
Germany), using an oil immersion 63× objective. Co-localization of staining was 
analyzed in single optical sections obtained for three channels by Imaris (Bitplane, 
Switzerland). The results were analyzed from cells expressing NR4A2/calnexin 
(n=32), NR4A2/eGFP-Rab5 (n = 35), NR4A2/eGFP-Rab7 (n = 36), and NR4A2/ 
eGFP-Lamp1 (n = 28). The intensity of foci was quantified by the function of 
‘Analysis Particles’, and the colocalization ratio of NR4A2/endolysosome was 
analyzed by JACoP plugin of ImageJ and Imaris ‘color’ function. 
 
IL-4 ELISA  
The IL-4 level in the cell culture supernatants were determined with an anti-human 
IL-4 ELISA kit (Peprotech, UK) according to the manufacturer’s instructions. Briefly, 
ELISA plates were coated with the capture antibody (0.5 µg/ml) by overnight 
incubation at RT. Nonspecific binding sites were blocked by 1 h incubation at RT 
with 1% BSA in PBS. The supernatants from the LAD-2 cultures were tested by 2 h 
incubation at RT. The plates were then incubated for 2 h at RT with the detection 
antibody (0.25 µg/ml), followed by 30 min incubation with avidin-HRP conjugate. 
Bound complexes were detected by reaction with ABTS liquid substrate. Absorbance 
was measured at 405 nm using an ELISA plate reader. The cytokine concentration in 
the samples was calculated as pg/ml using recombinant human IL-4 as a standard.  
 
Transient transfection and luciferase reporter gene assay 
1.5 × 106 LAD-2 cells in 1 ml were co-transfected with the tk-NBREx3-luc plasmid, 
which was a kind gift Dr. R Evans (Howard Hughes Medical Institute, San Diego, 
CA) or wt-κB and the pRL-TK vector (Promega, Switzerland) at a ratio 30:1 in Opi-
TEM medium containing 10 µl of Lipofectamine 2000 reagent. After 5 h of 
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incubation, the medium was replaced with complete medium and were allowed to 
recover at 37°C for 24 h and were subsequently stimulated as indicated. For luciferase 
activity assay, cell lysates were prepared and assayed using the Luciferase Assay 
System (Promega), according to the manufacturer’s instructions. All luminescent 
measurements were performed automatically in a 96 well-plate in a Luminescence 
Spectrometer (MLX, Dynex, Switzerland). 
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Results 
 
PMA and ionomycin triggers NR4A2 upregulation and phosphorylation-dependent 
ubiquitination  
Members of the NR4A subfamily of orphan receptors have emerged as key 
transcriptional regulators of cytokines that can be strongly induced by inflammatory 
stimuli. Here we wanted to establish the involvement of NR4A2 in PMA and 
ionomycin (P/I) signaling in LAD-2 mast cells. RT-PCR analysis showed that 6 h 
after treatment both PMA and Ionomycin induced a remarkable upregulation of 
NR4A2 in LAD-2 cells, and that the combined P/I treatment potentiated this effect 
(Fig 1A). In agreement with our previous results, NR4A2 induction with the 
adenosine analogue NECA at this time point was lower [1]. None of these treatments 
affected cell viability (supplementary Fig 1). Western blot analysis confirmed that 
NECA, PMA and Ionomycin treatment lead to increased NR4A2 protein levels (Fig 
1B). Interestingly, in addition to the bands at the expected NR4A2 molecular weight 
(66 kDa), P/I resulted in additional slow migrating bands, with a predominant one of 
about 77KDa (Fig 1B). To confirm the identity of this band, LAD-2 cells were 
transfected either with NR4A2 specific or scramble siRNA (efficiency of NR4A2 
silencing 74.2%, supplementary Fig 2) and analysed by western blot (Fig 2). This 
experiment confirmed the identity of these slow migrating bands, suggesting that P/I 
treatment induces post-translational modifications (PTM) on NR4A2.  
The size difference between the expected (66KDa) and the main slow migrating band 
(77KDa) would suggest that NR4A2 had been modified by ubiquitination. To test this 
hypothesis, cell lysates lysates were incubated with anti-NR4A2 antibody, and the 
enriched fractions tested by co-imunoprecipitation with an anti-ubiquintin antibody 
(Fig 3A). High molecular weight smear-like signals were detected between the 75 and 
the 100KDa MW marker. In addition, treatment with the E1 ubiquitination inhibitor 
41 (UBEI-41), attenuated the 77KDa NR4A2 band in a dose dependent manner (Fig 
3B). In fact, UBEI-41 concentrations of 25 µM and higher completely reverted the 
shifted pattern, resulting in abundant unmodified NR4A2 at 66KDa.  
Next, we wanted to determine whether ubiquitination is the primary PTM on NR4A2 
in response to P/I, or whether ubiquitination depends on other PTM. The presence of 
much weaker high-molecular weight bands associated to the main 77KDa band, 
would be compatible with phosphorylation. Therefore LAD-2 cells were pre-
45
incubated with alkaline phosphatase, which desphosphorylates phosphorylated 
proteins for 30 min (ALP, 20 U/ml). Pre-incubation with ALP in fact prevented the 
appearance of high molecular weight NR4A2 bands upon P/I treatment, suggesting 
that phosphorylation is involved in NR4A2 PTMs (Fig 3C). However, incubation of 
the cell lysate with ALP did not modify the pattern of NR4A2 modification, 
indicating that phosphorylation is required for ubiquitination, but not for the retention 
of the ubiquitin molecules on NR4A2.  
Since ubiquitin acts as a tag for proteosomal degradation, we next wanted to assess if 
proteasome blockage with MG132 affect the abundance of ubiquitinated NR4A2 
species. Indeed, pre-incubation with 1 µM of MG132 for 2 h, resulted in a remarkable 
accumulation of high-molecular weight NR4A2 6 h after treatment with P/I. 
Furthermore, 24 h after treatment ubiquitinated NR4A2 signals were also stronger, 
suggesting that proteasome inhibition prolongs NR4A2 turnover (Fig 3D). Altogether 
these results demonstrate that P/I induces both upregulation and phosphorylation 
dependent ubiquitination of NR4A2 and that proteasome inhibition seem to stabilize 
the modified NR4A2.     
 
Post-translational modifications induce NR4A2 accumulation in the endoplasmic 
reticulum and endolysosomes 
Beyond their role as transcription factors, nuclear orphan receptors 4A have been 
associated with alternative functions in different cellular organelles. Therefore, we 
wanted to examine whether ubiquitination of NR4A2 could influence its localization 
within the cell. Whole cell lysates were separated into nuclear and cytoplasmic 
fractions, and western blots were performed with α-NR4A2 antibody (Fig 4A). 
Nucleo-cytoplasmatic fractionation efficiency was confirmed both with α-tubulin 
(cytoplasmic) and α-PARP-1 (nuclear). This analysis showed that upon P/I treatment, 
the ubiquitinated NR4A2 (77KDa) predominantly localized to the cytoplasm. 
Interestingly, a much weaker band bellow the 77KDa band was detected in the 
nuclear fraction both in untreated and P/I-treated cells, suggesting that an alternative 
PTM pattern might be required for nuclear localization. However, unlike the 77KDa 
band, this nuclear NR4A2 fraction was not influenced by P/I treatment.   
To further characterize the cytoplasmic localization of NR4A2, mitochondrial (MIT), 
endoplasmic reticulum (ER) and lysosome (LYS) fractions were analysed 6 h after P/I 
treatment. MnSOD, PERK and LAMP1 antibodies were used as subcellular markers 
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of each of these fractions, respectively (Fig 4B). Ubiquitinated NR4A2 was 
predominantly detected in the ER and lysosomal fractions, while no NR4A2 signals 
were detected in the mitochondrial fraction. In addition, the localization patterns of 
NR4A2 induced by P/I with or without MG132 pre-treatment both at 6 and 24 h were 
analysed (Fig 4C).  While MG132 pre-treatment strongly enhanced the early (6 h) 
accumulation of high-MW NR4A2 both in ER and lysosome, weak NR4A2 signals 
could be detected exclusively in the lysosomal fraction at later time points (24 h). 
In order to further characterize NR4A2 localization in the LAD-2 cells, NR4A2 
trafficking was analysed by immunofluorescence with confocal microscopy. While no 
NR4A2 signals could be detected either in nucleus or cytopplasm, after 6 h P/I 
treatment NR4A2 positive foci could be detected in the cytoplasm, as well as a much 
weaker and difuse nuclear signal (Fig 5A). The identiy of these signals was confirmed 
by NR4A2 silencing, and MG132 pretreatment increased NR4A2 signals by 31% at 
this time point (Fig 5B). To confirm co-localization of NR4A2 to ER, LAD-2 cells 
were incubated with α-NR4A2 and α-calnexin (ER marker). 41% of P/I-induced 
NR4A2 colocalized with calnexin, while MG132 pre-treatment increased co-
localization to 62% (percentage of total NR4A2 signal). Next, LAD-2 cells were 
transfected with eGFP-Rab5 (early endosome marker), eGFP-Rab7 (late endosome 
marker) or eGFP-LAMP1 (lysosomal marker), co-stained with α-NR4A2. While the 
expression of eGFP-Rab5, eGFP-Rab7 and eGFP-LAMP1 remained unchangedwith 
all treatments tested, quantitative colocalization analysis revealed that 6 h after P/I 
treatment 18% of the NR4A2 cytoplasmic signals colocalized with Rab5, 21% with 
Rab7 and 17% with LAMP1 (Fig 5C). Pretreatment with MG132 further enhanced 
NR4A2 colocalization to the endolysosomal compartment to 37%, 32% and 26% to 
the early endosome, late endosome and lysosome, respectively.  
The previously decribed cell fractionation studies suggested that MG132 affects the 
turnover rate of NR4A2, resulting in increased accumulation of this factor in 
lysosome 24 h after P/I tretament (in the lysosome, Fig 4C). Therefore, we wanted to 
confirm the distribution pattern of NR4A2 in the different compartments by 
immunofluorescence at this late time point (Fig 5D). In agreement with western blot 
observations, NR4A2 IF signals were much weaker at this time point, which could not 
be mapped to the early endosome, late endosome or lysosome. However, MG132 
pretreatment enchanced NR4A2 signals by 17% which colocalized with Rab 7 (12%),  
cand LAMP1 (7%). 
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Taken together, these results indicate that P/I-induced ubiquitination consititues a 
signal for NR4A2 localization to the endoplasmic reticulum, early and late 
endosomes, and lysosomes, and that proteasome inhibition stabilizes ubiquitinated 
NR4A2, resulting in increased levels of this protein in these cytoplasmic structures 6 
h after P/I treatment and, to a lesser extent, at a late time points (24 h).  
 
NR4A2 mediates PMA and Ionomycin-induced IL-4  
We next wanted to establish the biological relevance of NR4A2 ubiquitination. 
Therefore, we first wanted to identify cytokines whose expression depends on NR4A2. 
Real time RT-PCR was carried out using a human chemokine RT-PCR array that 
allowed assessing the transcription of 90 human chemokines and chemokine receptor 
genes. This screening revealed 18 gene products that were up-regulated in LAD-2 
cells by P/I, 6 h after treatment (Suppl Fig 3). Remarkably, the induction of 8 of these 
gene products could be significantly reversed by silencing NR4A2, suggesting that 
the expression of these chemokines depend on this factor. The effect of NR4A2 
silencing was very pronounced for interleukin-4 (IL-4), a cytokine involved in T-cell 
differentiation into Th2 effector cells in allergen-driven responses. Therefore, this 
interleukin was selected for further analysis. RT-PCR confirmed the upregulation of 
this cytokine upon 6 h P/I stimulation (936-fold, as compared to untreated cells), 
which could be largely reversed by NR4A2 knockdown (81.6-fold, Fig 6A). Next, we 
wanted to confirm whether NR4A2 silencing also affects the release of IL-4 to the 
cellular milieu. Treatment with P/I indeed induced robust IL-4 release to the cell 
culture medium, from 39 pg/ml (unstimulated) to 423 pg/ml 6 h after treatment and to 
1152 pg/ml 24 h after treatment (11-fold and 29-fold respectively). Interestingly, the 
concentration of IL-4 was significantly decreased by NR4A2 silencing (Fig 6B), 
although this effect most more pronounced at the early time point (6 h: 63% reduction; 
24 h: 25% reduction). Next, we wanted to identify the signaling kinases involved in 
IL-4 induction. In a previous report we showed that AR-mediated NR4A2 
upregulation involved PKC, MEK and ERK kinases [1-3] . Here showed that 
blockage of either PKC or MEK with GF109203X (10 µM) or PD98059 (100 µM) 
respectively partially reverted P/I-induced IL-4 release 6 h (Fig 6C), but not 24 h after 
P/I stimulation. Next we evaluated P/I stimulation activated  ERK phosphorylation. 
Indeed, ERK1/2 was phosphorylated 6 h after P/I treatment, and it returm to basal 
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levels by 24 h. Interestingly, although MG132 pre-treatment further enhanced 
ERK1/2 phosphorylation at the early time point (Fig 6D), NR4A2 silencing did not 
affect ERK1/2 phosphorylation. Altogether, these results indicate that early release of 
P/I-induced IL-4 (6 h) is mediated by PKC and ERK kinases and largely dependent 
on NR4A2, although the late release of IL-4 (24 h) appears to involve additional 
signaling pathways.  
 
NR4A2 stabilization stimulates early IL-4 release but inversely correlates with late 
IL-4 concentrations  
Based on the observation that NR4A2 silencing extensively prevented IL-4 induction, 
particularly at an early time point, and that pre-treatment with MG132 enhanced 
NR4A2 abundance, we reasoned that proteasome inhibition might result in increased 
levels of these cytokine. To assess this hypothesis the effect of MG132 pre-treatment 
on IL-4 induction and release was assessed 6 h and 24 h after P/I treatment. At the 
transcriptional level, MG132 pre-treatment further upregulated IL-4 6 h after P/I 
treatment by 37.5% (1255-fold), although this effect was not longer observed 24 h 
after treatment (Fig 7A). Similarly, MG132 pre-treatment induced a robust release of 
IL-4 6 h after treatment, which reached 789.4 pg/ml (102%) higher than without 
MG132 pre-treatment), suggesting a casual relationship between the accumulation of 
NR4A2 and IL-4 release (Fig 7B). However, MG132 reduced the late release of P/I-
induced IL-4 induction by 59.0 % (from 1416.6 pg/ml to 581.5 pg/ml), suggesting a 
biphasic effect of proteasome inhibition on IL-4 synthesis. The fact that a reduction of 
IL-4 release was observed, despite the stabilization of NR4A2 by MG132, suggests 
that late P/I-induced late release of IL-4 may depend on another factor. 
 
NR4A2 and NF-κB control the early and late IL-4 release, respectively  
Since proteasomal degradation of IκB is required for the activation of NF-κB [30], we 
reasoned that this signaling pathway could be involved in late phase IL-4 release. To 
address this question we first wanted to assess the transcritional activity of NR4A2 by 
means of the NBRE-LUC reporter assay both 6 and 24 h after P/I treatment LAD2 
cells were transiently co-transfected with tk-NBREx3-luc and the pRL-TK plasmids 
(transfection normalization), stimulated with P/I and luciferase/renilla ratios 
calculated (Fig 8A). This analysis revealed a strong induction of the NBRE reporter at 
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both time points (7.0 and 8.7-fold against untreated, respectively). As expected, 
MG132 pre-treatment resulted in further increase in these signals (12.5 and 15.7-fold). 
In order to establish whether nuclear factor NF-kappa-B (NF-κB) activation 
conditions NR4A2 response, NBRE transcriptional activation was assessed after 
silencing of NF-κB p65 subunit. This assay revealed a strong NBRE activity 
independent of p65 at an early time point. However, 24 h after exposure p65 silencing 
resulted in a significant decrease in NBRE activity (31.5%), indicating a late cross-
talk between both transcription factors. 
Conversely, we next wanted to establish whether NR4A2 is required for NF-κB 
activation. Therefore, LAD-2 cells were co-transfected  with the wt-κB-LUC and the 
Renilla plasmids and transcriptional acitivity calculated as described (Fig 8B). P/I 
induced a robust luciferase responseboth 6 h and 24 h after P/I treatment (20.4-fold 
and 44.5-fold, respectively). As expected, p65 silencing completely blocked the 
induction of this reporter system. Also, this reponse strongly blocked by the NF-κB 
inhibtor BAY11-7082 (56.7% reduction at 6 h and 56.3% reduction at 24 h), and by 
MG132 pre-treatment, indicating that an intact proteasome is indeed required for NF-
κB activation. However, NR4A2 silencing revealed a dual effect on NF-κB activity; 
while early NF-κB activity was independent of this orphan receptor, wt-κB -LUC 24 
h after P/I stimulation was almost completely prevented by NR4A2 silencing, 
indicating that late NF-κB is dependent on NR4A2.  
To further characterize the downstream effects of NR4A2 and NF-κB signaling, we 
next assessed early and late IL-4 release (Fig 8C). In contrast to NR4A2 silencing, 
knockdown of p65 did not affect the release of IL-4 6 h after P/I treatment, 
confirming that the early IL-4 response depends on NR4A2. However, 24 h after P/I 
stimulation, silencing p65 had a dramatic effect in IL-4 release (from 1373.8 to 668.3 
pg/ml). In addition, treatment with BAY11-7082 also resulted in a remarkable 
reduction of IL-4 (from 1373.8 to 467.5 pg/ml), which was almost identical to the 
inhibition by MG132, indicating that NF-κB is required for the late phase response. 
Interestingly, the 24 h decrease in NF-κB activity observed by NR4A2 silencing (Fig 
8B) correlated with a partial  reduction of IL-4 at this late time point, suggesting that 
late NF-κB responses require a functional NR4A2. Altogether, these results confirm 
that while early IL-4 response is highly dependent on NR4A2, the involvement of 
NF-κB signaling in the late IL-4 release (24 h), in an NR4A2-dependent way. 
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Adenosine receptor A2A modulates NR4A2 expression, post-translational 
modifications and IL-4 release 
Activation of the adenosine receptor A2A (A2AAR) has been linked to inflammation 
suppresion and tissue remodelling [23, 31] and recently we observed that the 
stimulation of this A2AAR modulates NR4A2 induction by the adenosine analogue 
NECA and by PMA in human mast cells. Therefore, we now wanted to assess 
whether A2AAR activation could play a similar modulatory role on P/I-induced 
NR4A2 ubiquitination and downstream signaling. RT-PCR analysis revealed that pre-
treatment with 1 µM of the A2AAR agonist CGS-21680 reduced P/I-mediated NR4A2 
upregulation from 1120.7 fold to 575.7 fold (48.6% reduction), 6 h after treatment 
(Fig 10A). Furthermore, western blot analysis confirmed that CGS-21680 negatively 
influenced NR4A2 ubiquitination (Fig 10B) and also that A2AAR silencing 
exacerbated NR4A2 high molecular weight signlas, indicating that this AR receptor 
subtype negatively regulates NR4A2 ubiquitination. Next, we wanted to assess 
whether A2AAR-mediated decrease of NR4A2 post-translational modifications 
correlates with a decrease in NR4A2 localization to cytoplasmic organelles. Indeed, 
immunofluorescence confirmed that CGS21680 significantly reduced the number and 
intensity of NR4A2 foci (42.1%) (Fig 10C).  
Finally, we wanted to establish whether CGS-21680 modulatory effect on NR4A2 
signaling was associated with decreased NBRE and NF-κB activity and IL-4 release. 
Luciferase reporter assays indeed confirmed that CGS-21680 pre-treatment caused a 
significant reduction both in P/I-induced NBRE-LUC activity at 6 h (49.8%) and on 
P/I-induced NF-κB activity at 24 h (wt-κB -LUC, 38.1%) (Fig 10D), and these 
changes correlated with a significant decrease of IL-4 release 6 and 24 h after P/I 
treatment (48.7 and 53.0%, respectively; Fig 10E). In summary, these experiments 
show that activation of the A2AAR can modulate IL-4 release through downregulation 
of NR4A2 signaling and the associated NF-κB activity. 
 
Discussion 
In recent years the role of mast cells as regulators of immune responses have become 
better understood. Beside their involvement in immediate release of preformed 
inflammatory mediators in allergic responses, it is now widely accepted that mast 
cells can sustain inflammation through the  can differential release of inflammatory 
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mediators [32]. Our previous work identified a remarkable upregulation of NR4A2 
and NR4A3 receptors in HMC-1 mast cells in response to adenosinergic signaling [1], 
suggesting that this family of receptors could represent broader markers of mast cell 
activation. In fact, NR4A1 upregulation and phosphorylation has been reported in 
response to different mast cell stimuli [33]. The goal of this study was to further 
characterize NR4A2 pro-inflammatory signaling and downstream effectors in mast 
cells, and to assesses the effect of the antiinflammatory adenosine receptor A2AAR on 
this pathway.   
Nuclear orphan receptors 4A are structurally related to nuclear hormone receptors and 
have been shown to function as ligand-independent transcription factors expressed in 
a wide variety of metabolically active tissues [2, 34]. Because they are constitutively 
active transcription factors, activity of NR4As is tightly controlled at the level of 
expression, subcellular localization and post-translational modification [35]. NR4A2 
can be phosphorylated by ERK2 at S126 and T132, and these post-translational 
modifications appear to play a role in regulation in the expression of the tyrosine 
hydoxylase [36]. More recently, phosphorylation of NR4A2 by DNA-PK has been 
shown to be required for proficient DNA double-strand break repair [13]. NR4A2 has 
2 putative sumoylation sites at lysines 91 and 577 [14], although no sumoylation, 
ubiquitination or methylation of NR4A2 have yet been identified.  
The first main finding of the study was the identification of phosphorylation-
dependent ubiquitination of NR4A2 in mast cells, upon the concomitant treatment 
with PMA and ionomycin. First, we observed by western blot analysis that  P/I 
stimulation led to a high molecular band of approximately 75KDa, while the expected 
size of full length NR4A2 is 66KDa. Second, the appearance of this high molecular 
band could be inhibited UBEI-41, an inhibitor of the ubiquitin E1 enzymes, which 
catalyse the first step in the ubiquitination reaction. Third, immunoprecipitated 
NR4A2 specifically cross-reacted with ubiquitin antibodies, resulting in a signal 
suggestive of (poly)ubiquitination of about 75KDa. Fourth, proteasome inhibition 
with MG132 enhanced this high-molecular weight band both 6 h and 24 h after P/I 
treatment, suggesting that ubiquitination directs NR4A2 to proteasomal degradation. 
In addition, while treatment of cell lysates with alkaline phosphatase did not affect the 
ubiquitination pattern, pre-incubation with this phophatase significantly reduced 
ubiquitination of NR4A2, indicating that phosphorylation preceeds ubiquitination.  
Previous studies showed that phosphorylation of NR4A1 regulates nuclear export, and 
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cytoplasmic and mitochondrial localization [37]. Here we report that ubiquitinated 
NR4A2 locates in cytoplasma. Furthermore, cell fractionation and confocal 
microscopy allowed us to determine that unlike phosphorylated NR4A1, ubiquitinated 
NR4A2 localizes to ER, endosomes and lysosomes. Furthermore, proteasome 
inhibition with MG132 enhanced NR4A2 signals in these organelles 6 h after P/I 
stimulation, and prolonged the residence time of NR4A2 in the endolysosomal 
compartment (signals could be detected 24 h after P/I treatment at the later) . 
Secretory lysosomes in granulocytes are most often preformed structures storing 
secretory products while awaiting stimulation [13, 38]. Our result strongly suggested 
NR4A2 translocation to lysosome as a stimulation signal of the preformed IL-4 at the 
early phase. 
The second main finding in this study was the identification of a sustained, NR4A2-
dependent IL-4 release upon P/I treatment in mast cells. By a combination of 
silencing and reporter assay approaches, we showed that the early IL-4 response (6 h 
after P/I treatment depends on NR4A2. Proteasome inhibition could further increase 
both the tk-NBREx3-luc reporter activity and early IL-4 release. On the contrary, late 
IL-4 release did not correlate with NBRE activity, but with NF-κB activity as 
assessed with the wt-κB reporter assay. Three independent approaches support this 
hypothesis. First, in agreement with previous studies that demonstrated that MG132 
prevents IκB degradation, a step required for NF-κB translocation into the nucleus 
[39], pre-treatment with MG132 resulted in a reduced late IL-4 release. Second, NF-
κB inhibition with BAY11-7082 resulted in a similar effect. Third, silencing of NF-
κB subunit p65 almost completely abolished the release of this cytokine (Fig 8C). 
Interestingly, although NF-κB is already activated at an early time point, this 
transcription factor is not required for this early response, since at this time point 
neither p65 silencing nor MG132 pretreatment affected P/I-induced IL-4 levels (Fig 
8C). On the contrary, while NR4A2 silencing did not affect early NF-κB it had a very 
marked effect both on NF-κB activity and IL-4 release 24 h after P/I tratment (Fig 8B 
and 8C). These results suggest 2 phases of NF-κB activativity: an early phase, 
independent of NR4A2 and not required for early IL-4 release, plus a later phase 
dependent on NR4A2 and capable of driving IL-4 release at this stage. Several studies 
have investigated the cross-talk between NR4As and NF-κB. Both NR4A1 and 
NR4A2 have been proposed as a downstream target of NF-κB in response to 
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inflammatory mediators [40, 41]. More recently, NR4A2 has been shown to 
contribute with NF-κB towards the expression of IL-8 [42]. The data presented here 
complements these forms of cross-talk between NR4A2 and NF-κB, suggesting that 
P/I treatment generates a signal from NR42 to NF-κB, at least in the late time points 
(24 h). However, this data does not allow to conclude whether this effect is mediated 
by the direct upregulation of NF-κB subunits, or whether NF-κB activation is 
indirectly linked to NR4A2 signals such as NR4A2-induced ER stress. Here we show 
that the accumulation of ubiquitinated NR4A2 in the ER leads to the induction of 
CHOP, a surrogate of ER-stress [43, 44]. Interestingly, ER stress can lead to NF-κB 
activation by at least 3 different pathways: through TRAF2 dependent IKK 
phosphorylation; through PERK-induced phosphorylation of eIF2α, which decreases 
IκB protein by repression of IκB translation, leading to interference with the export of 
nuclear NF-κB to the cytoplasm; or through ATF6, which causes activation of NF-κB 
via the Akt pathway [45]. Further studies will be required to establish the relevance of 
NR4A2-mediated ER stress in late NF-κB activation and IL-4 induction.  
IL-4 is a prototypic immunoregulatory cytokine responsible for initiating allergic 
responses and it essential is uniquely required to polarize naïve helper cells (Th0 
cells) to a type 2 phenotype, characterized by secretion of IL-4 itself, plus IL-5, IL-9, 
IL-10, and IL-13. IL-4 also induces B cells to switch their immunoglobulin 
production to IgE secretion. Mast cells and basophils readily produce IL-4 after 
crosslinking of their FcεRI receptors [46]. Here we present a novel link between P/I 
activation of mast cells and IL-4 release, and we show that the late release of IL-4 
depends on NR4A2-induced NF-κB activity, suggesting that although proteasome 
inhibition enhances early IL-4 release, it could potentially translate in downregulation 
of sustained, IL-4 mediated allergic responses in vivo. 
Finally, we showed the inhibitory effect of the adenosine receptor A2A on NR4A2 and 
NF-κB dependent IL-4 induction. Although several lines of evidence support the anti-
inflammatory effect of the A2AAR, the mechanism behind these effects have remained 
elusive. In vitro studies using endothelial cells have indicated that the ability of the 
A2AAR to exert such wide-ranging anti-inflammatory effects could be explained by its 
ability to regulate pro-inflammatory signaling pathways [47, 48]. In addition, it has 
previously been shown that that activation of T lymphocytes can be suppresed by  
A2AAR activation [49], and that CGS21680 could succesfully suppress asthmatic 
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inflammation in animal models [31]. Therefore, the data presented here suggests that 
through the modulation of IL-4 release, A2AAR activation in mast cells can negatively 
influence the development of allergic Th2 responses.  
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Figure 1A 
 
 
 
Figure 1B 
 
Figure 1. P/I-induced NR4A2 expression (A) RT-PCR shows NR4A2 induction at 2 
h by PMA (25 nM), Ionomycin (1 µM), combination of PMA with ionomycin (P/I) 
and NECA (10 µM). Fold changes are calculated in relation to untreated controls. 
Values represent the means of three experiments ± SEM (B) Western blot analysis of 
NR4A2 expression. Cell extracts of untreated, treated with 0.1 µM ionomycin, 25 nM 
PMA, P/I and 10 µM NECA for 6 h, respectively. GAPDH is included as an internal 
control 
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Figure 2 
 
Figure 2. Transfection of LAD-2 cells with NR4A2 siRNA for 48 h. Western blot 
shows specific downregulation of NR4A2 expression induced by P/I. Scramble 
siRNA was included as a control. GAPDH is included as an internal control 
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Figure 3A 
 
 
 
Figure 3B 
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Figure 3C 
 
 
Figure 3D 
 
Figure 3. Phosphorylation-dependent ubiquitination of NR4A2 (A) LAD-2 cells were 
treated with or without P/I for 6 h. The total protein lysate was immunoprecipitated 
using anti-NR4A2 antibody or IgG control. Probing blots with anti-ubiquitin antibody 
revealed ubiquitinated NR4A2 by P/I. Migration of molecular mass standards is 
indicated in KDa (B) Pretreatment of ubiquitin E1 ligase inhibitor (UBEI) for 2 h, 
western blot shows the reversion NR4A2 induction by P/I in a dose-dependent 
manner (C) Phosphorylation dependent ubiquitination of NR4A2. LAD-2 was 
pretreated with alkaline phosphatase (ALP, 20 U) in cell culture or applied in protein 
lysate with P/I.  (D) LAD-2 was pretreated with MG132 (1 µM) for 2 h. Total protein 
was harvested after 6 h or 24 h with P/I treatment. GAPDH is included as an internal 
control 
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Figure 4A 
 
 
Figure 4B 
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Figure 4C 
 
 
 
 
Figure 4. NR4A2 was located at endoplasmic reticulum (ER) and lysosome. 
Subcellular fractionation of NR4A2 obtained by differential centrifugation and 
analyzed by western blot. LAD-2 cells were treated with P/I and protein was harvest 
after 6 h (A) Fractions obtained during the purification of cytoplasmic and nuclear 
were analyzed by western blot. Tubulin and PARP-1 were using as the markers for 
cytoplasmic and nuclear (B) Mitochondrial, endoplasmic reticulum (ER) and 
lysosome fractions were isolated. MnSOD, PERK and LAMP1 were using for cell 
compartmental markers, respectively (C) Fractionation by sucrose density or Percoll 
centrifugation. LAD-2 cells were pretreated with MG132 and treated with P/I for 6 or 
24 h. Equal volumes of each fraction were evaluated by western blot analysis for the 
presence of PERK and LAMP-1 
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Figure 5A 
 
 
Figure 5B 
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Figure 5C      Figure 5D 
 
 
 
Figure 5. Immunofluorescence analysis of NR4A2 in ER and endo-lysosomal system 
(A) LAD-2 cells were transfected with specific siNRA of NR4A2 gene for 48 h, and 
then stimulated with P/I for 6 h. Immunofluorescence showed the foci of NR4A2 (B) 
LAD-2 cells were treated as indicated in the figure. Immunofluorescence showed the 
colocalization of NR4A2 with calnexin (ER marker) (C, D) LAD-2 cells were 
transfected with eGFP-Rab5 (early endosome marker), eGFP-Rab7 (late endosome 
marker) or eGFP-LAMP1 (lysosome marker) for 24 h. Treated LAD-2 cells as 
indicated in the figure for 6 h (C) or 24 h (D). Immunofluorescence showed the 
colocalization of NR4A2 with endolysosomes 
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Figure 6A      Figure 6B 
 
 
 
Figure 6C     Figure 6D 
 
 
 
Figure 6. NR4A2 mediates PMA and Ionomycin-induced IL-4 at early phase. LAD-2 
were transfected with scramble RNA or NR4A2 siRNA for 48 h. (A) Real-time PCR 
analysis on the induction of IL-4 in LAD-2 cells stimulated with P/I for 6 h. The data 
were normalized to the housekeeping gene (β-actin gene). Fold changes are calculated 
against untreated controls (B) The culture supernatants were collected after 6 or 24 h. 
IL-4 concentrations determined by ELISA. Values represent the means of three 
independent experiments ±SEM (C) LAD-2 cells were pretreated GF109203X (10 
µM) or PD98059 (100 µM) for 30min, following treatment for 6 h as indicated in the 
figure.  The culture supernatants were collected IL-4 concentrations determined by 
ELISA. Values represent the means of three independent experiments ±SEM (D) 
Transfection of LAD-2 cells with NR4A2 siRNA for 48 h, treated with P/I with or 
without MG132 for 6 or 24 h as indicated. NR4A2, pERK1/2 and total ERK1/2 
expression were shown. ERK1/2 and GAPDH is included as an internal control 
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Figure 7A     Figure 7B 
 
 
 
Figure 7. Effect of NR4A2 PTM on IL-4 expression. LAD-2 were cultured in the 
presence or absence of the proteasome inhibitor MG132 (1 µM) for 2 h and 
stimulated with P/I for 6 or 24 h (A) Real-time PCR analysis on the induction of IL-4. 
The data were normalized to the housekeeping gene (β-actin gene). Fold changes are 
calculated against untreated controls (B) The culture supernatants were collected IL-4 
concentrations determined by ELISA. Values represent the means of three 
independent experiments ±SEM 
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Figure 8A 
 
Figure 8B 
 
Figure 8C 
 
Figure 8. Effect of NF-κB signaling on IL-4 expression at late phase (A) Co-
transfected of LAD-2 with 3xNBRE and pRL-TK vector (renilla plasmids) for 24 h. 
Treated with P/I with or without MG132 for 6 or 24 h as indicated. Firefly 
3xNBRE/renilla ratio was shown (B) Co-transfected of LAD-2 with wt-κB and pRL-
TK vector for 24 h. The cells were pretreated Bay 11-7082 (10 µM) for 1 h, following 
treatment for 6 or 24 h as indicated in the figure. Means and ±SEM of the 
firefly/renilla ratios of at least three independent experiments are shown (C) 
Transfection of LAD-2 cells with p65 siRNA for 48 h. Pretreated with Bay 11-7082 
(10 µM) for 1h, following treatment for 6 or 24 h as indicated in the figure. The 
culture supernatants were collected IL-4 concentrations determined by ELISA. Values 
represent the means of three independent experiments ±SEM 
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Figure 9A      Figure 9B 
 
Figure 9C 
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Figure 9D 
 
Figure 9E 
 
Figure 9. Adenosine A2A receptors modulated NR4A2 expression and chemokine 
release (A) Reduction of P/I-mediated NR4A2 transcriptional induction by CGS-
21680 (1 µM). The data were normalized to the housekeeping gene (β-actin gene). 
Fold changes are calculated against untreated controls (B) Cells were silenced by 
A2AAR siRNA or pretreated with CGS-21680 (1 µM) for 15min then stimulated as 
indicated in the figures. GAPDH is included as an internal control (C) and (D) The 
culture supernatants were collected IL-4 concentrations determined by ELISA. Values 
represent the mean of three independent experiments ±SEM (E) Co-transfected of 
LAD-2 with 3xNBRE or wt-κB and pRL-TK vector for 24 h. Cells were treated as 
indicated. Firefly (NBRE or wt-κB)/renilla ratio was shown. Means and ±SEM of the 
firefly/renilla ratios of at least three independent experiments are shown 
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Supplementary Figure 1 
 
Cell viability was tested by Alamar blue assay?none of these treatments affected cell 
viability. LAD-2 cells were seeded in 96-well plates (45,000 cells/well/90 µl). 
Different stimuli were added as indicated in the figure, after 2 h or 20 h, 10 µl Alamar 
blue (Serotec) was applied for each well. After 4 h, fluorescence was monitored at 
530-nm excitation and 590-nm emission wavelength (LS55 luminescence 
spectrometer, Perkin-Elmer).  
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Supplementary Figure 2 
 
Analysis of efficiency of NR4A2 silencing. Transfection of LAD-2 cells with NR4A2 
siRNA specifically downregules NR4A2 expression induced by P/I. Scramble siRNA 
was included as a control 74.2%, 
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Supplementary Figure 3 
 
P/I induced NR4A2-dependent Genes by 96-well RT-PCR screening. LAD-2 cells 
were transfected with scramble or NR4A2 siRNA for 48 h. Total RNA were 
harvested after 6 h with or without PMA/ionomycin (P/I, PMA: 25 nM, ionomycin: 
0.1 µM). Fold changes are calculated against untreated. * Fold changes 
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5- Discussion and Conclusions 
 
 
Mast cells are granulated immune cells that often act as the first line of immune 
defense. They have been traditionally associated to immediate-type hypersensitivity 
reactions through the release of preformed inflammatory mediators. However, today it 
is well accepted that mast cells exert various other physiological functions. Dependent 
on the model of activation, mast cells can release distinct mediator profiles thereby 
enabling the initiation, maintenance and modulation of both innate and acquired 
immune responses [173-175]. To serve this function, mast cells are equipped with a 
multitude of receptors serving directly or indirectly as sensors of external stimuli. The 
engagement of activating and inhibitory cell-surface receptors, as well as the intensity 
and duration of these signals determines the activation state of mast cells. In response 
to these stimuli, gene expression patterns of inflammatory mediators are altered 
according to the sum of positive and negative signaling events, thereby affecting the 
course of inflammation [176]. The potency of adenosine as a modulator of mast cell 
function is well recognized, and ARs have been the center of much interest as 
therapeutic targets for asthma and allergy [65, 115]. Although in vitro studies have 
suggested roles for each AR subtype on mast cells, the transcriptional effectors 
downstream of ARs activation as well as the biological consequences of their 
activation have remained largely unknown.  
In the first part of this study, we employed the extensively characterized HMC-1 
human mast cell line to investigate downstream AR signaling. By combining selective 
AR targeting and transcriptomics, we were able to establish a novel link between AR 
activation and NR4A orphan receptors. Interestingly, our genome-wide screening and 
RT-PCR confirmatory experiments revealed a rapid and strong upregulation of 
NR4A2 and NR4A3 (but not NR4A1) upon treatment with the adenosine analogue 
NECA, suggesting that these transcription factors may act as important transcriptional 
mediators of inflammatory signals. Further, we showed that selective activation of the 
A2AAR negatively regulates the induction of these factors, demonstrating divergent 
effects between the AR subtypes on the induction of these orphan receptors. On one 
hand, the activation of pro-inflammatory ARs (i.e. A2B and A3ARs) act as an 
amplification signal resulting in not only very high levels of NR4A2 and NR4A3 
mRNA (but not of NR4A1), and also induced NR4A2 protein accumulation and 
NBRE transcriptional activity. On the other, this upregulation is multiplied by 
blocking the anti-inflammatory A2AAR. This results support previous reports that 
indicated that NR4As participate in inflammation related conditions, such as synovitis 
[191, and proposes one mechanism of A2AAR-mediated anti-inflammatory effect for 
such conditions adenosine’s effect on this group of transcription factors could have 
broad biological implications.  
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Activation of mast cells (for example by the high affinity IgE receptor) requires the 
activation of receptor-proximal tyrosine kinases, mobilization of internal Ca2+ and the 
formation of signaling complexes coordinated by adaptor proteins [177]. PI3K is a 
central player in mast cell activation that signals to regulatory enzymes such as PKC, 
PLC as well as PLD among others. Thereby Ca2+ ultimately regulates mast cell 
degranulation, the biosynthesis of inflammatory molecules such as arachidonic acid 
metabolites, as well as cytokine transcription [178]. Adenosine receptor activation has 
traditionally been linked to stimulation or inhibition of the AC; A2AAR and A2BAR 
activation lead to increased cAMP levels that in turn activate the canonical PKA 
pathway and the exchange protein directly activated by cAMP (Epac) [179],while 
A1AR and A3AR activation leads to cAMP decrease [75]. In addition, AR signaling in 
mast cells has also been linked to PLC and Ca2+ mobilization (A2BAR and A3AR), 
PI3K (A3AR), as well as PKC and MAP kinases (A1, A2A and A3AR) [65, 180]. Here, 
we analyzed the signaling pathways involved in AR-induced NR4A upregulation and 
we found that AR-mediated NR4A2 and NR4A3 upregulation in HMC-1 did not 
involve PKA, PI3K nor p38. Instead, PKC and MEK kinase inhibition could partially 
revert the induction of these factors and, moreover, the activity of these kinases 
correlated with ERK1/2 phosphorylation. Interestingly, some studies have also shown 
the involvement of ERKs and Ca2+ signaling pathways in adenosine signaling [181], 
but downstream targets of ERK upon AR activation had not been identified. The 
results presented here suggest that activation of ERK1/2 kinases downstream of PKC 
mediates NR4As induction by AR. Remarkably, A2AAR can counterbalance NECA-
induced ERK1/2 phosphorylation, correlating with its modulatory effect on NR4A2 
and NR4A3 induction.  
NR4As also influence the function of other inflammation-associated transcription 
factors. For example, NR4A1 and NR4A2 form heterodimers with retinoic acid 
receptor and can influence retinoid signaling [182]. Therefore, AR activation could 
affect the number of NR4A-containing complexes. In addition, NR4A receptors can 
also crosstalk with other transcriptional factors and influence their activity without 
necessarily interacting with them. For example, NR4A receptors and the estrogen-
related receptor NR3B mutually repress each other’s transcriptional activity [183]. 
Similarly, NR4A1 has been shown to negatively cross-talk with NF-κB [184]. As a 
consequence, by virtue of the induction of remarkably high levels of functional 
NR4A2 and NR4A3, adenosine is likely profoundly affect the expression of large sets 
of genes both directly (NBRE-responsive transcripts) and indirectly, by affecting the 
nature of transcriptional complexes and/or crosstalking with other transcriptional 
factors. Conversely, A2AAR activation could limit the availability of NR4A2 and 
NR4A3 for heterodimerization or cross-talk with other transcriptional factors. 
The focus in the second part of this thesis was on investigating whether the inhibitory 
effect of A2AAR on NR4A2 induction was preserved to other mast cell activating 
stimuli. For this we employed the more mature LAD-2 cell line, which possess 
several characteristics of fully differentiated mast cells [171]. To achieve this goal, we 
first characterized the signaling mechanisms triggered by the concomitant treatment 
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of mast cells with PMA and ionomycin (P/I). Our results showed not only the 
upregulation of NR4A2, but also established a previously undescribed pattern of post-
translational modifications of this transcription factor. Ubiquitination of NR4A2 and 
the associated re-localization and downstream effects observed imply an additional 
level of regulation of this transcription factor, supplementing the well-characterized 
regulation at the transcriptional level of this ligand-independent, constitutively active 
factors. Ubiquitination can be an essential step for rapid degradation of a protein with 
short half-life and can therefore regulate the transcriptional activity of transcriptional 
factors [185]. The results presented here supports this this hypothesis, since 
proteasome inhibition and inhibition of ubiquitinating enzyme I (UBE1, which 
catalyzes the first step in the ubiquitination process) effectively resulted in 
accumulation of ubiquitinated NR4A2 species. This was confirmed by 
immunoprecipitation of NR4A2, which specifically cross-reacted with ubiquitin 
antibodies. Further, we established that NR4A2 ubiquitination was phosphorylation-
dependent, suggesting a link between kinase signaling cascades and NR4A2 
modifications. In support of this hypothesis, NR4A1 has been shown to be a 
downstream phosphorylation target of JNK kinases, which resulted in its 
ubiquitination and degradation [28]. Our experiments in fact show that both 
upregulation and post-translational modifications of NR4A2 are at least partially 
dependent on PKC and MEK kinases, although it remains unclear whether both 
events are equally dependent on these kinases, or whether the negative effect of 
PKC/MEK inhibition on NR4A2 post-translational modifications is a consequence of 
their effect on NR4A2 abundance. Previous studies showed that phosphorylation of 
NR4A1 regulates nuclear export, and cytoplasmic and mitochondrial localization 
[186]. Here we employed a combination of approaches, including cell fractionation 
and western blotting, confocal microscopy to establish that ubiquitinated NR4A2, 
unlike phosphorylated NR4A1, locates in to ER, endosomes and lysosomes, and that 
these cytoplasmic signals can be stabilized by proteasome inhibition.  
The second major finding of this study was the identification of NR4A2 as a central 
factor in IL-4 release upon P/I stimulation, supporting a pro-inflammatory role for the 
NR4A2 on human mast cells in response to activating stimuli. Furthermore, 
ubiquitination of NR4A2 seemed to play a role in IL-4 induction, with MG132 having 
a biphasic effect on IL-4 release: treatment with this proteasome inhibitor further 
increased its release in an early time point (6 h), while it dramatically decreased IL-4 
secretion at late phase (24 h). By a combination of silencing and NF-κB and NR4A 
reporter assay approaches, we showed that the early IL-4 response (6 h) after P/I 
treatment depends on NR4A2, while NF-κB appears to be the main driver of the late 
responses. Several studies have investigated the cross-talk between NR4As and NF-
κB. Both NR4A1 and NR4A2 have been proposed as a downstream target of NF-κB 
in response to inflammatory mediators [42, 187]. More recently, NR4A2 has been 
shown to contribute with NF-κB towards the expression of IL-8 [188]. The data 
presented further expands our understanding on the cross-talk between NR4A2 and 
NF-κB. Further, we show that the accumulation of ubiquitinated NR4A2 in the ER 
77
leads to the induction of CHOP, a surrogate of ER-stress [189, 190]. ER stress can 
lead to NF-κB activation by at least 3 different pathways: through TRAF2 dependent 
IKK phosphorylation; through PERK-induced phosphorylation of eIF2α, which 
decreases IκB protein by repression of IκB translation, leading to interference with the 
export of nuclear NF-κB to the cytoplasm; or through ATF6, which causes activation 
of NF-κB via the Akt pathway [191]. Further studies will be required to establish the 
relevance of NR4A2-mediated ER stress in late NF-κB activation and IL-4 induction. 
IL-4 is a prototypic immunoregulatory cytokine responsible for initiating allergic 
responses and it essential is uniquely required to polarize naïve helper cells (Th0 
cells) to a type 2 phenotype, characterized by secretion of IL-4 itself, plus IL-5, IL-9, 
IL-10, and IL-13. IL-4 also induces B cells to switch their immunoglobulin 
production to IgE secretion. Mast cells and basophils readily produce IL-4 after 
crosslinking of their FcεRI receptors [192]. Here we present a novel link between P/I 
activation of mast cells and IL-4 release, and we show that the late release of IL-4 
depends on NR4A2-induced NF-κB activity, suggesting that although proteasome 
inhibition enhances early IL-4 release, it could potentially translate in downregulation 
of sustained, IL-4 mediated allergic responses in vivo. 
Finally we addressed the question on how A2AAR activation could influence NR4A2 
and NF-κB dependent IL-4 induction, and showed that the concomitant activation of 
this AR subtype has a broad modulatory effect on at all levels tested, which resulted 
in a significant decrease of IL-4 release, suggesting that A2AAR activation could 
modulate influence the development of allergic Th2 responses, in support of previous 
studies that observed that A2AAR activation successfully suppressed asthmatic 
inflammation in animal models [97] . 
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6- Additional publications 
 
 
6.1 Adenosine signaling in equine recurrent airway 
obstruction  
 
Recurrent airway obstruction (RAO, also known as COPD or heaves) and 
inflammatory airway disease (IAD) in the lower airway are common diseases of 
horses characterized by airway narrowing, airway hyper-reactivity, chronic lower 
airway inflammation, reversible airflow obstruction and respiratory difficulty [193, 
194]. RAO appears to be happened in older horses, while IAD affects most in 
younger horses [195] and the prevalence of RAO can be as high as 50%, ranging from 
subclinical to overtly manifested cases. It has been shown that RAO involves 
hypersensitivity to inhaled antigens, although multiple theories exist regarding exactly 
why it occurs [193]. Several lines of evidence suggest that adenosine plays a central 
role in the pathogenesis of lower airway inflammation (in chapter 2.2.4). Based on the 
potential of AR modulation in chronic airway disease, this project was aimed at 
identifying and characterizing adenosinergic signaling in equine airways.  
 
Here, 2 publications are presented. In the first one, the adenosine content in 
bronchoalveolar lavage fluid samples from healthy and airway-compromised equines 
was investigated. In the second one the effects of AR signaling in the equine airways 
is established though ex vivo stimulation of bronchoalveolar lavage-recovered cells. 
 
In summary, the results of this research project confirms the presence of measurable 
adenosine levels in lower airways in the horse, which are increased during 
inflammatory processes, and also the presence of functional adenosine signaling axis 
which may constitute the basis for more specific research of AR-based therapies for 
equine RAO and possibly for other chronic airway diseases in the horse. 
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6.2 Increased adenosine concentration in bronchoalveolar 
lavage fluid of horses with lower airway inflammation 
 
 
 
Zhang L, Franchini M, Wehrli Eser M, Jackson EK and Dip R 
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Several reports have suggested a role for adenosine in the pathogenesis of chronic airway conditions and
this has led to new therapeutic strategies to limit airway inﬂammation. In this study, detectable levels of
adenosine in bronchoalveolar lavage (BAL) samples from 11 horses with non-infectious lower-airway
inﬂammation and 14 healthy controls are reported, with signiﬁcantly higher values in horses with airway
inﬂammation. Although these increased levels did not correlate with changes in neutrophil percentage in
BAL, a positive association between adenosine levels and signs of lower airway inﬂammation (clinical
score) was observed. These novel ﬁndings support the hypothesis that adenosine may contribute to bron-
choconstriction and also act as a pro-inﬂammatory mediator in the bronchoalveolar milieu of horses with
airway inﬂammation. Further investigation of this axis could lead to new approaches for the treatment of
highly prevalent lower airway inﬂammatory conditions in the horse.
 2011 Elsevier Ltd. All rights reserved.
Adenosine is an endogenous nucleoside that accumulates in
bronchoalveolar lavage (BAL) in patients with asthma (Driver
et al., 1993). Administration of adenosine by inhalation induces
bronchoconstriction of asthmatic (but not of normal) airways. Re-
cently, adenosine 50-monophosphate has been shown to have a
similar effect on cats affected with chronic airway disease (Hirt
et al., 2011). In addition, adenosine modulates the course of inﬂam-
mation through the release of cytokines and chemokines from var-
ious cell types in the airways (Caruso et al., 2009). Therefore,
strategies based on adenosine receptor ligands are currently being
developed aimed at controlling adenosine-mediated inﬂammatory
signalling (Dip, 2009).
Persistent inﬂammation is a central feature of chronic non-
infectious airway conditions, such as recurrent airway obstruction
(RAO) and inﬂammatory airway disease (IAD). RAO is characterised
by bronchospasm, mucus secretion, airway wall thickening and
deterioration of lung function, and affects older individuals. IAD
presents clinical and cytological similarities with RAO, but usually
affects younger horses and clinical signs are mild (Couetil et al.,
2007).
In the current study, we wanted to determine whether in-
creased adenosine levels are associated with lower airway inﬂam-
mation in the horses. A total of 11 adult horses (three mares and
eight geldings; age range 7–17 years, median 9.5 years) with mild
to moderate signs of airway inﬂammation were included in the
study. Lower airway inﬂammatory disease (either IAD or RAO)
was diagnosed based on clinical signs, history, mucus (amount,
quality and cellularity) and cytological examination of BAL sam-
ples. Horses medicated within 28 days prior to the examination
and those with concomitant signs of infectious or systemic disease
were excluded from the study. In addition, 14 healthy controls
(four mares and 10 geldings; age range 5–22 years, median
11 years) with no history of airway inﬂammation or clinical signs
of respiratory disease and normal BAL cytology were employed
as a control group.
Each horse was clinically examined and given a weighted score,
using a scale with range 0–25 as described by Tesarowski et al.
(1996; see Appendix 1, Supplementary data). Two individuals per-
formed all clinical observations. All healthy controls had clinical
scores of 2 or lower (range 0–2, median 0.5) while horses with air-
way inﬂammation had higher scores (range 0–8, median 4), corre-
sponding to moderate clinical sings (horses with experimentally
induced RAO had mean scores of approximately 12; Tesarowski
et al., 1996).
The BAL and cytological analysis was performed as previously
described (Zhang et al., 2011). BAL-samples were collected in
vials containing 0.1 lM iodotubericidin and 10 lM of erythro-9-
(2-hydroxy-3-nonyl)adenine (Sigma), centrifuged, and cell-free
fractions immediately frozen. All samples were analysed by a spe-
ciﬁc spectrometry-based assay at a later time point (Ren et al.,
1090-0233/$ - see front matter  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tvjl.2011.11.012
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2008). Brieﬂy, a Zorbax eclipse XBD-C-18 column (Agilent) was
used with a TSQ Quantum-Ultra system and the HSE source
(Thermo Electron). The mobile phase consisted of linear gradient
changes of 0.1% formic acid in water and 0.1% formic acid in
methanol.
The use of dilutional markers has been investigated in the horse,
but remains a matter of controversy (Kirschvink et al., 2001). To
avoid dilutional artefact, urea concentrations were determined
(QuantiChrom assay, BioAssay Systems) in both in BAL and serum
samples that had been collected simultaneously. The ratio between
urea concentrations served as an indicator of epithelial lining ﬂuid
dilution and was employed for normalisation (corrected adenosine
concentration).
The BAL cytology, clinical score, and uncorrected and corrected
adenosine concentrations are summarised in Table 1. Interestingly,
these data suggested a limited dilution effect on BAL samples when
considered collectively, despite dilution differences of individual
samples. Uncorrected adenosine values were employed for further
analysis, following the recommendation of the European Respira-
tory Society that acellular BAL components should be expressed
as concentration per volume recovered.1
Each BAL sample revealed adenosine levels above the limit of
detection (LOD: 0.02 pg/lL BAL). Furthermore, adenosine concen-
tration was signiﬁcantly higher in horses with airway conditions
(range 26.4–377.3 pg/lL, median 112.8 pg/lL), compared to
healthy controls (range 17–191 pg/lL, median 43.6 pg/lL), which
suggested a link between lower airway inﬂammation and adeno-
sine in this species (Fig. 1).
The association between adenosine concentration in BAL and
clinical ﬁndings was then assessed quantitatively, independently
of disease state. Fig. 2A shows the signiﬁcant correlation (Spear-
man) between adenosine concentration and clinical score. A simi-
lar correlation was observed when only horses with airway
inﬂammation were considered.
Since the assessment of BAL cytological alterations (neutrophils
relative counts) remains a major diagnostic tool for lower airway
disease, the association between neutrophil percentage and aden-
osine concentration was investigated. In contrast to clinical score, a
correlation between these two variables could not be established
(Fig. 2B). Yet this observation should be interpreted with care be-
cause only three samples with neutrophil count indicative of mod-
erate to severe airway inﬂammation (>20%) were tested. Analysis
of a larger set of samples with high percentage of neutrophils
(i.e. acute RAO phase) would be required to clarify the relationship
between these two parameters.
The presence of increased adenosine concentrations in horses
with airway inﬂammation suggested that adenosine could rep-
resent a marker of inﬂammation. However, in view of the par-
tial overlap in the values of both groups of horses analysed,
assessment of adenosine levels in BAL did not seem to be suit-
able as the sole indicator of disease, but should be interpreted
in combination with other diagnostic parameters (i.e. clinical
signs).
Table 1
BAL cytology, clinical score and adenosine concentration from horses with airway inﬂammation (15–25) and healthy controls (1–14).
Horse Sex Age Neutrophils (%)
[RV 6 5%]a
Lymphocytes (%)
[RV 30–50%]
Macrophages (%)
[RV 40–60%]
Eosinophils (%)
[RV 6 0.5%]
Basophils (%)
[RV 6 2%]
Clinical
score
Uncorrected
adenosine
concentration
(pg/lL)
Corrected
adenosine
concentration
(pg/lL)
1 M 10 1.3 46.6 52.1 0.0 0.0 0 40.5 51.1
2 F 10 1.3 45.9 52.1 0.7 0.0 1 43.1 67.9
3 M 17 1.9 52.2 45.4 0.0 0.5 0 46.9 25
4 M 5 5.7 56.3 36.8 0.0 1.2 1 108.6 140.1
5 F 15 6.1 69.3 24.2 0.0 0.4 1 52.9 32.8
6 M 5 0.8 48.9 46.8 0.0 3.5 0 38.7 64
7 F 8 2.1 41.6 55.2 0.0 1.1 0 44.1 41
8 M 16 3.4 62.4 33.3 0.0 0.9 1 29.0 20.9
9 F 9 1.9 46.9 48.3 0.5 2.4 0 127.7 237.5
10 M 5 3.5 57.9 38.2 0.0 0.4 0 31.2 27.1
11 M 5 1.2 36.0 62.2 0.0 0.6 0 101.1 174.3
12 M 10 6.0 39.0 53.4 0.0 1.6 2 17.0 20.6
13 M 13 3.5 32.2 60.4 0.0 0.0 2 17.2 23.8
14 M 9 0.5 60.5 37.0 0.5 1.5 1 191.8 180.1
Average 9.8 2.8 49.6 46 0.1 1 0.6 63.57 79.02
Range 5–16 0.5–6.1 32.2–69.3 24.2–62.2 0–0.7 0–3.5 0–2 17.0–191.8 20.6–237.5
15b M 6 5.7 61.9 31.5 0.0 1.0 1 85.4 71.7
16 M 12 5.6 38.1 53.8 0.2 2.5 8 215.8 231.4
17 M 7 10.4 53.9 35.7 0.0 0.7 4 26.4 21.5
18 M 7 7.3 61.4 31.3 0.1 1.0 0 57.8 64.9
19 F 15 4.1 25.2 67.4 0.0 0.5 5 34.7 50
20 M 5 4.5 46.8 47.8 0.0 0.2 4 377.3 315.1
21 F 11 31.9 20.2 43.7 0.5 0.0 3 112.8 101
22 F 13 12.4 59.7 27.2 0.0 0.7 8 316.3 367.7
23 M 8 16.0 48.1 31.4 0.0 4.5 8 201.7 217.1
24 M 22 76.3 11.8 11.4 0.1 0.5 8 352.0 228.9
25 M 13 50.0 23.9 25.7 0.0 0.4 2 103.5 131.1
Average 10.8 20.7 41.1 37.1 0.1 1.1 4.6 171.23 163.68
Range 5–22 4.1–76.3 11.8–61.9 11.4–67.4 0–0.5 0–4.5 0–8 26.4–377.3 21.5–367.7
RV, reference value.
a Neutrophil counts higher than 5% were considered indicative of airway inﬂammation. However, values between 4% and 6% were interpreted in relation to other diagnostic
criteria.
b Lower airway inﬂammation was diagnosed on the basis of medical history and decreased exercise tolerance.
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Two initial reports suggested the presence of an adenosine-sig-
nalling axis in equine airways. One early study indicated that aden-
osine inﬂuences contractility in equine tracheal smooth muscle
(Norris and Eyre, 1982). Our own research group then recently
showed enhanced interleukin (IL)-6 transcriptional responses to
adenosine receptor ligands in BAL cells from horses with lower air-
way inﬂammation (Zhang et al., 2011). The increased adenosine
levels reported in the current study therefore supported the
hypothesis that this nucleoside both contributes to bronchocon-
striction and acts as a pro-inﬂammatory mediator in the broncho-
alveolar milieu of horses with airway inﬂammation. Further
characterisation of this inﬂammatory signalling axis could poten-
tially lead to new approaches for the treatment of highly prevalent
lower airway inﬂammatory conditions, such as RAO and IAD.
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Summary
Reasons for performing study: Accumulation of extracellular adenosine has been closely associated with human asthmatic responses. However, the
relevance of adenosine signalling in equine airways has not previously been investigated.
Objectives: To determine the expression of adenosine receptors (AR) in bronchoalveolar lavage (BAL) cells and assess the reactivity of these cells to AR
ligands ex vivo, employing IL-6 as readout of adenosinergic inﬂammatory signalling.
Methods: Eight horses with varying degrees of lower airway inﬂammation and 10 healthy controls were analysed. Expression of AR-subtypes in each BAL
sample was determined by quantitative RT-PCR and compared to that in 13 other tissues. Bronchoalveolar lavage cells were stimulated either with
the adenosine analogue NECA, CGS-21680 (A2AAR selective agonist) or with a combination of NECA and SCH-58261 (A2AAR antagonist) and IL-6
expression assessed.
Results: Bronchoalveolar lavage cells predominantly expressed A2BAR, with lower A2AAR levels andmarginal A3AR expression; A1AR was not detected. This
patternwas similar to that of PBMCsbutdifferent from theother tissues tested.Nosigniﬁcantdifferences inARexpression inBALcells frombothgroupswere
detected, although a trend for decreased A2BAR in airway-compromised horses was observed. Treatment of BAL cells with the nonselective agonist
NECA upregulated IL-6 expression in cells from airway-compromised horses, but levels remained unchanged in control animals. Furthermore, blockage of
A2AAR with SCH-58261 enhanced IL-6 mRNA induction by NECA in both groups, with higher levels in airway-compromised horses; the amplitude of this
response correlated with neutrophil count.
Conclusions: These results demonstrate the presence of an adenosine/IL-6 inﬂammatory axis in the bronchoalveolarmilieu of airway-compromised horses.
While A2BAR is the predominant proinﬂammatory AR subtype expressed, A2AAR appears tomodulate inﬂammatory signalling (IL-6 expression) by adenosine.
Potential relevance: This study supports selective AR targeting as a potential therapeutic approach for themodulation of inﬂammation in the equine lower
respiratory tract.
Keywords: horse; airway inﬂammation; adenosine; IL-6; adenosine receptorevj_350 81..87
Introduction
Chronic inﬂammatory airway diseases are remarkably prevalent in the
horse. Recurrent airway obstruction (RAO) and inﬂammatory airway
disease (IAD) are 2 such conditions that share a number of clinical,
cytological and functional similarities. Recurrent airway obstruction is
characterised by bronchospasm, mucus secretion, airway hyperreactivity
and airwaywall thickening together with deterioration of lung function and
affects older individuals, while IAD-affected horses are usually younger
with clinically milder signs (Couetil et al. 2007).
Adenosine is an endogenous byproduct of ATP metabolism normally
presentat lowconcentrations intheextracellularspace. Its levelsaregreatly
increased under metabolically stressful conditions such as tissue injury,
hypoxiaandacuteorchronic inﬂammation, reaching localconcentrationsof
up to 30 mmol/l, a 150-fold increase over basal levels (Van Belle et al. 1987).
This nucleoside activates 4 types of G-coupled adenosine receptors (ARs),
which are expressed on various inﬂammatory and stromal cells: A1, A2A, A2B
and A3. ARs have well characterised anti-inﬂammatory and wound healing
activities, demonstrating the importance of these signalling pathways
in tissue protection (Hasko et al. 2008). In some situations, however,
adenosine generation and AR activation have proinﬂammatory activities
that amplify tissue injury (Blackburn 2003). These observations have driven
research efforts to develop selective agonists or antagonists for AR
subtypes foruse innovel therapies for chronic inﬂammatory conditions.
There is growing evidence that adenosine plays an important role in
respiratorydisorders in the lower airways. Increasedamountsof adenosine
are found in bronchoalveolar lavage and exhaled breath condensate of
human patients with asthma (Driver et al. 1993; Huszar et al. 2002) and,
when administered by inhalation, adenosine was shown to be a powerful
bronchoconstrictor in asthmatics but not in healthy subjects (Cushley et al.
1983). Furthermore, blockade of adenosine reuptake by dipyridamole
increased the bronchoconstrictor response to adenosine in asthma
indicating that its accumulation is closely associated with the asthmatic
airway response (Cushleyet al. 1985).
Recent studies have investigated the adenosine pathway in the horse.
The afﬁnity of several ligands to AR subtypes has been studied in horse
neutrophils (Sun et al. 2007). EquineA2A andA3ARs havebeen cloned in this
species (Brandon et al. 2006a,b). Furthermore, activation of A2AAR in
equine monocytes has been shown to inhibit lipopolysaccharide-induced
TNF-a production, suggesting a therapeutic potential for ARmodulation in
inﬂammation (Sun et al. 2008a). However, the relevance of adenosine
signalling on the regulation of inﬂammatory cytokines in the equine
respiratory tract has not previously been examined.
Here,weemployedanexvivoapproach toassess the roleof adenosine in
the physiopathology of lower airway inﬂammation in the horse. First, we
established the expression proﬁle of ARs in BAL cells and compared it to
cerebellum, cortex, myocardium, aorta, spleen, stomach, jejunum,
caecum, kidney, adrenal gland, eye, fat and peripheral blood mononuclear
cells (PBMCs). Second, we determined that AR levels do not differ
signiﬁcantly between compromised and control animals. Third, we
investigated the reactivity of BAL-recovered cells from horses with lower
airway inﬂammation and healthy controls to AR ligands and determined
that nonselective pharmacological activation of ARs leads to increased
expression of the pro-inﬂammatory cytokine IL-6 in cells from horses with
lower airway inﬂammation but not from control animals. Finally, we
observed that selective blockage of A2AAR further increases IL-6
transcription, leading to remarkably high levels in horses with lower airway
inﬂammation. These data suggest that adenosine signalling is a relevant
inﬂammatory mechanism during lung inﬂammatory conditions and that
A2AAR acts as an endogenous modulator of inﬂammatory signalling in the
equine airway.
Materials and methods
Horses
Eight adult horses (2mares and 6 geldings; age range 5–18 years,median =
13 years; weight range 450–516 kg) were presented with varying degrees
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of lower airway inﬂammation at the Equine Clinic at theUniversity of Zurich.
Clinical signs included exercise intolerance, coughing, nasal discharge and
the horses were diagnosedwith lower airway inﬂammatory disease (either
IAD or RAO) on the basis of history, clinical ﬁndings, mucus and cytological
examination of BAL samples.
Tenhealthyhorseswithnohistoryof airway inﬂammationor clinical signs
of respiratorydisease andnormal BAL cytologywereemployedas a control
group (7 mares and 3 geldings; age range 8–17 years, median = 9 years;
weight range 480–605 kg). These horses belonged to the same stud, were
vaccinated and dewormed regularly, stabled in the same barn and fed hay
and grain twice a day. Sample collection of control horseswas approved by
the veterinary district authorities; anaylsis of samples obtained for
diagnostic purposes did not require approval.
Bronchoalveolar lavage and differential cytology
Horses were sedated with a combination of xylazine (0.1 mg/kg bwt i.v.)1
and butorphanol (0.02 mg/kg bwt i.v.)2. A ﬁbroscope was introduced into a
nostril, directed into the trachea and advanced until it wedged in a
bronchus. During the advancement of the bronchoscope the bronchial
surfacewas continuously anaesthetisedwith 50 ml of a solution containing
0.4% lidocaine and 0.9% sodium chloride injected through a sterile catheter
passed through the biopsy channel. Two-hundred-and-ﬁfty ml of
prewarmed (37°C) sterile physiological saline solution were then infused
into thebronchus and immediately reaspirated into a sterile glass ﬂask kept
on ice.
Bronchoalveolar ﬂuid was centrifuged at 200 g for 10 min and rinsed x1
with PBS. A cytospin slide was prepared and stained with May-Grünwald
Giemsa for cytological analysis. At least 400 cells from each lavage sample
were counted.
Cell culture and ex vivo stimulation
The remaining cells were resuspended in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM), supplemented with 10% FBS3, 0.1 u/ml penicillin and
0.1 mg/ml streptomycin3 at a concentration of 2 ¥ 106/ml, 106 cells were
seeded in each well of a 24 well plate and cultured overnight at 37°C under
humidiﬁed air containing 5% CO2. The following day cells were treated for
either 3 h with the AR ligands 5′-N-ethylcarboxamidoadenosine (NECA,
10 mmol/l), 2-p-(2-carboxyethyl)phen ethylamino-NECA (CGS-21680,
0.1 mmol/l) or the combination of NECA and 5-amino-7-(2-phenylethyl)-
2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine (SCH-58261,
1 mmol/l). All chemicals were from Sigma4. The use of lidocaine as a local
anesthetic during the BAL procedure did not contribute to any observed
effect as there was an extensive rest period before the cells were used.
RNA extraction and cDNA synthesis
Total RNAwas isolated and cDNA synthesised as described (Franchini et al.
2000). Brieﬂy, RNA was isolated using the total RNA isolation kit, which
includes a DNAse treatment step5. RNA concentration was measured by
optical density at 260 nmandRNAquality assessedby260/280absorvance
ratio and cDNA synthesised with the cDNA reverse transcription kit6
following the manufacturer’s instructions. Brieﬂy, 0.5 mg of total RNA was
mixed with 1 ml of random primers, 2 ml of reverse transcription buffer and
0.8 ml dNTP mix, 1 ml multiScribe reverse transcriptase and 1 ml RNA
inhibitor to a ﬁnal volumeof 20 ml. Themixwas incubatedat 25°C for 10 min
and at 37°C for 120 min and then heated at 85°C for 5 s. The reactionswere
stored at -20°C until used.
Samples for adenosine receptor expression proﬁling
Immediate post mortem samples were obtained from one healthy horse.
200 mg of cerebellum, cortex, myocardium (left ventricle), aorta, spleen
parenchyma, jejunum and caecum (submucosa and muscular), kidney
(cortex),adrenal (cortexandmedulla),eye (conjunctiva)andretroperitoneal
fat were mechanically disrupted in a 3 ml Dounce homogeniser in lysis
buffer5. Additionally, 10 ml of whole blood were obtained from this animal
and PBMCs isolated employing a Ficoll reagent, following the
manufacturer’s instructions7. Ribonucleic acid fromeach tissue andPBMCs
wasextractedandcDNAsynthesisedasdescribedabove.
Selection of primers for expression analysis
The ARs primers for RT-PCR were designed based on the complete (A2A),
predicted (A1, A2B) or partial cd sequences (A3) (GenBank accession
numbers: NM_001081897, XM_001496410, XM_001918390 and
AY_011243, respectively). Primers were selected for RT-PCR performance
and absence of artifacts. The speciﬁcity of the ampliﬁed product was
conﬁrmedby sequencing. Ampliﬁcation efﬁciencywas calculated based on
the CT values obtained from a serial dilution of a positive control cDNA
(90–110%). Sequences for A1, A2A, A2B and A3-ARs, IL-6 and GAPDH primers
and their expected product lengths are listed in Table 1. PCR reactionswith
these primers yielded single bands of the expected sizes. No unspeciﬁc
secondary primer bands were observed (Supplementary Fig S1).
Quantitative real-time polymerase chain reaction
(RT-PCR)
One mgcDNAwasampliﬁed in a20 ml PCR reaction containing10 ml of SYBR
green supermix8 and 10 mmol/l of forward and reverse primers. The PCR
was performed in the iCycle IQmulticolour real time PCR detection system8
with an initial incubation step at 95°C for 10 min to activate the enzymeand
45 cycles of ampliﬁcation, including a denaturation at 95°C for 15 s and a
1 min extension at 60°C. Samples without cDNA were always included in
the ampliﬁcation reactions to check for contamination. All reactions were
performed in triplicates. Fold changes in the expression of each gene was
calculated using the 2-DDCTmethod (Livak and Schmittgen 2001), with the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript as an
internal standard. Relative AR and IL-6 levels in resting cells are expressed
as the ratio of the CT value for the gene of interest/CT for GAPDH. Mean
GAPDH CT values for airway and control horses are 19.98 and 20.35
(difference not signiﬁcant), with coefﬁcients of variation are 3.68 and3.65%,
respectively. Finalised RT-PCR reactions were loaded in a 2% agarose gel
containing 0.1 mg/ml etidium bromide for visualisation of DNA and
subjected to electrophoresis.
Data analysis
Statistical analysiswasperformedusing thePASWStatistics software9.Data
were analysed by nonparametric tests (Mann-Whitney U test, Spearman
correlation coefﬁcient) orwith the t test withWelch correctionwhen values
showed normal distribution (A2BAR expression). Differences between
groupswereconsideredsigniﬁcantwhenPvalueswere less than0.05.
Results
Cytological characterisation of BAL samples
Control horses had cytological values within physiological range
(neutrophils <5%, lymphocytes 30% to 60%, macrophages 40–70%,
TABLE 1: Primer sequences and expected product lengths of the genes analysed
Gene GenBank accession No. Forward primer (5′-3′) Reverse primer (5′-3′) Product length (bp)
A1AR XM_001496410 TCAACATCGGGCCACGGACC CAGGTTGTTCCAGCCAAACAGAG 242
A2AAR NM_001081897 CGCGAGTTCCGCCACACCTT CCTGCTCTGCATCGCTGCCA 124
A2BAR XM_001918390 TCACDCAGAGCTCCATCTTC CAAAGGCAAGGACCCAGAGG 141
A3AR AY_011243 AGGGACACAGGAAGCCAGCTCA GGAAGCCCTGCAGCTTCTGTTCC 213
IL-6 NM_001082496 ATGAGTGGCTGAAGAACACAACAAC AGGAATGCCCATGAACTACAACAAT 131
GAPDH NM_001163856 TGGCATGGCCTTCCGTGTCC GCCCTCCGATGCCTGCTTCAC 118
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eosinophils <0.5%, basophils <2%), with the exception of 2 horses with a
marginal increase of neutrophils and one horse with high basophil count.
On the contrary, airway-compromised horses showed signiﬁcantly
higher counts for nondegenerate neutrophils. Interestingly, 2 horses also
had increased eosinophils (Horses 15 and 16, 6.3 and 2.8%, respectively),
suggesting that this is a rather heterogeneous group with varied
pathophysiological conditions and/or disease states. The cytological
ﬁndings of the horses included in the study are summarised in Table 2.
Tissue-speciﬁc AR expression proﬁles
RT-PCR analysis from one healthy horse revealed a heterogeneous
expression proﬁle for the 4 AR subtypes across the tissues explored. The
RT-PCR reactions were loaded on an agarose gel (Fig 1a) and analysed
quantitatively (Fig 1b). Product length, speciﬁcity and the absence of
primer-dimer products were conﬁrmed in BAL cells and cerebellum
(Supplementary Fig S1).
While A1AR could not be detected in BAL–recovered cells, this AR was
expressed both in cerebellum and cortex, jejunum, caecum and eye.
Exceptionally high A1AR levels were detected in fat, in agreement with
previous reports showing that this subtype is heavily expressed in this
tissue,mediatingmostof theeffectsof adenosineonadipocytes (Kaartinen
et al. 1991). A2AAR could be detected in all samples, although levels were
very low in cerebellum, cortex and kidney. Signiﬁcant levels of this ARwere
identiﬁed in spleen (where it was the predominant AR type), in adrenal and
in myocardium, while high levels were detected in PBMCs. Among all ARs,
the A2B subtype was the most commonly detected. Expression in PBMCs
was very prominent, with high levels in BAL cells and cerebellum, and
intermediate in cortex, aorta andadrenal gland.A2BAR transcriptswere less
abundant in myocardium, stomach, spleen, fat and eye. In contrast,
expression of the A3ARwas less common,with highest levels in PBMCs and
lower ones in BAL cells, jejunum, adrenal, fat and eye. Interestingly, the
expression pattern in PBMCs was similar to that of BAL-cells, but with
overall expression values about 10-fold higher than BAL.
AR expression in BAL cells from airway-compromised
and healthy horses
Studies examining the expression of ARs in asthmatics and COPD patients
support the hypothesis of a fundamental alteration in adenosine signalling
in these patients (Varani et al. 2006). The analysis presented here revealed
A2BAR as the predominant subtype in equine BAL cells, with lower levels of
A2AAR and marginal A3AR expression. Therefore, we wanted to assess the
expression pattern of ARs in BAL from airway-compromised horses as
compared to healthy controls. Although the differences inA2AAR andA2BAR
expression between both groups were not signiﬁcant, a tendency for
decreased A2BAR expression in airway-compromised horses was observed
(Fig 2, P = 0.084). This trend is in agreement with data from human with
chronic airway inﬂammation who exhibit lower A2BAR expression,
suggesting a role for adenosinergic signalling in equine airway disease.
Note that A1AR was not detected in any BAL samples and that A3AR
expression levels weremarginal in both groups (not shown).
Induction of IL-6 by the adenosine analogue NECA
Based on these observations, we wanted to determine whether AR
activation could trigger the expression of inﬂammatory cytokines in
BAL-cells. Because IL-6 is a major inﬂammatory cytokine regulated by
several stimuli, we decided to investigate whether AR engagement could
affect its expression in BAL cells. First, we determined IL-6 baseline
expression levels in all samples relative to thoseofGAPDH. Figure 3a shows
expression levels in nonstimulated cells from airway-compromised and
from healthy controls. IL-6 mRNA abundance did not differ signiﬁcantly
between both groups. Furthermore, RT-PCR cycle numbers for this
cytokine in both groups were close to threshold of detection (cycle 35),
implying that IL-6 was minimally transcribed in resting cells from
either group.
Subsequently, the cells were treated for 3 h with the nonselective AR
agonist NECA and IL-6 induction reassessed (Fig 3b). While cells from
healthycontrols failedtoupregulatethiscytokine (1.54-fold,notsigniﬁcant),
stimulation of cells from airway-compromised horses resulted in a
signiﬁcant increase of IL-6 transcript (2.51-fold), which was maximal at this
time point. This increase in IL-6 expression in NECA-stimulated BAL cells
from diseased horses was signiﬁcantly greater than that of control horses
(P<0.01). This suggests that BAL-cells from affected animals differentially
react to theendogenousnucleosideadenosine.
Differential induction of IL-6 in BAL-recovered cells
by AR-subtypes
The A2AAR subtype has been linked with anti-inﬂammatory functions at
several levels and it has been suggested to be a critical part in negative
TABLE 2: Cytological ﬁndings in BAL cells from healthy (1–10) and airway-compromised horses (11–18)
Horse Sex Age
Neutrophils
(%)
Lymphocytes
(%)
Macrophages
(%)
Eosinophils
(%)
Basophils
(%)
1 F 10 1.3 45.9 52.1 0.7 0
2 M 17 1.9 52.2 45.4 0 0.5
3 M 5 5.7 56.3 36.8 0 1.2
4 F 15 6.1 69.3 24.2 0 0.4
5 M 5 0.8 48.9 46.8 0 3.5
6 F 8 2.1 41.6 55.2 0 1.1
7 M 16 3.4 62.4 33.3 0 0.9
8 M 9 0.5 60.5 37 0.5 1.5
9 M 5 3.5 57.9 38.2 0 0.4
10 F 6 1.8 47.6 49.8 0.3 0.5
Median (min, max) 2.7 (0.5, 6.1)* 54.3 (41.6, 69.3) 41.8 (24.3, 55.2) 0.2 (0, 0.7) 0.7 (0, 3.5)
11 M 5 5.3 49.3 43.9 0 1.5
12 F 13 50 23.9 25.7 0 0.4
13 F 6 12.6 48 37.4 0 2
14 M 17 5.8 38.7 55.5 0 0
15 M 18 16.7 43.4 30.8 6.3 2.8
16 M 16 5.6 30.1 60.6 2.8 0.9
17 F 10 12.8 51.4 34.5 0.7 0.7
18 M 16 26.5 48.1 22.7 0 2.7
Median (min, max) 12.7 (5.3, 50)* 45.7 (23.9, 51.4) 36 (22.7, 60.6) 0 (0, 6.3) 1.2 (0, 2.8)
*P0.01 (MannWhitney test).
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feedback mechanisms for the limitation and termination of inﬂammatory
responses (Ohta and Sitkovsky 2001). Therefore, we wanted to assess the
role of this receptor subtype in inﬂammatory disease in equine airways.
More precisely, our aim was to determine whether activation of this
AR-subtype could inﬂuence adenosinergic proinﬂammatory signalling in
BAL-recovered cells. Therefore, we ﬁrst tested whether A2AAR activation
could inﬂuence IL-6 expression. As expected, activation of A2AAR with the
selective agonist CGS-21680, at a concentration that has been shown to
effectively inhibit LPS-mediated ROS production in equine neutrophils (Sun
et al. 2007), did not induce IL-6 expression in BAL cells either from airway-
compromised or healthy controls (Fig 4a). Further, we evaluated whether
A2AAR blockage could inﬂuence IL-6 upregulation by NECA, by treating
cells with a combination of NECA plus the A2AAR antagonist SCH-58261.
Because this is the ﬁrst study in which equine cells are exposed to SCH-
58261 the concentration of 1 mmol/l was extrapolated from binding
studies in rat and bovine tissues and functional assays in rabbit and
porcine systems (Zocchi et al. 1996). While SCH-58261 did not affect IL-6
expression, the combined treatment of NECA and SCH-58261 resulted in a
moderate but signiﬁcant increase of IL-6 expression in healthy controls
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Fig 1: Expression proﬁles of ARs in tissue samples from a single healthy horse, assessed by RT-PCR. a) Finalised reactions (cycle 45) were loaded in an agarose gel for side by side for
comparison. GAPDH reactions are included as a loading control. ML: DNAmolecular ladder, sizes are given in base pairs. b) Quantitative analysis. The values are relative to GAPDH
and indicatemean and standard deviation of 3 independentmeasurements.
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Fig 2: AR expression in BAL-samples fromairway-compromised and control horses, by
RT-PCR. Expression values are relative to GAPDH and indicate mean and standard
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(median 5.28; s.d. = 1.96), when compared to NECA alone. Similarly, A2AAR
blockage in airway-affected horses resulted in prominent increases in IL-6
induction by NECA, reaching up to 29-fold upregulation (median = 13.04;
s.d. = 7.84). In addition, IL-6 upregulation by combined NECA and SCH-
58261 treatment was signiﬁcantly different between both groups (Fig 4a).
Altogether, this data shows that activation of A2AAR in BAL-recovered cells
can modulate proinﬂammatory signalling by other ARs, particularly in
airway-affected horses.
Finally, we examined whether this differential IL-6 induction by AR
activation could be associated with the changes in BAL cytology. Indeed,
we detected a correlation between neutrophil count and IL-6 induction by
NECA plus SCH-58261 for all 18 horses included in this study (Fig 4b),
suggesting a causal relationship between the neutrophil number and
AR-dependent IL-6 induction. A similar correlation was observed with IL-6
induction by NECA (not shown).
Discussion
In this studyweﬁrst characterised theexpressionof adenosine receptors in
BAL samples, as compared to other tissues. Besides the tissue-speciﬁc
variations that hint towards divergent adenosinergic pathways in different
organs and systems, whose interpretation exceeds the scope of this study,
we observed a remarkable similarity between the AR proﬁles of BAL-cells
and PBMCs. A2BAR was predominantly expressed in both of these cell
types, followed by A2AAR and lower A3AR levels. This analogy and the fact
that neutrophils express primarily A3AR (Varani et al. 2009) insinuate that
lymphocytes andmacrophages are the predominant AR-expressing cells in
BAL (together they represent over 90% of BAL cells). Furthermore, these
observations suggest that adenosine could play an immunomodulatory
function in the airways in the horse.
In line with this hypothesis, we show enhanced reactivity of BAL-cells
from airway-compromised horses upon ex vivo AR stimulation, thereby
establishing a link between adenosine signalling and airway inﬂammation
in this species. RT-PCR analysis revealed increased expression of IL-6 upon
nonselective AR activationwith the adenosine analogue NECA in cells from
airway-affected horses, while this response was absent in control animals.
This ampliﬁed response to adenosine could be explained by adaptive
responses of airway/BAL-cells to the inﬂammatory milieu. Long-term in
vitro exposure studies have indeed shown desensitisation of ARs by
adenosine in target cells (Fredholm et al. 2001). In COPD patients, for
example, elevated concentrations of adenosine and other inﬂammatory
mediators in the peripheral lung tissue correlated with downregulation of
the A2BAR and with increased densities of the A2A and A3AR (Varani et al.
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2006). In line with that report we detected a trend towards a decrease in
A2BAR in airway-affected horses, which was not signiﬁcant (possibly
because of the heterogeneity in AR expression, particularly among healthy
horses). A systematic analysis of AR expression by cell type in a larger
sample groupwould be necessary to conﬁrm of this trend.
The exaggerated response of airway-affected horses can also be
explained by the alterations in their BAL cytology. In fact, we identiﬁed a
correlation between percentage of neutrophils in BAL and cell reactivity to
adenosinergic proinﬂammatory signalling. This observation, however,
does not allow to establish whether IL-6 upregulation depends on
neutrophil count, or, on the contrary,whether higher neutrophils in BAL are
the result of increased proinﬂammatory AR signalling with elevated levels
of IL-6 and probably of other neutrophil chemotactic factors.
IL-6 is a multifunctional cytokine that has been associated with
inﬂammation and the development of immune responses. Although
initially considered a surrogate marker of inﬂammation (similar to IL-1b
and TNF-a) it is now clear that IL-6 can also inﬂuence the effector
functions of various CD4+ T cell subsets. IL-6 inhibits Th1 differentiation
and promotes Th2 differentiation during early CD4+ T cell activation, and
also induces the differentiation of Th17 effector cells in the presence of
TGF-b (Mangan et al. 2006). IL-6 also inhibits regulatory T cell
development, most likely by suppressing Foxp3 expression (Dominitzki
et al. 2007). Its role in promoting Th2 and Th17 differentiation, along with
inhibiting regulatory T cell activity, suggests that IL-6 might play a role in
the onset and/or progression of diseases associated with these types of
immune responses, including RAO. Interestingly, engagement of
proinﬂammatory ARs has been linked to increased release of IL-6 from
epithelial cells, astrocytes and ﬁbroblasts (Sitaraman et al. 2001; Zhong
et al. 2005). In addition, a recent study using Calu-3 human epithelial cells
demonstrated that extracellular adenosine induces a robust release of
IL-6, establishing a connection between adenosine and neutrophil
inﬁltration in the airway lumen (Sun et al. 2008b).
Activation of A2AAR has been associated to anti-inﬂammatory effects,
including modulation of neutrophil and mast cell activation and
degranulation, downregulation of oxidative species and adhesion
moleculesand inhibitionofcytokinerelease (Lappaset al. 2005). In the lung,
activation of the A2AAR was linked to downregulation of inﬂammation in
models of allergic asthma (Koshiba et al. 1999; Fozard et al. 2002). A2AAR
activation also attenuated IL-6 levels associated with inﬂammatory lung
injury ina ratmodel for cardiopulmonarybypass (Mohseninet al. 2007) and
recent evidence indicates this AR canmodulate inﬂammatory signals in the
horse. Forexample,activationof theequineA2AAR inaheterologoussystem
was shown to inhibit the proinﬂammatory factor NF-kB (Sun et al. 2008a).
Also, engagement of A2AAR on LPS-activated equine peripheral blood
monocytes led to a decrease in expression of COX-2 and TNF-a and
upregulation of IL-8 and IL-10, implying a role of this receptor in the
modulation of inﬂammatory signals (Sun et al. 2010). Here,we investigated
for the ﬁrst time the role of A2AAR in the airways. Selective blockage of the
A2AAR in BAL-cells with SCH-58261 allowed us to distinguish between the
effect of this receptor subtype and the composite effect of all ARs byNECA,
thereby revealing the existence of functional A2AAR in equine airways.
Because activation of nonA2AARs in BAL cells with NECA plus SCH-58261
resulted in exaggerated IL-6 transcription, it can be reasoned that A2AAR
downregulates the induction of the proinﬂammatory IL-6 induction by the
other ARs expressed in these cells (mainly A2BAR). This effect on the
expression of this proinﬂammatory cytokine supports the idea of selective
pharmacological activation of A2AAR as a therapeutic principle in airway
inﬂammation in thehorse.
In summary, this study shows that IL-6 is rapidly induced in BAL-cells of
airway-compromised horses in response to adenosine exposure, probably
through A2BAR activation and that this effect can be modulated by A2AAR.
Further analysis of the effect of A2AAR activation on other inﬂammatory
stimuli will be required for a more complete assessment of the therapeutic
potential of selective AR activation in the horse.
Acknowledgements
Theauthorswould like to thank F. Althaus for his support, D. Trachsel for the
BAL samples from control horses and M. Bollhalder for assisting with
primer design.
Authors’ declaration of interests
No conﬂicts of interest have been declared.
Source of funding
This work was funded by the Research grant 3122 (Forschungskredit,
University of Zurich) and by the Foundation for Equine Research (Stiftung
Forschung für das Pferd, Switzerland).
Manufacturers’ addresses
1Streuli Pharma AG, Uznach, Switzerland.
2Virbac AG, Glattbrugs, Switzerland.
3Invitrogen, Carlsbad, California, USA.
4Sigma-Aldrich, St. Louis, Montana, USA.
5Macherey-Nagel, Düren, Germany.
6Applied Biosystems, Carlsbad, California, USA.
7Ficoll-Paque PLUS, GE Healthcare Biosciences, Uppsala Sweden.
8Bio-Rad, Richmond, California, USA.
9SPSS Inc., Chicago, Illinois, USA.
References
Blackburn, M.R. (2003) Too much of a good thing: adenosine overload in
adenosine-deaminase-deﬁcient mice. Trends Pharmacol. Sci. 24, 66-70.
Brandon, C.I., Vandenplas, M., Dookwah, H., Linden, J. and Murray, T.F. (2006a)
Cloning and pharmacological characterization of the equine adenosine A2A
receptor: a potential therapeutic target for the treatment of equine
endotoxemia. J. vet. Pharmacol. Ther. 29, 243-253.
Brandon, C.I., Vandenplas, M., Dookwah, H. and Murray, T.F. (2006b) Cloning and
pharmacological characterization of the equine adenosine A3 receptor. J. vet.
Pharmacol. Ther. 29, 255-263.
Couetil, L.L., Hoffman, A.M., Hodgson, J., Buechner-Maxwell, V., Viel, L., Wood, J.L.
and Lavoie, J.P. (2007) Inﬂammatory airway disease of horses. J. vet. intern. Med.
21, 356-361.
Cushley, M.J., Tattersﬁeld, A.E. and Holgate, S.T. (1983) Inhaled adenosine and
guanosine on airway resistance in normal and asthmatic subjects. Br. J. Clin.
Pharmacol. 15, 161-165.
Cushley, M.J., Tallant, N. and Holgate, S.T. (1985) The effect of dipyridamole on
histamine- and adenosine-induced bronchoconstriction in normal and asthmatic
subjects. Eur. J. Respir. Dis. 67, 185-192.
Dominitzki, S., Fantini, M.C., Neufert, C., Nikolaev, A., Galle, P.R., Scheller, J.,
Monteleone, G., Rose-John, S., Neurath, M.F. and Becker, C. (2007) Cutting edge:
trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive
CD4+CD25 T cells. J. Immunol. 179, 2041-2045.
Driver, A.G., Kukoly, C.A., Ali, S. and Mustafa, S.J. (1993) Adenosine in
bronchoalveolar lavage ﬂuid in asthma.Am. Rev. Respir. Dis. 148, 91-97.
Fozard, J.R., Ellis, K.M., Villela Dantas, M.F., Tigani, B. andMazzoni, L. (2002) Effects
of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways
inﬂammation in the rat. Eur. J. Pharmacol. 438, 183-188.
Franchini, M., Gill, U., von Fellenberg, R. and Bracher, V.D. (2000) Interleukin-8
concentration and neutrophil chemotactic activity in bronchoalveolar lavage
ﬂuid of horseswith chronic obstructive pulmonary disease following exposure to
hay.Am. J. vet. Res. 61, 1369-1374.
Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.-N. and Linden, J. (2001)
International union of pharmacology. XXV. Nomenclature and classiﬁcation of
adenosine receptors. Pharmacol. Rev. 53, 527-552.
Hasko, G., Linden, J., Cronstein, B. and Pacher, P. (2008) Adenosine receptors:
therapeutic aspects for inﬂammatory and immune diseases. Nat. Rev. Drug
Discov. 7, 759-770.
Huszar, E., Vass,G., Vizi, E., Csoma, Z., Barat, E.,MolnarVilagos,G., Herjavecz, I. and
Horvath, I. (2002) Adenosine in exhaled breath condensate in healthy volunteers
and in patients with asthma. Eur. Respir. J. 20, 1393-1398.
Kaartinen, J.M., Hreniuk, S.P., Martin, L.F., Ranta, S., LaNoue, K.F. and Ohisalo, J.J.
(1991) Attenuated adenosine-sensitivity and decreased adenosine-receptor
number in adipocyte plasma membranes in human obesity. Biochem. J. 279
(Pt 1), 17-22.
Koshiba, M., Rosin, D.L., Hayashi, N., Linden, J. and Sitkovsky, M.V. (1999)
Patterns of A2A extracellular adenosine receptor expression in
different functional subsets of human peripheral T cells. Flow cytometry
Adenosine receptor-mediated IL-6 induction in horses with lower airway inﬂammation L. Zhang et al.
86 Equine Veterinary Journal 44 (2012) 81–87© 2011 EVJ Ltd
90
studies with anti-A2A receptor monoclonal antibodies. Mol. Pharmacol. 55,
614-624.
Lappas, C.M., Rieger, J.M. and Linden, J. (2005) A2A adenosine receptor induction
inhibits IFN-gamma production in murine CD4+ T cells. J. Immunol. 174,
1073-1080.
Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
25, 402-408.
Mangan, P.R., Harrington, L.E., O’Quinn,D.B., Helms,W.S., Bullard,D.C., Elson, C.O.,
Hatton, R.D., Wahl, S.M., Schoeb, T.R. and Weaver, C.T. (2006) Transforming
growth factor-beta induces development of the T(H)17 lineage. Nature 441,
231-234.
Mohsenin, A., Mi, T., Xia, Y., Kellems, R.E., Chen, J.F. and Blackburn, M.R.
(2007) Genetic removal of the A2A adenosine receptor enhances
pulmonary inﬂammation, mucin production, and angiogenesis in adenosine
deaminase-deﬁcientmice.Am. J. Physiol. Lung CellMol. Physiol.293, L753-L761.
Ohta, A. and Sitkovsky, M. (2001) Role of G-protein-coupled adenosine receptors in
downregulation of inﬂammation and protection from tissue damage. Nature
414, 916-920.
Sitaraman, S.V., Merlin, D., Wang, L., Wong, M., Gewirtz, A.T., Si-Tahar, M. and
Madara, J.L. (2001) Neutrophil-epithelial crosstalk at the intestinal lumenal
surface mediated by reciprocal secretion of adenosine and IL-6. J. clin. Invest.
107, 861-869.
Sun, W.C., Moore, J.N., Hurley, D.J., Vandenplas, M.L., Linden, J.M. and Murray, T.F.
(2007) Pharmacologic characterization of novel adenosine A2A receptor
agonists in equine neutrophils.Am. J. vet. Res. 68, 981-987.
Sun,W.C.,Moore, J.N.,Hurley,D.J., Vandenplas,M.L., Linden, J., Cao, Z. andMurray,
T.F. (2008a)AdenosineA2A receptor agonists inhibit lipopolysaccharide-induced
production of tumor necrosis factor-alpha by equine monocytes. Vet. Immunol.
Immunopathol. 121, 91-100.
Sun, Y., Wu, F., Sun, F. and Huang, P. (2008b) Adenosine promotes IL-6 release in
airway epithelia. J. Immunol. 180, 4173-4181.
Sun,W.C., Moore, J.N., Hurley, D.J., Vandenplas, M.L., Fortes, B., Thompson, R. and
Linden, J. (2010) Differential modulation of lipopolysaccharide-induced
expression of inﬂammatory genes in equine monocytes through activation of
adenosine A(2A) receptors. Vet. Immunol. Immunopathol. 134, 169-177.
Van Belle, H., Goossens, F. and Wynants, J. (1987) Formation and release of purine
catabolites during hypoperfusion, anoxia, and ischemia. Am. J. Physiol. Heart
Circ. Physiol. 252, H886-H893.
Varani, K., Caramori, G., Vincenzi, F., Adcock, I., Casolari, P., Leung, E., Maclennan,
S., Gessi, S., Morello, S., Barnes, P.J., Ito, K., Chung, K.F., Cavallesco, G., Azzena,
G., Papi, A. andBorea, P. (2006)Alterationof adenosine receptors in patientswith
chronic obstructive pulmonary disease. Am. J. Respir. crit. care Med. 173,
398-406.
Varani, K., Massara, A., Vincenzi, F., Tosi, A., Padovan, M., Trotta, F. and Borea, P.A.
(2009) Normalization of A2A and A3 adenosine receptor up-regulation in
rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha
but notmethotrexate.Arthritis Rheum. 60, 2880-2891.
Zhong, H., Belardinelli, L., Maa, T. and Zeng, D. (2005) Synergy between A2B
adenosine receptors and hypoxia in activating human lung ﬁbroblasts. Am. J.
Respir. cell mol. Biol. 32, 2-8.
Zocchi, C., Ongini, E., Conti, A., Monopoli, A., Negretti, A., Baraldi, P.G. and
Dionisotti, S. (1996) The non-xanthine heterocyclic compound SCH 58261 is a
new potent and selective A2a adenosine receptor antagonist. J. Pharmacol.
expt. Ther. 276, 398-404.
Supporting information
Additional Supporting Information may be found in the online
version of this article: www.wileyonlinelibrary.com/journal/evj
Fig S1. Primer speciﬁcity. RT-PCR reactions were performed with the
indicated primers and BAL or cerebellum cDNA. The reactions yielded
single bands at the expected sizes and no unspeciﬁc secondary bands are
observed.A reaction for GAPDHampliﬁcationwithoutDNA is shown (-).ML:
DNAmolecular ladder, sizes are given in base pairs.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors. Any
queries (other than missing material) should be directed to the
corresponding author for the article.
L. Zhang et al. Adenosine receptor-mediated IL-6 induction in horses with lower airway inﬂammation
87Equine Veterinary Journal 44 (2012) 81–87© 2011 EVJ Ltd
91
7-Bibliography 
 
 
1. Driver, A.G., et al., Adenosine in bronchoalveolar lavage fluid in asthma. Am 
Rev Respir Dis, 1993. 148(1): p. 91-7. 
2. Giguere, V., Orphan nuclear receptors: from gene to function. Endocr Rev, 
1999. 20(5): p. 689-725. 
3. Milbrandt, J., Nerve growth factor induces a gene homologous to the 
glucocorticoid receptor gene. Neuron, 1988. 1(3): p. 183-8. 
4. Law, S.W., et al., Identification of a new brain-specific transcription factor, 
NURR1. Mol Endocrinol, 1992. 6(12): p. 2129-35. 
5. Ohkura, N., M. Hijikuro, and K. Miki, Antisense oligonucleotide to NOR-1, a 
novel orphan nuclear receptor, induces migration and neurite extension of 
cultured forebrain cells. Brain Res Mol Brain Res, 1996. 35(1-2): p. 309-13. 
6. Maruyama, K., et al., Retinoic acids differentially regulate NOR-1 and its 
closely related orphan nuclear receptor genes in breast cancer cell line MCF-
7. Biochem Biophys Res Commun, 1997. 231(2): p. 417-20. 
7. Martinez-Gonzalez, J. and L. Badimon, The NR4A subfamily of nuclear 
receptors: new early genes regulated by growth factors in vascular cells. 
Cardiovasc Res, 2005. 65(3): p. 609-18. 
8. Wang, Z., et al., Structure and function of Nurr1 identifies a class of ligand-
independent nuclear receptors. Nature, 2003. 423(6939): p. 555-60. 
9. Flaig, R., et al., Structural basis for the cell-specific activities of the NGFI-B 
and the Nurr1 ligand-binding domain. J Biol Chem, 2005. 280(19): p. 19250-
8. 
10. Maxwell, M.A. and G.E. Muscat, The NR4A subgroup: immediate early 
response genes with pleiotropic physiological roles. Nucl Recept Signal, 2006. 
4: p. e002. 
11. Zhang, L., C. Paine, and R. Dip, Selective regulation of nuclear orphan 
receptors 4A by adenosine receptor subtypes in human mast cells. J Cell 
Commun Signal, 2010. 4(4): p. 173-83. 
12. Kovalovsky, D., et al., Activation and induction of NUR77/NURR1 in 
corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and 
MAPK pathways. Mol Endocrinol, 2002. 16(7): p. 1638-51. 
13. Darragh, J., et al., MSKs are required for the transcription of the nuclear 
orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling. 
Biochem J, 2005. 390(Pt 3): p. 749-59. 
14. Bourhis, E., et al., Extracellular signal-regulated kinases (ERK) and protein 
kinase C (PKC) activities are involved in the modulation of Nur77 and Nor-1 
expression by dopaminergic drugs. J Neurochem, 2008. 106(2): p. 875-88. 
15. Saucedo-Cardenas, O., et al., Cloning and structural organization of the gene 
encoding the murine nuclear receptor transcription factor, NURR1. Gene, 
1997. 187(1): p. 135-9. 
16. Wilson, T.E., et al., Participation of non-zinc finger residues in DNA binding 
by two nuclear orphan receptors. Science, 1992. 256(5053): p. 107-10. 
17. Meinke, G. and P.B. Sigler, DNA-binding mechanism of the monomeric 
orphan nuclear receptor NGFI-B. Nat Struct Biol, 1999. 6(5): p. 471-7. 
18. Philips, A., et al., Novel dimeric Nur77 signaling mechanism in endocrine and 
lymphoid cells. Mol Cell Biol, 1997. 17(10): p. 5946-51. 
92
19. Forman, B.M., et al., Unique response pathways are established by allosteric 
interactions among nuclear hormone receptors. Cell, 1995. 81(4): p. 541-50. 
20. Aarnisalo, P., et al., Defining requirements for heterodimerization between the 
retinoid X receptor and the orphan nuclear receptor Nurr1. J Biol Chem, 
2002. 277(38): p. 35118-23. 
21. Sacchetti, P., et al., Requirements for heterodimerization between the orphan 
nuclear receptor Nurr1 and retinoid X receptors. J Biol Chem, 2002. 277(38): 
p. 35088-96. 
22. Pearen, M.A. and G.E. Muscat, Minireview: Nuclear hormone receptor 4A 
signaling: implications for metabolic disease. Mol Endocrinol, 2010. 24(10): 
p. 1891-903. 
23. Maira, M., et al., Dimer-specific potentiation of NGFI-B (Nur77) 
transcriptional activity by the protein kinase A pathway and AF-1-dependent 
coactivator recruitment. Mol Cell Biol, 2003. 23(3): p. 763-76. 
24. Sohn, Y.C., et al., Silencing mediator of retinoid and thyroid hormone 
receptors and activating signal cointegrator-2 as transcriptional coregulators 
of the orphan nuclear receptor Nur77. J Biol Chem, 2001. 276(47): p. 43734-
9. 
25. Codina, A., et al., Identification of a novel co-regulator interaction surface on 
the ligand binding domain of Nurr1 using NMR footprinting. J Biol Chem, 
2004. 279(51): p. 53338-45. 
26. Hirata, Y., et al., The phosphorylation and DNA binding of the DNA-binding 
domain of the orphan nuclear receptor NGFI-B. J Biol Chem, 1993. 268(33): 
p. 24808-12. 
27. Galleguillos, D., et al., PIASgamma represses the transcriptional activation 
induced by the nuclear receptor Nurr1. J Biol Chem, 2004. 279(3): p. 2005-11. 
28. Liu, B., et al., Regulation of the orphan receptor TR3 nuclear functions by c-
Jun N terminal kinase phosphorylation. Endocrinology, 2007. 148(1): p. 34-44. 
29. Davis, I.J., et al., Functional domains and phosphorylation of the orphan 
receptor Nur77. Mol Endocrinol, 1993. 7(8): p. 953-64. 
30. Katagiri, Y., et al., Modulation of retinoid signalling through NGF-induced 
nuclear export of NGFI-B. Nat Cell Biol, 2000. 2(7): p. 435-40. 
31. Li, H., et al., Cytochrome c release and apoptosis induced by mitochondrial 
targeting of nuclear orphan receptor TR3. Science, 2000. 289(5482): p. 1159-
64. 
32. Lin, B., et al., Conversion of Bcl-2 from protector to killer by interaction with 
nuclear orphan receptor Nur77/TR3. Cell, 2004. 116(4): p. 527-40. 
33. Nsegbe, E., et al., Congenital hypoventilation and impaired hypoxic response 
in Nurr1 mutant mice. J Physiol, 2004. 556(Pt 1): p. 43-59. 
34. Fernandez, P.M., et al., Nuclear receptors Nor1 and NGFI-B/Nur77 play 
similar, albeit distinct, roles in the hypothalamo-pituitary-adrenal axis. 
Endocrinology, 2000. 141(7): p. 2392-400. 
35. Murphy, E.P., et al., Involvement of the nuclear orphan receptor NURR1 in 
the regulation of corticotropin-releasing hormone expression and actions in 
human inflammatory arthritis. Arthritis Rheum, 2001. 44(4): p. 782-93. 
36. Woronicz, J.D., et al., Requirement for the orphan steroid receptor Nur77 in 
apoptosis of T-cell hybridomas. Nature, 1994. 367(6460): p. 277-81. 
37. Liu, Z.G., et al., Apoptotic signals delivered through the T-cell receptor of a 
T-cell hybrid require the immediate-early gene nur77. Nature, 1994. 
367(6460): p. 281-4. 
93
38. Lee, S.L., et al., Unimpaired thymic and peripheral T cell death in mice 
lacking the nuclear receptor NGFI-B (Nur77). Science, 1995. 269(5223): p. 
532-5. 
39. Cheng, L.E., et al., Functional redundancy of the Nur77 and Nor-1 orphan 
steroid receptors in T-cell apoptosis. EMBO J, 1997. 16(8): p. 1865-75. 
40. Sekiya, T., et al., The nuclear orphan receptor Nr4a2 induces Foxp3 and 
regulates differentiation of CD4+ T cells. Nat Commun, 2011. 2: p. 269. 
41. Kim, S.O., et al., Orphan nuclear receptor Nur77 is involved in caspase-
independent macrophage cell death. J Exp Med, 2003. 197(11): p. 1441-52. 
42. Pei, L., et al., Induction of NR4A orphan nuclear receptor expression in 
macrophages in response to inflammatory stimuli. J Biol Chem, 2005. 280(32): 
p. 29256-62. 
43. Bonta, P.I., et al., Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in 
atherosclerotic lesion macrophages reduce lipid loading and inflammatory 
responses. Arterioscler Thromb Vasc Biol, 2006. 26(10): p. 2288-94. 
44. Pei, L., A. Castrillo, and P. Tontonoz, Regulation of macrophage 
inflammatory gene expression by the orphan nuclear receptor Nur77. Mol 
Endocrinol, 2006. 20(4): p. 786-94. 
45. Saijo, K., et al., A Nurr1/CoREST pathway in microglia and astrocytes 
protects dopaminergic neurons from inflammation-induced death. Cell, 2009. 
137(1): p. 47-59. 
46. Zhang, X.K., Targeting Nur77 translocation. Expert Opin Ther Targets, 2007. 
11(1): p. 69-79. 
47. Li, Q.X., et al., NR4A1, 2, 3--an orphan nuclear hormone receptor family 
involved in cell apoptosis and carcinogenesis. Histol Histopathol, 2006. 21(5): 
p. 533-40. 
48. Wu, H., et al., Regulation of Nur77 expression by beta-catenin and its 
mitogenic effect in colon cancer cells. FASEB J, 2011. 25(1): p. 192-205. 
49. Lee, S.O., et al., Inactivation of the orphan nuclear receptor TR3/Nur77 
inhibits pancreatic cancer cell and tumor growth. Cancer Res, 2010. 70(17): p. 
6824-36. 
50. Inamoto, T., et al., Cytoplasmic mislocalization of the orphan nuclear receptor 
Nurr1 is a prognostic factor in bladder cancer. Cancer, 2010. 116(2): p. 340-6. 
51. Kolluri, S.K., et al., Mitogenic effect of orphan receptor TR3 and its 
regulation by MEKK1 in lung cancer cells. Mol Cell Biol, 2003. 23(23): p. 
8651-67. 
52. Mullican, S.E., et al., Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads 
to development of acute myeloid leukemia. Nat Med, 2007. 13(6): p. 730-5. 
53. Drury, A.N. and A. Szent-Gyorgyi, The physiological activity of adenine 
compounds with especial reference to their action upon the mammalian heart. 
J Physiol, 1929. 68(3): p. 213-37. 
54. Ballarin, M., et al., Extracellular levels of adenosine and its metabolites in the 
striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol 
Scand, 1991. 142(1): p. 97-103. 
55. Hagberg, H., et al., Extracellular adenosine, inosine, hypoxanthine, and 
xanthine in relation to tissue nucleotides and purines in rat striatum during 
transient ischemia. J Neurochem, 1987. 49(1): p. 227-31. 
56. Dux, E., et al., Protective effect of adenosine and a novel xanthine derivative 
propentofylline on the cell damage after bilateral carotid occlusion in the 
gerbil hippocampus. Brain Res, 1990. 516(2): p. 248-56. 
94
57. Zimmermann, H., et al., New insights into molecular structure and function of 
ectonucleotidases in the nervous system. Neurochem Int, 1998. 32(5-6): p. 
421-5. 
58. Arch, J.R. and E.A. Newsholme, The control of the metabolism and the 
hormonal role of adenosine. Essays Biochem, 1978. 14: p. 82-123. 
59. Lloyd, H.G. and B.B. Fredholm, Involvement of adenosine deaminase and 
adenosine kinase in regulating extracellular adenosine concentration in rat 
hippocampal slices. Neurochem Int, 1995. 26(4): p. 387-95. 
60. Cristalli, G., et al., Adenosine deaminase: functional implications and different 
classes of inhibitors. Med Res Rev, 2001. 21(2): p. 105-28. 
61. Adair, T.H., Growth regulation of the vascular system: an emerging role for 
adenosine. Am J Physiol Regul Integr Comp Physiol, 2005. 289(2): p. R283-
R296. 
62. Ralevic, V., G. Knight, and G. Burnstock, Effects of hibernation and arousal 
from hibernation on mesenteric arterial responses of the golden hamster. J 
Pharmacol Exp Ther, 1998. 287(2): p. 521-6. 
63. Dip, R.G., Adenosine receptor modulation: potential implications in 
veterinary medicine. Vet J, 2009. 179(1): p. 38-49. 
64. Muller, C.E., Adenosine receptor ligands-recent developments part I. Agonists. 
Curr Med Chem, 2000. 7(12): p. 1269-88. 
65. Jacobson, K.A. and Z.G. Gao, Adenosine receptors as therapeutic targets. Nat 
Rev Drug Discov, 2006. 5(3): p. 247-64. 
66. Baraldi, P.G., et al., Recent improvements in the development of A(2B) 
adenosine receptor agonists. Purinergic Signal, 2009. 5(1): p. 3-19. 
67. Cooper, D.M., C. Londos, and M. Rodbell, Adenosine receptor-mediated 
inhibition of rat cerebral cortical adenylate cyclase by a GTP-dependent 
process. Mol Pharmacol, 1980. 18(3): p. 598-601. 
68. Rogel, A., et al., Phospholipase C is involved in the adenosine-activated 
signal transduction pathway conferring protection against iodoacetic acid-
induced injury in primary rat neuronal cultures. Neurosci Lett, 2005. 373(3): 
p. 218-21. 
69. Fredholm, B.B., et al., International Union of Pharmacology. XXV. 
Nomenclature and classification of adenosine receptors. Pharmacol Rev, 2001. 
53(4): p. 527-52. 
70. Belardinelli, L., et al., 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a 
potent, specific and selective A1 adenosine receptor antagonist in the guinea 
pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther, 1995. 
275(3): p. 1167-76. 
71. Fresco, P., C. Diniz, and J. Goncalves, Facilitation of noradrenaline release 
by activation of adenosine A(2A) receptors triggers both phospholipase C and 
adenylate cyclase pathways in rat tail artery. Cardiovasc Res, 2004. 63(4): p. 
739-46. 
72. Offermanns, S. and M.I. Simon, G alpha 15 and G alpha 16 couple a wide 
variety of receptors to phospholipase C. J Biol Chem, 1995. 270(25): p. 
15175-80. 
73. Brackett, L.E. and J.W. Daly, Functional characterization of the A2b 
adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol, 1994. 47(5): 
p. 801-14. 
95
74. Feoktistov, I. and I. Biaggioni, Adenosine A2b receptors evoke interleukin-8 
secretion in human mast cells. An enprofylline-sensitive mechanism with 
implications for asthma. J Clin Invest, 1995. 96(4): p. 1979-86. 
75. Zhou, Q.Y., et al., Molecular cloning and characterization of an adenosine 
receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A, 1992. 89(16): 
p. 7432-6. 
76. Fossetta, J., et al., Pharmacological analysis of calcium responses mediated by 
the human A3 adenosine receptor in monocyte-derived dendritic cells and 
recombinant cells. Mol Pharmacol, 2003. 63(2): p. 342-50. 
77. Mozzicato, S., et al., Role of direct RhoA-phospholipase D1 interaction in 
mediating adenosine-induced protection from cardiac ischemia. FASEB J, 
2004. 18(2): p. 406-8. 
78. Gessi, S., et al., Expression of A3 adenosine receptors in human lymphocytes: 
up-regulation in T cell activation. Mol Pharmacol, 2004. 65(3): p. 711-9. 
79. Stiles, G.L., Adenosine receptors. J Biol Chem, 1992. 267(10): p. 6451-4. 
80. Sun, C.X., et al., Role of A2B adenosine receptor signaling in adenosine-
dependent pulmonary inflammation and injury. J Clin Invest, 2006. 116(8): p. 
2173-2182. 
81. Marx, D., et al., Therapy of bronchial asthma with adenosine receptor 
agonists or antagonists. Drug News Perspect, 2001. 14(2): p. 89-100. 
82. Ansari, H.R., et al., A(1) adenosine receptor-mediated PKC and p42/p44 
MAPK signaling in mouse coronary artery smooth muscle cells. Am J Physiol 
Heart Circ Physiol, 2009. 297(3): p. H1032-9. 
83. Bayes, M., X. Rabasseda, and J.R. Prous, Gateways to clinical trials. Methods 
Find Exp Clin Pharmacol, 2003. 25(10): p. 831-55. 
84. Zambrowicz, B.P., C.A. Turner, and A.T. Sands, Predicting drug efficacy: 
knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin 
Pharmacol, 2003. 3(5): p. 563-70. 
85. Dong, Q., H.N. Ginsberg, and B.F. Erlanger, Overexpression of the A1 
adenosine receptor in adipose tissue protects mice from obesity-related insulin 
resistance. Diabetes Obes Metab, 2001. 3(5): p. 360-6. 
86. Maemoto, T., et al., Pharmacological characterization of FR194921, a new 
potent, selective, and orally active antagonist for central adenosine A1 
receptors. J Pharmacol Sci, 2004. 96(1): p. 42-52. 
87. Wilcox, C.S., et al., Natriuretic and diuretic actions of a highly selective 
adenosine A1 receptor antagonist. J Am Soc Nephrol, 1999. 10(4): p. 714-20. 
88. Moreau, J.L. and G. Huber, Central adenosine A(2A) receptors: an overview. 
Brain Res Brain Res Rev, 1999. 31(1): p. 65-82. 
89. Ohta, A. and M. Sitkovsky, Role of G-protein-coupled adenosine receptors in 
downregulation of inflammation and protection from tissue damage. Nature, 
2001. 414(6866): p. 916-20. 
90. Lappas, C.M., G.W. Sullivan, and J. Linden, Adenosine A2A agonists in 
development for the treatment of inflammation. Expert Opin Investig Drugs, 
2005. 14(7): p. 797-806. 
91. Hasko, G., et al., Adenosine A2A receptor activation reduces lung injury in 
trauma/hemorrhagic shock. Crit Care Med, 2006. 34(4): p. 1119-25. 
92. Dianzani, C., et al., Adenosine modulation of primed human neutrophils. Eur J 
Pharmacol, 1994. 263(1-2): p. 223-6. 
96
93. Sitkovsky, M.V., Use of the A(2A) adenosine receptor as a physiological 
immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol, 
2003. 65(4): p. 493-501. 
94. Olah, M.E. and G.L. Stiles, Adenosine receptor subtypes: characterization 
and therapeutic regulation. Annu Rev Pharmacol Toxicol, 1995. 35: p. 581-
606. 
95. Liu, Q., et al., Adenosine signaling mediates SUMO-1 modification of 
IkappaBalpha during hypoxia and reoxygenation. J Biol Chem, 2009. 284(20): 
p. 13686-95. 
96. Fredholm, B.B., et al., Aspects of the general biology of adenosine A2A 
signaling. Prog Neurobiol, 2007. 83(5): p. 263-76. 
97. Fozard, J.R., et al., Effects of CGS 21680, a selective adenosine A2A receptor 
agonist, on allergic airways inflammation in the rat. Eur J Pharmacol, 2002. 
438(3): p. 183-8. 
98. Day, Y.J., et al., Protection from ischemic liver injury by activation of A2A 
adenosine receptors during reperfusion: inhibition of chemokine induction. 
Am J Physiol Gastrointest Liver Physiol, 2004. 286(2): p. G285-93. 
99. Sullivan, G.W., et al., A2A adenosine receptor activation improves survival in 
mouse models of endotoxemia and sepsis. J Infect Dis, 2004. 189(10): p. 1897-
904. 
100. Odashima, M., et al., Activation of A2A adenosine receptor attenuates 
intestinal inflammation in animal models of inflammatory bowel disease. 
Gastroenterology, 2005. 129(1): p. 26-33. 
101. Peirce, S.M., et al., Selective A(2A) adenosine receptor activation reduces skin 
pressure ulcer formation and inflammation. Am J Physiol Heart Circ Physiol, 
2001. 281(1): p. H67-74. 
102. Barrett, R.J., et al., Pharmacokinetics and safety of binodenoson after 
intravenous dose escalation in healthy volunteers. J Nucl Cardiol, 2005. 12(2): 
p. 166-71. 
103. Hauser, R.A., J.P. Hubble, and D.D. Truong, Randomized trial of the 
adenosine A(2A) receptor antagonist istradefylline in advanced PD. 
Neurology, 2003. 61(3): p. 297-303. 
104. Polosa, R., Adenosine-receptor subtypes: their relevance to adenosine-
mediated responses in asthma and chronic obstructive pulmonary disease. Eur 
Respir J, 2002. 20(2): p. 488-96. 
105. Gessi, S., et al., Novel selective antagonist radioligands for the 
pharmacological study of A(2B) adenosine receptors. Purinergic Signal, 2006. 
2(4): p. 583-8. 
106. Feoktistov, I., et al., Differential expression of adenosine receptors in human 
endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ 
Res, 2002. 90(5): p. 531-8. 
107. Mino, R.P., et al., Adenosine receptor antagonists and retinal 
neovascularization in vivo. Invest Ophthalmol Vis Sci, 2001. 42(13): p. 3320-
4. 
108. Feoktistov, I. and I. Biaggioni, Adenosine A2B receptors. Pharmacol Rev, 
1997. 49(4): p. 381-402. 
109. Dubey, R.K., et al., Endogenous cyclic AMP-adenosine pathway regulates 
cardiac fibroblast growth. Hypertension, 2001. 37(4): p. 1095-100. 
97
110. Dubey, R., et al., Dysregulation of extracellular adenosine levels by vascular 
smooth muscle cells from spontaneously hypertensive rats. Arterioscler 
Thromb Vasc Biol, 2001. 21(2): p. 249-54. 
111. Sexl, V., et al., Stimulation of human umbilical vein endothelial cell 
proliferation by A2-adenosine and beta 2-adrenoceptors. Br J Pharmacol, 
1995. 114(8): p. 1577-86. 
112. Grant, M.B., et al., Adenosine receptor activation induces vascular endothelial 
growth factor in human retinal endothelial cells. Circ Res, 1999. 85(8): p. 
699-706. 
113. Varani, K., et al., Pharmacological characterization of novel adenosine 
ligands in recombinant and native human A2B receptors. Biochem Pharmacol, 
2005. 70(11): p. 1601-12. 
114. Hasko, G., et al., A(2B) adenosine receptors in immunity and inflammation. 
Trends Immunol, 2009. 30(6): p. 263-70. 
115. Holgate, S.T., The Quintiles Prize Lecture 2004. The identification of the 
adenosine A2B receptor as a novel therapeutic target in asthma. Br J 
Pharmacol, 2005. 145(8): p. 1009-15. 
116. Harada, H., et al., 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine 
receptor antagonists: their synthesis and structure-activity relationships 
toward hepatic glucose production induced via agonism of the A(2B) receptor. 
J Med Chem, 2001. 44(2): p. 170-9. 
117. Linden, J., Cloned adenosine A3 receptors: pharmacological properties, 
species differences and receptor functions. Trends Pharmacol Sci, 1994. 15(8): 
p. 298-306. 
118. Gessi, S., et al., The A3 adenosine receptor: an enigmatic player in cell 
biology. Pharmacol Ther, 2008. 117(1): p. 123-40. 
119. Fredholm, B.B., et al., Comparison of the potency of adenosine as an agonist 
at human adenosine receptors expressed in Chinese hamster ovary cells. 
Biochem Pharmacol, 2001. 61(4): p. 443-8. 
120. Schulte, G. and B.B. Fredholm, Signalling from adenosine receptors to 
mitogen-activated protein kinases. Cell Signal, 2003. 15(9): p. 813-27. 
121. Bar-Yehuda, S., et al., The anti-inflammatory effect of A3 adenosine receptor 
agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin 
Investig Drugs, 2007. 16(10): p. 1601-13. 
122. Fishman, P., et al., Pharmacological and therapeutic effects of A3 adenosine 
receptor agonists. Drug Discov Today, 2012. 17(7-8): p. 359-66. 
123. Madi, L., et al., The A3 adenosine receptor is highly expressed in tumor versus 
normal cells: potential target for tumor growth inhibition. Clin Cancer Res, 
2004. 10(13): p. 4472-9. 
124. Tracey, W.R., et al., Novel N6-substituted adenosine 5'-N-methyluronamides 
with high selectivity for human adenosine A3 receptors reduce ischemic 
myocardial injury. Am J Physiol Heart Circ Physiol, 2003. 285(6): p. H2780-7. 
125. Shneyvays, V., et al., Activation of A(3)adenosine receptor protects against 
doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol, 2001. 33(6): p. 1249-
61. 
126. Holgate, S.T., R.A. Lewis, and K.F. Austen, Role of adenylate cyclase in 
immunologic release of mediators from rat mast cells: agonist and antagonist 
effects of purine- and ribose-modified adenosine analogs. Proc Natl Acad Sci 
U S A, 1980. 77(11): p. 6800-4. 
98
127. Cushley, M.J., A.E. Tattersfield, and S.T. Holgate, Inhaled adenosine and 
guanosine on airway resistance in normal and asthmatic subjects. Br J Clin 
Pharmacol, 1983. 15(2): p. 161-5. 
128. Basoglu, O.K., et al., Effects of aerosolized adenosine 5'-triphosphate vs 
adenosine 5'-monophosphate on dyspnea and airway caliber in healthy 
nonsmokers and patients with asthma. Chest, 2005. 128(4): p. 1905-9. 
129. Polosa, R. and S.T. Holgate, Adenosine receptors as promising therapeutic 
targets for drug development in chronic airway inflammation. Curr Drug 
Targets, 2006. 7(6): p. 699-706. 
130. Ryzhov, S., et al., Effect of A2B adenosine receptor gene ablation on 
proinflammatory adenosine signaling in mast cells. J Immunol, 2008. 180(11): 
p. 7212-20. 
131. Zhong, H., et al., Activation of murine lung mast cells by the adenosine A3 
receptor. J Immunol, 2003. 171(1): p. 338-45. 
132. Salvatore, C.A., et al., Disruption of the A(3) adenosine receptor gene in mice 
and its effect on stimulated inflammatory cells. J Biol Chem, 2000. 275(6): p. 
4429-34. 
133. Zhong, H., et al., A(2B) adenosine receptors increase cytokine release by 
bronchial smooth muscle cells. Am J Respir Cell Mol Biol, 2004. 30(1): p. 
118-25. 
134. Zhong, H., et al., A2B adenosine receptors induce IL-19 from bronchial 
epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol, 
2006. 35(5): p. 587-92. 
135. Zhong, H., et al., Synergy between A2B adenosine receptors and hypoxia in 
activating human lung fibroblasts. Am J Respir Cell Mol Biol, 2005. 32(1): p. 
2-8. 
136. Reutershan, J., et al., Therapeutic anti-inflammatory effects of myeloid cell 
adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. 
J Immunol, 2007. 179(2): p. 1254-63. 
137. Nadeem, A., et al., Enhanced airway reactivity and inflammation in A2A 
adenosine receptor-deficient allergic mice. Am J Physiol Lung Cell Mol 
Physiol, 2007. 292(6): p. L1335-44. 
138. Pagonopoulou, O., et al., Modulatory role of adenosine and its receptors in 
epilepsy: possible therapeutic approaches. Neuroscience research, 2006. 56(1): 
p. 14-20. 
139. Shi, Y., et al., Interaction of mechanisms involving epoxyeicosatrienoic acids, 
adenosine receptors, and metabotropic glutamate receptors in neurovascular 
coupling in rat whisker barrel cortex. J Cereb Blood Flow Metab, 2008. 28(1): 
p. 111-25. 
140. Sawynok, J. and X.J. Liu, Adenosine in the spinal cord and periphery: release 
and regulation of pain. Prog Neurobiol, 2003. 69(5): p. 313-40. 
141. Schwarzschild, M.A., et al., Targeting adenosine A2A receptors in 
Parkinson's disease. Trends Neurosci, 2006. 29(11): p. 647-54. 
142. Basheer, R., et al., Adenosine and sleep-wake regulation. Prog Neurobiol, 
2004. 73(6): p. 379-96. 
143. Lahiri, S., et al., Purines, the carotid body and respiration. Respir Physiol 
Neurobiol, 2007. 157(1): p. 123-9. 
144. Das, P., et al., Combinatorial roles of protein kinase A, Ets2, and 3',5'-cyclic-
adenosine monophosphate response element-binding protein-binding 
99
protein/p300 in the transcriptional control of interferon-tau expression in a 
trophoblast cell line. Mol Endocrinol, 2008. 22(2): p. 331-43. 
145. Hansen, P.B., et al., Attenuated renovascular constrictor responses to 
angiotensin II in adenosine 1 receptor knockout mice. Am J Physiol Regul 
Integr Comp Physiol, 2003. 285(1): p. R44-9. 
146. Vallon, V., B. Muhlbauer, and H. Osswald, Adenosine and kidney function. 
Physiol Rev, 2006. 86(3): p. 901-40. 
147. Edlund, A., H. Ohlsen, and A. Sollevi, Renal effects of local infusion of 
adenosine in man. Clin Sci (Lond), 1994. 87(2): p. 143-9. 
148. Merighi, S., et al., A glance at adenosine receptors: novel target for antitumor 
therapy. Pharmacol Ther, 2003. 100(1): p. 31-48. 
149. Synowitz, M., et al., A1 adenosine receptors in microglia control 
glioblastoma-host interaction. Cancer Res, 2006. 66(17): p. 8550-7. 
150. Koshiba, M., et al., Memory of extracellular adenosine A2A purinergic 
receptor-mediated signaling in murine T cells. J Biol Chem, 1997. 272(41): p. 
25881-9. 
151. Merighi, S., et al., Caffeine inhibits adenosine-induced accumulation of 
hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and 
interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol, 
2007. 72(2): p. 395-406. 
152. Feoktistov, I., et al., Mast cell-mediated stimulation of angiogenesis: 
cooperative interaction between A2B and A3 adenosine receptors. Circ Res, 
2003. 92(5): p. 485-92. 
153. Gessi, S., et al., Elevated expression of A3 adenosine receptors in human 
colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res, 2004. 
10(17): p. 5895-901. 
154. Merighi, S., et al., A3 adenosine receptor activation inhibits cell proliferation 
via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular 
signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J 
Biol Chem, 2005. 280(20): p. 19516-26. 
155. Fishman, P., et al., A3 adenosine receptor as a target for cancer therapy. 
Anticancer Drugs, 2002. 13(5): p. 437-43. 
156. Hoskin, D.W., et al., Adenosine acts through an A3 receptor to prevent the 
induction of murine anti-CD3-activated killer T cells. Int J Cancer, 2002. 
99(3): p. 386-95. 
157. Hasko, G., et al., Adenosine receptors: therapeutic aspects for inflammatory 
and immune diseases. Nat Rev Drug Discov, 2008. 7(9): p. 759-70. 
158. Linden, J., Molecular approach to adenosine receptors: receptor-mediated 
mechanisms of tissue protection. Annu Rev Pharmacol Toxicol, 2001. 41: p. 
775-87. 
159. Hua, X., et al., Enhanced mast cell activation in mice deficient in the A2b 
adenosine receptor. J Exp Med, 2007. 204(1): p. 117-28. 
160. Hasko, G., et al., Adenosine inhibits IL-12 and TNF-[alpha] production via 
adenosine A2a receptor-dependent and independent mechanisms. FASEB J, 
2000. 14(13): p. 2065-74. 
161. Kreckler, L.M., et al., Adenosine inhibits tumor necrosis factor-alpha release 
from mouse peritoneal macrophages via A2A and A2B but not the A3 
adenosine receptor. J Pharmacol Exp Ther, 2006. 317(1): p. 172-80. 
100
162. Ryzhov, S., et al., Effect of A2B adenosine receptor gene ablation on 
adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol 
Exp Ther, 2008. 324(2): p. 694-700. 
163. Csoka, B., et al., A2A adenosine receptors and C/EBPbeta are crucially 
required for IL-10 production by macrophages exposed to Escherichia coli. 
Blood, 2007. 110(7): p. 2685-95. 
164. Cronstein, B.N., et al., Adenosine: a physiological modulator of superoxide 
anion generation by human neutrophils. J Exp Med, 1983. 158(4): p. 1160-77. 
165. Varani, K., et al., [3H]-SCH 58261 labelling of functional A2A adenosine 
receptors in human neutrophil membranes. Br J Pharmacol, 1998. 123(8): p. 
1723-31. 
166. McColl, S.R., et al., Immunomodulatory impact of the A2A adenosine receptor 
on the profile of chemokines produced by neutrophils. FASEB J, 2006. 20(1): 
p. 187-9. 
167. Mayne, M., et al., Adenosine A2A receptor activation reduces 
proinflammatory events and decreases cell death following intracerebral 
hemorrhage. Ann Neurol, 2001. 49(6): p. 727-35. 
168. Walker, B.A., et al., Adenosine A2a receptor activation delays apoptosis in 
human neutrophils. J Immunol, 1997. 158(6): p. 2926-31. 
169. Yasui, K., et al., Theophylline induces neutrophil apoptosis through adenosine 
A2A receptor antagonism. J Leukoc Biol, 2000. 67(4): p. 529-35. 
170. Erdmann, A.A., et al., Activation of Th1 and Tc1 cell adenosine A2A receptors 
directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. 
Blood, 2005. 105(12): p. 4707-14. 
171. Guhl, S., et al., Mast cell lines HMC-1 and LAD2 in comparison with mature 
human skin mast cells--drastically reduced levels of tryptase and chymase in 
mast cell lines. Exp Dermatol, 2010. 19(9): p. 845-7. 
172. Nilsson, G., et al., Phenotypic characterization of the human mast-cell line 
HMC-1. Scand J Immunol, 1994. 39(5): p. 489-98. 
173. Brightling, C.E., et al., New insights into the role of the mast cell in asthma. 
Clin Exp Allergy, 2003. 33(5): p. 550-6. 
174. Blatner, N.R., et al., In colorectal cancer mast cells contribute to systemic 
regulatory T-cell dysfunction. Proc Natl Acad Sci U S A, 2010. 107(14): p. 
6430-5. 
175. Groot Kormelink, T., A. Abudukelimu, and F.A. Redegeld, Mast cells as 
target in cancer therapy. Curr Pharm Des, 2009. 15(16): p. 1868-78. 
176. Abraham, S.N. and A.L. St John, Mast cell-orchestrated immunity to 
pathogens. Nat Rev Immunol, 2010. 10(6): p. 440-52. 
177. Rivera, J. and A.M. Gilfillan, Molecular regulation of mast cell activation. J 
Allergy Clin Immunol, 2006. 117(6): p. 1214-25; quiz 1226. 
178. Roth, K., W.M. Chen, and T.J. Lin, Positive and negative regulatory 
mechanisms in high-affinity IgE receptor-mediated mast cell activation. Arch 
Immunol Ther Exp (Warsz), 2008. 56(6): p. 385-99. 
179. Palmer, T.M. and M.A. Trevethick, Suppression of inflammatory and immune 
responses by the A(2A) adenosine receptor: an introduction. Br J Pharmacol, 
2008. 153 Suppl 1: p. S27-34. 
180. Spicuzza, L., G. Di Maria, and R. Polosa, Adenosine in the airways: 
implications and applications. Eur J Pharmacol, 2006. 533(1-3): p. 77-88. 
181. Feoktistov, I., A.E. Goldstein, and I. Biaggioni, Role of p38 mitogen-activated 
protein kinase and extracellular signal-regulated protein kinase kinase in 
101
adenosine A2B receptor-mediated interleukin-8 production in human mast 
cells. Mol Pharmacol, 1999. 55(4): p. 726-34. 
182. Wallen-Mackenzie, A., et al., Nurr1-RXR heterodimers mediate RXR ligand-
induced signaling in neuronal cells. Genes Dev, 2003. 17(24): p. 3036-47. 
183. Lammi, J., et al., Cross-talk between the NR3B and NR4A families of orphan 
nuclear receptors. Biochem Biophys Res Commun, 2007. 359(2): p. 391-7. 
184. Harant, H. and I.J. Lindley, Negative cross-talk between the human orphan 
nuclear receptor Nur77/NAK-1/TR3 and nuclear factor-kappaB. Nucleic 
Acids Res, 2004. 32(17): p. 5280-90. 
185. Genini, D. and C.V. Catapano, Block of nuclear receptor ubiquitination. A 
mechanism of ligand-dependent control of peroxisome proliferator-activated 
receptor delta activity. J Biol Chem, 2007. 282(16): p. 11776-85. 
186. Pekarsky, Y., et al., Akt phosphorylates and regulates the orphan nuclear 
receptor Nur77. Proc Natl Acad Sci U S A, 2001. 98(7): p. 3690-4. 
187. McEvoy, A.N., et al., Activation of nuclear orphan receptor NURR1 
transcription by NF-kappa B and cyclic adenosine 5'-monophosphate 
response element-binding protein in rheumatoid arthritis synovial tissue. J 
Immunol, 2002. 168(6): p. 2979-87. 
188. Aherne, C.M., et al., Identification of NR4A2 as a transcriptional activator of 
IL-8 expression in human inflammatory arthritis. Mol Immunol, 2009. 46(16): 
p. 3345-57. 
189. Wang, X.Z. and D. Ron, Stress-induced phosphorylation and activation of the 
transcription factor CHOP (GADD153) by p38 MAP Kinase. Science, 1996. 
272(5266): p. 1347-9. 
190. Wang, X.Z., et al., Signals from the stressed endoplasmic reticulum induce 
C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol, 1996. 16(8): p. 
4273-80. 
191. Yamazaki, H., et al., Activation of the Akt-NF-kappaB pathway by subtilase 
cytotoxin through the ATF6 branch of the unfolded protein response. J 
Immunol, 2009. 183(2): p. 1480-7. 
192. Wedemeyer, J., M. Tsai, and S.J. Galli, Roles of mast cells and basophils in 
innate and acquired immunity. Curr Opin Immunol, 2000. 12(6): p. 624-31. 
193. Robinson, N.E., et al., The pathogenesis of chronic obstructive pulmonary 
disease of horses. Br Vet J, 1996. 152(3): p. 283-306. 
194. Tsoumakidou, M., et al., Inflammatory cell profiles and T-lymphocyte subsets 
in chronic obstructive pulmonary disease and severe persistent asthma. Clin 
Exp Allergy, 2004. 34(2): p. 234-40. 
195. Couetil, L.L., et al., Inflammatory airway disease of horses. J Vet Intern Med, 
2007. 21(2): p. 356-61. 
 
 
102
8-Curriculum Vitae 
 
Personal data 
Name                                Zhang Li       
Date of Birth    April 25th, 1980  
Nationality                       Chinese 
 
Education 
• 2008-present  
 
• 2005-2008 
PhD student. Graduate School for Cellular and Biomedical 
Sciences, University of Bern, Switzerland 
 
Master of Biomedical Engineering  
Martin-Luther-University Halle-Wittenberg, Germany 
 
• 1998-2003 Bachelor degree of Clinical Medicine  
Peking University, Beijing, P. R. China  
 
Work and Research Experience  
 
• 08/2008-07/2012  
 
Institute of Pharmacology and Toxicology, Vetsuisse-Faculty. 
University of Zurich, Switzerland 
Supervisor: PD Dr. Ramiro Dip ?
Research project: Characterization of nuclear orphan receptors 
NR4A in inflammatory signaling in human mast cells and their 
modulation by adenosine receptors 
 
• 08/2006-06/2008 
 
Laboratory of Clinical Inner Medical Department III. Martin-Luther-
University Halle-Wittenberg, Germany 
Supervisor: Prof. Dr. Harald Loppnow 
Research project:  Reduction of interleukin-6 production of human 
smooth muscle cells and mononuclear cells coculture by statins 
 
• 04/2006-07/2006 Martin-Luther-University Halle-Wittenberg, Germany. Scientific 
rotations 
• Institute of Environmental Toxicology, Group work of Influence 
of mini particle on arthrosclerosis 
• Institute of Pathology, Group work of Using comparative 
genomic hybridization (CGH) method to analyze DNA-gains and 
losses in leukemia 
• Institute of Neurology, Group work of Enzymatic provisions 
(Mitochondrial respiratory chain complexes) 
• Institute of Bioengineering, Group work of Investigate cell 
growth on different material surface 
 
• 08/2003- 07/2005 
 
Work in HaiDian hospital, Beijing, China  
Job responsibilities: Diagnosis and care of inpatients and outpatients 
 
 
103
Publications 
1. Zhang L, Franchini M, Wehrli Eser M, Dip R. Enhanced IL-6 transcriptional response to 
adenosine receptor ligands in horses with lower airway inflammation. Equine Vet J. 2012 
Jan;44(1):81-7.  
2. Zhang L, Franchini M, Wehrli Eser M, Jackson EK, Dip R. Increased adenosine 
concentration in bronchoalveolar lavage fluid of horses with lower airway inflammation. 
Vet J. 2012 Dec 27 [Epub ahead of print] 
3. Zhang L, Paine C, Dip R. Selective regulation of nuclear orphan receptors 4A by 
adenosine receptor subtypes in human mast cells. J Cell Commun Signal. 2010 
Dec;4(4):173-83.  
4. Loppnow H, Zhang L, Buerke M, Lautenschläger M, Chen L, Frister A, Schlitt A, Luther 
T, Song N, Hofmann B, Rose-John S, Silber RE, Müller-Werdan U, Werdan K. Statins 
potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol 
Med. 2011 Apr;15(4):994-1004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104
9-Acknowledgements 
 
 
The work on this thesis, during the last three and half years, was exciting! I was 
inspired and supported by many people, colleagues, friends and relatives. I would like 
to express my thanks to:  
 
PD Dr. Ramiro Dip for the opportunity to join his group, for the supervision of this 
thesis, critical advice, continuous support in the experimental work and helpful 
discussions,  
 
Prof. Felix R. Althaus for giving me the opportunity to conduct my PhD project at the 
Institute of Veterinary Pharmacology and Toxicology, Vetsuissue-Zürich, 
 
PD Dr. Lloyd Vaughan for the co-supervision this thesis,  
 
Dr. Kristijan Ramadan for constructive discussions,  
 
The Functional Genomics Center Zurich (FGCZ), University of Zürich-Irchel, for 
their technical support for the microarray experiments and data analysis,  
 
My colleagues at the Institute of Veterinary Pharmacology and Toxicology,  
 
My special thanks go to my parents and my husband for their steady support and 
encouragement during my studies and thesis work. I could not wish for a more 
understanding and loving family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105
Declaration of Originality 
 
 
 
Last name, first name:  Zhang, Li 
 
Matriculation number:  08‐762‐486 
 
 
 
 
 
I hereby declare that this thesis represents my original work and that I have used no 
other sources except as noted by citations. 
All  data,  tables,  figures  and  text  citations  which  have  been  reproduced  from  any 
other source, including the internet, have been explicitly acknowledged as such. 
I am aware that in case of non‐compliance, the Senate is entitled to divest me of the 
doctorate degree awarded to me on the basis of  the present  thesis,  in accordance 
with  the  “Statut  der  Universität  Bern  (Universitätsstatut;  UniSt)”,  Art. 20,  of 
17 December 1997. 
 
 
 
Place, date  Signature 
 
 
………………………………………  ………………………………………………… 
 
106
